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Introduction 
Drug exposures and poisonings in children continue to be an important public health concern. 
Among different drugs involved in pediatric exposures and poisonings, opioids are an important 
class due to their increased medical and nonmedical use. The main objectives of this study were: 
1) to examine the prevalence and characteristics of opioid exposures, 2) to estimate the economic 
costs associated with opioid poisonings, and 3) to examine the characteristics associated with 
opioid poisoning-related health care resource use (HCRU) and costs in children. 
Methods 
Data from the National Poison Data System from January 1, 2010 to December 31, 2014 were 
utilized to identify opioid exposures and poisonings in children <18 years. Standardized prevalence 
xvi 
 
 
 
rates were calculated. Opioid exposures were characterized based on sociodemographic and 
clinical factors. 
Economic costs were estimated using the 2012 Nationwide Emergency Department Sample, Kids’ 
Inpatient Database, Multiple Cause-of-Death file and other published sources, applying a societal 
perspective. Direct costs included costs associated with ED visits, hospitalizations and ambulance 
transports. Indirect cost were estimated using the human capital method and included productivity 
costs due to caregivers’ absenteeism and premature mortality among children.  
Results 
There were a total of 83,418 pediatric opioid exposures over the 5-year period and nearly half of 
them resulted in poisoning. The epidemiology of opioid exposures differed considerably by age. 
Opioid exposures were more prevalent and mainly accidental in young children. Exposures in 
adolescents were more likely to be intentional and severe.  
The total economic costs of pediatric opioid poisonings in the United States were calculated at 
$230.8 million in 2012. Total direct costs were estimated to be over $21.1 million, the majority 
resulting from opioid poisoning-related ED visits and inpatients stays. Total productivity costs 
were calculated at $209.7 million, and 98.6% of these costs were attributed to opioid poisoning-
related mortality.  
Conclusions 
Opioid exposures and poisonings in children continue to occur and impose an economic burden 
on the society. Development of targeted age-specific prevention efforts is warranted. Quantified 
xvii 
 
 
 
HCRU and costs associated with pediatric opioid poisonings can help decision-makers to 
understand the economic trade-offs in planning interventions. 
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Chapter 1: Introduction 
 
Opioids and their therapeutic uses 
Opioids are any natural, semi-synthetic or synthetic substances that bind to the opioid receptors in 
the body. The three classical opioid receptors, mu, kappa and delta are found in the brain, spinal 
cord, gastrointestinal tract, and other organs in the body. Opioids are broadly classified as agonist, 
partial agonist or antagonist, depending on their strength of interaction and the ability to bind at 
the receptors to produce a response. Opioid agonists exhibit their effect by binding to the opioid 
receptors and activating them. Opioid antagonists bind to the opioid receptors without stimulating 
them. These agents do not produce any functional effect and simultaneously block the receptors to 
prevent an agonist from producing an effect. Partial agonists have a mixed agonist-antagonist 
effect. They show agonist properties by exhibiting some functional effects when used in low doses 
or in combination with a strong agonist, but at high doses they may exhibit an antagonist effect. 
Morphine, codeine, oxycodone, hydrocodone and fentanyl are examples of opioid agonists, 
buprenorphine is a partial agonist-antagonist, and naloxone is an opioid antagonist. These opioids 
also differ in their potency and plasma half-life. Opioid formulations are further classified as short- 
or long-acting depending of their duration of action.1–3 Opioids are widely used for their analgesic 
properties to relieve pain (opioid analgesics) although some opioids are used in antidiarrheal or 
antitussive preparations. 
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Opioid analgesics and pain 
Opioid analgesics are a mainstay of treatment for moderate-to-severe cancer pain as well as acute 
and chronic non-cancer pain. A survey by the Stanford University Medical Center reported that 
more than half of the adults in the United States lived with chronic or recurrent pain in 2005.4,5 In 
2009, the Institute of Medicine (IOM) pain report indicated that at least 116 million American 
adults are affected by one or more common chronic pain conditions such as low back pain, arthritis 
pain, and neuropathic pain.6 This high prevalence of pain, coupled with expanded clinical 
guidelines, has resulted in an increase in the number of opioid analgesic prescriptions over the past 
decade.  
In l998, Federation of State Medical Board (FSMB) released model guidelines for use of opioid 
analgesics for treatment of pain which reassured physicians that no disciplinary action will be 
taken based on quantity and amount of opioids prescribed as long as there was a good cause for 
making such treatment decision.7 Around the same time, the American Pain Society (APS) pushed 
for the concept of "pain as the fifth vital sign" i.e., in addition to the four vital signs examined 
during a routine physical (temperature, heart rate, blood pressure and breathing), the examining 
clinician should also assess patient’s pain.8 This, followed by the implementation of new pain 
management standards by the Joint Commission on Accreditation of Healthcare Organizations 
(JCAHO) in 2000, led to an increase of pain awareness and management in inpatient and outpatient 
settings, with the idea of "patient’s right to pain relief".9 These initiatives were in parallel to small 
clinician groups’ efforts to destigmatize use of opioid analgesics for pain treatment and patient 
advocacy group campaigns against undertreatment of pain. These movements conjoined with the 
release of new prescription opioid analgesics and the aggressive marketing by pharmaceutical 
manufacturers, resulted in the "opioid epidemic" of our generation.10,11  
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Rise in the use of opioid analgesics  
The number of opioid analgesic prescriptions per 100 persons rose from 61.9 in 2000 to 83.7 in 
2009 and this increase was more apparent for stronger opioids.12,13 The sales of opioid analgesics 
in 2010 were four times that in 1999, with 710 mg per person of opioid analgesics sold in the 
United States.14 There were 259 million prescriptions written for opioid analgesics in 2012 alone, 
which the Centers for Disease Control and Prevention (CDC) noted “is enough for every American 
adult to have a bottle”.15 The rise in the use of prescription opioid analgesics is a global problem, 
but it is distinct in the United States since American adults are reported to consume more than 80% 
of the world’s opioid supply, and opioids such as hydrocodone have been one of the top prescribed 
drugs nationally.16–18  
Opioid analgesics side-effects and concerns 
Constipation, sedation, nausea and vomiting are some common side-effects associated with the 
use of opioid analgesics. Opioid-induced respiratory depression is reported in patients starting on 
high doses of opioids or using them in combination with psychoactive drugs such as 
benzodiazepines or alcohol. Additionally, opioid analgesics are associated with the risk of aberrant 
drug-related behavior and high abuse liability. This includes potential for misuse or nonmedical 
use, abuse, dependence and addiction. Diversion is also a major concern with the use of opioid 
analgesics.19,20 The definitions of these terms are presented in Table 1.21 
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Table 1: Terminology and definition 
Terminology Definition 
Aberrant drug- 
related 
behaviora 
A constellation of behaviors that have grown to be recognized by clinicians as 
potentially indicative of prescription opioid abuse. 
Abuseb Persistent or sporadic excessive drug use inconsistent with or unrelated to 
acceptable medical practice. 
Addictionb Repeated use of a psychoactive substance or substances, to the extent that the 
user is periodically or chronically intoxicated, shows a compulsion to take the 
preferred substance, has great difficulty in voluntarily ceasing or modifying 
substance use, and exhibits determination to obtain psychoactive substances 
by almost any means. 
Diversiona The intentional removal of a medication from legitimate distribution and 
dispensing channels. 
Dependenceb The experience of impaired control over drug use. 
Misuseb Use of a substance for a purpose not consistent with legal or medical 
guidelines, as in the nonmedical use of prescription medications. 
Nonmedical 
useb 
Use of a prescription drug, whether obtained by prescription or otherwise, 
other than in the manner or for the time period prescribed, or by a person for 
whom the drug was not prescribed. 
Overdoseb Use of any drug in such an amount that acute adverse physical or mental 
effects are produced. 
 
aTufts Health Care Institute expert panel definition 
bWorld Health Organization (WHO) definition  
 
The number of persons aged 12 or older that had used opioid analgesics for nonmedical purposes 
for the first time in the past year increased by 41% from 1998 to 2008. Consumption of prescription 
opioid analgesics for nonmedical reasons was second to marijuana and more frequent than cocaine 
or heroin, even in youths aged 12 to 17 years. The National Survey on Drug Use and Health 
(NSDUH) reported that 4.9 million people 12 years or older were current nonmedical users of 
prescription opioid analgesics in 2012. Of these, 2.1 million people were reported to have a 
substance use disorder, defined as substance abuse or dependence, related to prescription opioid 
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analgesics.22 Another investigation suggested that the prevalence rate of aberrant drug related 
behavior ranged from 5% to 24%, and that of abuse ranged from 18% to 41% among patients 
treated with chronic opioids.16 Majority of nonmedical use related to opioids involves opioid 
analgesics. However, recent reports have suggested that adults with a history of opioid abuse or 
addition are using combination opioid products such as antidiarrheals for nonmedical purposes 
due to low cost and easy accessibility of these drugs compared to opioid analgesics.23  
The wide accessibility of opioid analgesics and parallel surge in their nonmedical use has resulted 
in an increased number of opioid overdoses and poisonings.14 The dramatic rise in opioid 
analgesics such as hydrocodone and oxycodone is reported to be significantly associated with an 
increase in drug-related emergency department (ED) visits.24 There were nearly 366,181 ED visits 
involving nonmedical use of opioid analgesics in 2011, an increase of 117% from 2005.25  
Recently, the CDC reported approximately 1.5 times more drug overdose deaths compared to 
deaths from car crashes. Opioids were involved in 61% of these drug overdose deaths.26 Owing to 
this ubiquitous use of opioids in the community, much research in the past decade has focused on 
opioid overdoses, especially fatal overdoses, due to nonmedical use and abuse among adults. Few 
studies have examined the simultaneous rise in unintentional opioid exposures and poisonings in 
young children.  
Opioid exposures and poisonings in children  
Exposure is defined as, “an actual or suspected contact with any substance that has been ingested, 
inhaled, absorbed, applied to, or injected into the body”.27 Poisoning is, “a state of major 
disturbance of consciousness level, vital functions, and behavior following the administration in 
excessive dosage (deliberately or accidentally) of a psychoactive substance”.28 Although the two 
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terms are used interchangeably in the literature, poisoning may indicate more severe exposure. 
Exposure and poisoning can be intentional (or deliberate) or unintentional (or accidental) in nature, 
and can occur in the intended or unintended recipient of the drug.  
Unintentional exposure and poisoning due to accidental ingestions by young children is an 
important public health concern. The CDC reports that over 300 children less than 20 years of age 
are treated in the ED every day and at least two children die due to medicinal or nonmedicinal 
poisonings.29 Research over the past decade shows that majority of these childhood poisonings are 
due to medicinal drugs. Although child fatalities related to unintentional drug poisonings have 
decreased in the late 2000s, the number of pediatric unintentional drug exposures and poisonings 
reported to poison centers (PCs) and the associated morbidity i.e., rates of ED visits and hospital 
admissions, and rates of injury (moderate or major medical outcome) have risen.30,31 PCs receive 
about 500,000 calls annually for drug ingestions among children less than 6 years of age.32 Each 
year, there are over 70,000 ED visits related to unintentional drug exposures and poisonings 
involving children, with peak incidence among 1-2 year olds. 33,34 In fact a 2009 study reported 
that drug poisonings had sent 1 of every 150 two-year olds to the ED, majority due to accidental 
exposures.35,36 From 2005 to 2009, ED visits due to unintentional drug poisonings were highest 
among children less than 15 years of age, compared to any other age group in Rhode Island alone.37  
Among different drugs involved in pediatric exposures and poisonings, opioids are an important 
class not only due to their increased legitimate use but also due to a rise in their nonmedical use. 
The 30th Annual Report of the American Association of Poison Control Centers’ (AAPCC) noted 
that over 60% of drug exposure calls in 2012 involved children less than 20 years of age. 
Analgesics, specifically opioids, were reported to be the most common substance involved in these 
exposure calls.32 The increase in opioid exposures among children is significantly associated with 
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an increase in adults’ opioid prescriptions.38,39 This association was seen for opioid analgesics used 
for pain treatments, such as hydrocodone, oxycodone, and morphine, as well as for agents used for 
opioid addiction treatment such as buprenorphine and methadone.38–40 In the state of Utah alone, 
the annual number of patients filling buprenorphine prescriptions increased by over 444-fold, from 
22 in 2002 to 9,793 in 2011. At the same time, the total number of buprenorphine exposures rose 
by 13-fold, and 39% of these exposures were among children aged 5 years or under.41 While in 
Indiana, adolescent opioid exposure cases reported to the PC almost doubled and the medical 
complications (moderate or major medical outcome, or death) resulting from these exposures more 
than doubled, following the release of 2000 JCAHO pain initiative. The increase in the number of 
exposures among adolescents was significant for hydrocodone and methadone. The number of 
deaths per adolescent opioid cases with medical complications rose by 11% between the two time 
periods i.e., the period before (1994 to 2000) and after (2001 to 2007) the release of JCAHO pain 
management standards.42 At a national level, there were over 10,000 intentional opioid exposures 
among adolescents recorded in the Researched Abuse, Diversion, and Addiction-Related 
Surveillance (RADARS) system from 2007 to 2009. Hydrocodone, oxycodone and tramadol were 
the most frequently misused opioids by these children.43  
Opioid exposures in children are high-risk due to the high toxicity associated with these drugs, 
even for combination opioids such as acetaminophen combinations. Ingestion of a single tablet of 
opioids such as buprenorphine and methadone can be fatal in young children.38,39,44 Opioid 
exposures and poisonings in children are unique because they constitute a majority of accidental 
exposures, especially among children 12 years or younger, as opposed to poisonings in adults. 
Morbidity and mortality related to these opioid exposures and poisonings in children is 
preventable. 
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Clinical presentation of opioid exposures and poisonings in children 
Opioid poisonings in children can result in serious symptoms or complications including 
respiratory disorders such as apnea, respiratory failure, and respiratory depression; psychiatric or 
nervous system disorders such as agitation, seizures, and coma; and cardiac disorders such as 
tachycardia, bradycardia and cardiac arrest.39,44 Presentation of opioid poisonings in children can 
differ from that in adults. Opioid poisonings in children can have delayed onset of symptoms, and 
severe and prolonged toxic effects. ED or hospital admission is recommended for young children 
with exposure to any long-acting opioid formulations; exposure to fentanyl, methadone or any 
buprenorphine formulations; or exposure to a high amount of any opioid. Treatment with naloxone 
is recommended in children with for respiratory depression following an opioid exposure, 
particularly methadone or buprenorphine exposures. 44,45 
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Chapter 2: Literature Review and Conceptual Framework 
 
2.1: Literature Review 
A comprehensive literature search of MEDLINE through PubMed and Google Scholar was 
performed. The search strategy combined multiple search terms and MeSH terms to retrieve 
relevant articles including, "Analgesics, Opioid"; "Poisoning", "Drug overdose" or "Opioid-related 
disorders"; "Infant", "Child" or "Adolescent"; and "Cost and cost analysis", "Emergency 
treatment" or "Economic burden". A manual search of the cited references in the originally 
retrieved articles was also conducted to identify additional research articles. The research articles 
were not reviewed if they were published in non-English language, if the research was based 
outside the United States, or if the article was published prior to 2000.  
A total of 19 studies were identified for full-text review. Table 2 summarizes 16 studies that 
examined prevalence and characteristics related to opioid poisonings in children. These 16 studies 
include original research articles and case reports. Table 3 summarizes 3 studies that investigated 
health care resource use (HCRU) and costs associated with opioid poisonings. Five studies from 
Table 2 and one study from Table 3 are described further due to their relevance to the current 
research.
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Table 2: Literature review articles – Prevalence and characteristics 
Study Data source(s) Sample  Methods Results 
Research studies 
Hayes et al. 
200746 
RADARS (2002-
05) 
Children <6 years 
with 
buprenorphine 
exposures  
Examined and 
characterized 
exposures 
Identified 86 children, 52% boys, mean age of 2 
years, 96% at-home exposures, and all exposures 
were unintentional and acute. 74% were treated 
at a HCF. Drowsiness, lethargy, vomiting and 
miosis were common clinical effects. 7% 
suffered from respiratory depression. Severity of 
symptoms increased with increased mean dose 
ingested. Decontamination and naloxone 
administration were commonly performed.  
Cohen et al. 
200833 
NEISS (2004-05) Children ≤18 
years with ED 
visit for an ADE  
Estimated the rate of 
ED visits for ADE due 
to unintentional 
overdose or ingestion, 
and examined the 
drugs involved 
Total of 71,224 children treated in ED for 
unintentional overdoses and 18% were 
hospitalized. About 66.6% of children were 1 to 
4 years. Analgesics were involved in 20.5% of 
the unintentional overdoses.  
Schillie et al. 
200935 
NEISS (2004-05) Children ≤18 
years presented to 
ED for drug and 
non-drug 
exposures 
Estimated the rate of 
ED visits from 
unintentional drug 
exposures due to 
unsupervised 
ingestions, medication 
errors and misuse 
ED visit rates for drug exposures were twice that 
of non-drugs, majority due to unsupervised 
ingestions. Total of 71,224 ED visits for drug 
exposures annually, mostly among 1-2 year olds 
and boys. Opioids were second most commonly 
implicated drug class in unsupervised ingestions. 
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Bailey et al. 
2009(a)38 
RADARS (2003-
06)  
Children <6 years 
with Rx opioid 
exposures  
Examined exposures 
and its association 
with Rx opioid 
availability at 3-digit 
ZIP Code level 
Total of 9,179 children with Rx opioid 
exposures. The median age was 2 years, 54% 
were boys, and ≥98% of these exposures 
involved ingestions or occurred at home. About 
265 children had a moderate-to-major effect and 
naloxone was commonly used for treatment. A 
positive correlation was found between 
childhood opioid exposures and the number of 
opioid Rxs filled in an area. 
Coben et al. 
201047 
NIS (1999-2006) Inpatient stays 
with any drug 
poisoning ICD-9-
CM code in first-
listed diagnosis 
Compared poisoning 
by Rx opioids, 
sedatives and 
tranquilizers to other 
drug poisonings 
Admissions for poisoning by Rx opioids, 
sedatives and tranquilizers increased by 65% 
from 1999 to 2006, which was twice that of 
increase in other drug poisonings. Largest 
percentage increase was for methadone (400%). 
Among children ≤18 years, 44.2% admissions 
were related to intentional and 37.4% were 
related to unintentional poisoning by Rx opioids, 
sedatives and tranquilizers. 
Tormoehlen et 
al. 2011(a)42  
Indiana PC data 
(1994-2007) 
Children aged 12 
to 18 years with a 
Rx opioid 
exposure 
Compared exposures 
in the pre-period 
(1994-2000) and post-
period (2001-07), 
following the release 
of JCAHO 2000 pain 
initiative 
Identified 1,634 opioid exposure cases, 632 in the 
pre-period and 1,002 in the post-period. The 
opioid exposure rate and complication (moderate-
to-major effects) rate per 1,000 adolescent Indiana 
PC cases were 1.8 times and 3 times higher in the 
post-period, compared to the pre-period. The 
number of deaths increased from 0 to 15 in the two 
time periods. 
Bond et al. 
2012(a)48 
NPDS (2001-08) Children <6 years 
exposed to one Rx 
or OTC drug 
through self-
ingestion or 
Examined proportion 
of admissions and 
injuries (moderate-to-
major effects) 
Total of 453,559 ED visits of which 58% were 
due to Rx drug exposures. Unintentional Rx drug 
self-ingestions were higher among children 1 to 
<3 years (71%), and boys (53%). Rx opioid 
analgesics were associated with about 12% of 
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therapeutic error, 
and presented to 
ED 
following exposure-
related ED visits 
unintentional Rx drug exposures. There was a 
101% increase in the number of ED visits, 86% 
rise in admission rates, and 92% increase in 
injury rates, due to unintentional self-ingestions 
of Rx opioids. 
Burghardt et al. 
2013(a)31 
NPDS and 
NAMCS (2000-
09) 
Children <20 
years with oral, 
single-ingredient 
Rx drug 
exposures 
Compared mean 
monthly number of 
pediatric exposures 
and poisonings, and 
the number of adults’ 
drug prescriptions 
Identified 62,416 pediatric prescription opioid 
exposures and poisonings, which was highest 
compared to the other drug classes. Nearly 48.4% 
of the total opioid exposures were associated 
with an ED visit of these, 26.3% had a moderate-
to-major effect and 41.5% had a medical or 
psychiatric admission. The association between 
adults’ opioids use and pediatric opioid 
exposures and poisonings was twice as strong 
compared to other drug classes. 
Lavonas et al. 
201339 
RADARS, 
pharmacovigilance 
and IMS Rx data 
(2009-12) 
Children 28d to 
<6 years with 
buprenorphine 
exposures 
Examined and 
characterized 
exposures 
Total of 2,380 pediatric exposures, common in 1 
to <3 year olds (74.5%) and males (51.6%), and 
>90% at-home exposures. About 236 cases with 
severe outcome including death. Drug stored in 
sight and parent’s medication was identified as 
the common root cause and source. 
Lovegrove et 
al. 2014(a)49 
NEISS and IMS 
Health (2007-11) 
Children <6 years 
presented to ED 
for unsupervised 
ingestion of oral 
Rx drugs 
Estimated and 
characterized ED 
visits resulting in 
hospitalization 
Nearly 34,503 ED visits of which 27.5% resulted 
in hospitalization. Admissions were higher 
among children 1 to 2 years (75.4%) and boys 
(52%), and 21.9% involved ingestion to >1 drug. 
About 36.5% of all ED visits for unsupervised 
ingestion of opioid analgesics resulted in 
hospitalization. Buprenorphine, hydrocodone and 
oxycodone were most commonly implicated. 
One child was hospitalized for every 500 unique 
patients receiving buprenorphine.   
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Hasegawa et al. 
201450 
NHAMCS 1993-
2010 
Visit with an 
opioid poisoning 
ICD-9-CM code 
Examined ED visits 
across different age 
groups and other 
demographic 
characteristics 
There were 74,000 ED visits for children <20 
years. The visit rate per 100,000 population and 
per 100,000 ED visits increased 
disproportionately among <20 year olds.  
Borys et al. 
201551 
NPDS (2008-13) Children <18 
years with single 
ingestion of 
tapentadol 
Determined the 
incidence of exposures 
and associated clinical 
characteristics 
Total of 104 children, 76.9% were ≤6 years, all 
had acute ingestions and 93 ingestions were 
unintentional. About 78.8% were treated in a 
HCF and 40.4% had a clinical effect, mostly 
drowsiness and lethargy. 
Case reports, case series or reviews 
Geib et al. 
200652 
Case series review 
of cases presented 
to the ED at an 
academic medical 
center 
5 children <2 
years with 
buprenorphine 
exposures 
Investigated adverse 
effects following 
unintentional 
exposures 
Drowsiness, lethargy, apnea and respiratory 
depression were common symptoms. Naloxone 
was used in 4 cases. LOS varied from 1 to 3 
days. 
Pedapati and 
Bateman 
201153 
Case series review 
of cases admitted 
in PICU at an 
academic medical 
center (2007-09) 
9 children <3 
years with 
buprenorphine 
exposures 
Examined the 
prevalence and 
clinical characteristics 
of exposures 
Drowsiness, lethargy were common symptoms 
followed by miosis, respiratory depression, 
vomiting, agitation or confusion. Most toddlers 
were treated with naloxone.  
Martin and 
Rocque 201140 
Review of cases 
admitted at a  
medical center  
(1999-2009) 
Children ≤18 
years admitted for 
methadone and 
buprenorphine 
ingestions 
Examined the increase 
in the number of 
patients on opioid 
dependence treatment 
in the area and 
corresponding 
Rate of admissions per yearly ED visits increased 
significantly. Total of 22 children were admitted, 
16 were in PICU and mean LOS was 2.3 days. 
Majority were infants and toddlers, and the drug 
mostly belonged to parents.    
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admissions for 
pediatric ingestions 
Spatial analyses study 
Nguyen et al. 
201654 
Pittsburg PC at 5-
digit ZIP Code 
level (2006-10) 
Children <5 years 
with unintentional 
drug exposures 
wherein, the calls 
were made from a 
non-HCF. ZIPs 
from out-of-state 
or with no 
children <5 years 
were excluded. 
Identified ZIP Code 
clusters of pediatric 
exposure calls, and 
examined associated 
population 
characteristics. 
Identified 26,685 exposures, and 22 exposure 
clusters with 324 ZIP areas. Area-level 
population density, education, proportion of Non-
white race and household size was significantly 
associated with the odds of ZIP area being within 
an exposure cluster.   
 
(a)Study is described further (below).  
RADARS = Researched Abuse, Diversion and Addiction-Related Surveillance, HCF = Health care facility, ADE = Adverse drug event, 
NEISS = National Electronic Injury Surveillance System, NIS = Nationwide Inpatient Sample, ED = Emergency department, Rx(s) = 
Prescription(s), OTC = Over-the-counter, NHAMCS = National Hospital Ambulatory Medical Care Survey, NPDS = National Poison 
Data System, PICU = Pediatric Intensive Care Unit,  LOS = Length of stay, PC = Poison center, HH = Household, ICD-9-CM = 
International Classification of Diseases, 9th Revision, Clinical Modification.
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Bailey et al. 200938 
Bailey et al.38 examined prescription opioid exposures in children under 6 years of age, and its 
association with prescription opioid availability in a region at 3-digit ZIP Code level. Prescription 
opioids examined were limited to hydrocodone, oxycodone, buprenorphine, fentanyl, 
hydromorphone, methadone and morphine. The authors used PCs data from the Researched Abuse, 
Diversion and Addiction-Related Surveillance (RADARS) system, from first quarter of 2003 to 
second quarter for 2006 (3.5 years). The RADARS is a surveillance system that comprises multiple 
signal detection systems to monitor prescription drug misuse, diversion and abuse throughout the 
United States. One of the RADARS systems captures detailed data from the PCs on childhood 
drug exposures. 
There were a total of 9,240 opioid exposure mentions in 9,179 children with a median age of 2 
years and about 54% were boys. Most of these exposures involved ingestions and were 
unintentional (≥99%), and commonly occurred at one’s own or other’s residence (98%). In 
majority of these exposures, the opioid was intended for an adult. Exposures to hydrocodone (65%) 
and oxycodone (22%) were most common. About 265 children had a moderate-to-major effect 
including a total of 8 deaths. Naloxone was commonly used for treating children experiencing a 
major effect or death. The proportion of opioid mentions associated with any clinical effect was 
significantly greater for buprenorphine (0.68). Of the total 176 buprenorphine exposures, 136 
involved buprenorphine/naloxone combination, and about 30 buprenorphine exposures resulted in 
a moderate-to-major effect. Naloxone was commonly used for treating children experiencing a 
major effect or death. 
The authors also examined the association between opioid exposures in children and adults’ opioid 
availability in a region by using the unique recipient of dispensed drug (URDD) at 3-digit ZIP 
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Code level. URDD provides a measure of drug availability, and it represents the number of unique 
individuals filling a prescription for a particular opioid, excluding refills. A positive correlation 
coefficient of 0.67 was found between childhood opioid exposure mentions and URDD. This 
association was highest for hydrocodone (0.81) and oxycodone (0.69).  
The RADARS PCs’ data used for this study may be more detailed and accurate compared to the 
NPDS due to additional opioids coding-related training provided to the participating PCs. 
However, 11 PCs participated in the RADARS in 2003, and about 40 PCs participated in 2006. 
Compared to the National Poison Data System (NPDS), these data may not be nationally 
representative. Also, the authors limited these analyses to children aged 6 years or under, and 
examined a limited number of prescription opioids. 
Tormoehlen et al. 201142  
Tormoehlen et al.42 compared prescription opioid exposures involving children aged 12 to 18 years 
in the period before and after the release of JCAHO 2000 pain initiative. The authors used data 
from the Indiana PC from 1994 to 2000 (pre-period) and 2001 to 2007 (post-period). Records were 
examined for exposures involving one of the following opioids: hydrocodone, morphine, 
methadone, codeine, oxycodone, meperidine, fentanyl, buprenorphine, hydromorphone, 
propoxyphene, and oxymorphone. Correlation was examined between the Indiana state opioid 
distribution and the percent of adolescent exposures cases. 
There were a total of 1,634 opioid exposure cases, 632 in the pre-period and 1,002 in the post-
period, and majority involved females. Total number of adolescent cases increased significantly 
for hydrocodone exposures (71 to 480 cases) and methadone (8 to 72 cases) however, it decreased 
for codeine exposures (242 to 124 cases). The opioid exposure rate and complication rate (defined 
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as moderate or major outcome, or death) per 1,000 adolescent Indiana PC cases were 1.8 times 
and 3 times higher in the post-period, compared to the pre-period respectively. The number of 
deaths increased from 0 to 15 in the two time periods. There was a strong positive correlation 
between the amount of opioids distributed in Indiana and the rate of adolescent cases reported to 
the Indiana PC. 
Tormoehlen et al. concluded that the number of reported adolescent opioid exposures and the 
associated medical complications have risen following the JCAHO pain initiative, but they did not 
examine the intent of exposure or the HCRU used following an opioid exposure. They limited the 
analyses to specific opioids that were listed as the first or second substances involved in an 
exposure. In addition, this study was based on a single state’s PC adolescent cases. Hence these 
results may not be generalizable to other age groups or states. 
Bond et al. 201248 
Bond et al.48 used NPDS data from 2001 to 2008, to examine unintentional pediatric exposures to 
prescription or OTC pharmaceutical drugs including opioid analgesics. The NPDS is described in 
the following chapter. The authors examined NPDS records of children less than 6 years that were 
exposed to one product (single or combination product) through self-ingestion or therapeutic error, 
and were presented to an ED.  Proportion of admissions and injuries following exposure-related 
ED visits were assessed. Injuries comprised any exposure with a moderate-to-major effect 
including death. The authors compared ED visits, hospital admissions and injuries associated with 
drug exposures, with the changes in pediatric population and the number of pediatric drug exposure 
calls received by the PCs. Although the increase in childhood drug exposure ED visits, admissions, 
and injuries was significantly greater than the population changes over the 8-year period, these 
trends were not specifically assessed for opioids. Of the total 453,559 ED visits identified, 
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prescription drugs were associated with about 58% of unintentional exposures in children, majority 
due to self-ingestions (95%). Prescription drug exposures due to unintentional self-ingestions were 
highest for children 1 to 3 years of age (71%), while therapeutic errors were common among ≤1 
year olds (37%). These exposures were disproportionately higher for boys (53% to 58%).  
Prescription opioid analgesics were associated with approximately 12% of unintentional 
prescription drug exposures, and were mostly due to self-ingestions. The authors reported a 101% 
increase in the number of ED visits, 86% rise in admission rates, and 92% increase in injury rates, 
from 2001 to 2008, due to unintentional self-ingestions of prescription opioids. The authors also 
examined unintentional exposures due to acetaminophen and cough and cold products, but they 
not identify opioid-containing formulations within these categories 
Although Bond et al. examined unintentional pediatric during exposures over 8-year period, 
several limitations exist. These analyses excluded children that were exposed to multiple products, 
exposed through non-ingestion route, were managed at home or at a non-ED setting, and those 
who did not have complete follow-up information. This may have underestimated the actual 
burden of unintentional drug and opioid exposures in young children. Additionally, clinical 
characteristics of exposures were not specifically examined for opioids. 
Burghardt et al. 201331 
A study by Burghardt et al.31 used the 2000 through 2009 NPDS and National Ambulatory Medical 
Care Survey (NAMCS) data to examine the exposures and poisonings in children less than 20 
years, and its association with monthly adult prescriptions for hypoglycemics, 
antihyperlipidemics, β-blockers, and opioid analgesics. Mean monthly number of pediatric 
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exposures and poisonings was calculated and compared to the mean monthly number of adults’ 
drug prescriptions using time series analyses.  
There were 62,416 pediatric prescription opioid exposures and poisonings, which was highest 
compared to other drug classes. Children under 6 years experienced the greatest number of drug 
exposure events across all drug classes including opioids. Monthly opioid exposures and 
poisonings increased by 0.09 per 1,000,000 children under 6 years of age, 0.006 per 1,000,000 
children among 6 to 12 year olds, and 0.04 per 1,000,000 children among 13 to 19 year olds. The 
mean yearly opioid exposures and poisonings in these age groups were 3,293, 590 and 2,330, 
respectively. Nearly 48.4% of the total opioid exposures were associated with an ED visit of these, 
26.3% had a moderate-to-major effect (including death), 35% had a medical admission, and 6.5% 
had a psychiatric admission.   
The association between adults’ opioids use and pediatric opioid exposures and poisonings was 
twice as strong compared to other drug classes, especially for children under 6 years. A 1% 
increase in adults’ opioid use was associated with 1.53 times more exposures and poisonings per 
1,000,000 children in this age group.  
Although these analyses were done separately for opioids, they were limited to prescription opioids 
that were single-ingredient or oral formulations. This excluded commonly used opioid 
combination drugs such as acetaminophen-hydrocodone combinations (e.g., Vicodin®), or non-
oral opioids such as fentanyl patch. The authors also excluded exposure and poisoning records that 
had an indication of the child’s own prescription. Further, for HCRU analyses, about 17% of opioid 
exposure cases were identified as lost to follow-up. These factors would result in an underestimate 
of the actual burden of pediatric opioid exposures. Lastly, analyses were not separated for one or 
multiple product ingestions, and by reason (or intent) of exposure. 
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Lovegrove et al. 201449 
Lovegrove et al.49 used data from the National Electronic Injury Surveillance System - Cooperative 
Adverse Drug Event Surveillance (NEISS-CADES) and IMS Health, from 2007 to 2011, to 
estimate ED visits resulting in hospitalizations (emergency hospitalizations) for unsupervised 
ingestion of oral prescription drugs in children under 6 years. NEISS is an ED-based adverse drug 
events surveillance system using a nationally representative sample of hospitals in the United 
States. The authors calculated rates of emergency hospitalization per 100,000 dispensed outpatient 
prescriptions and per 100,000 unique patients receiving dispensed prescriptions.  
Of the total 34,503 ED visits identified, 27.5% resulted in hospitalization. Annual national 
emergency hospitalizations were highest among children 1 to 2 years of age (75.4%) and boys 
(52%), and 21.9% involved ingestion to more than 1 medication. Opioid analgesics was the most 
commonly involved drug class in these emergency hospitalizations (17.6%). About 36.5% of all 
ED visits for unsupervised ingestion of opioid analgesics resulted in hospitalization. 
Buprenorphine, hydrocodone and oxycodone were the most commonly implicated opioid 
analgesics. Over 62% of ED visits for unsupervised ingestion of buprenorphine, 30.5% of ED 
visits for hydrocodone ingestions, and 26.1% of visits for oxycodone ingestions resulted in 
hospitalization. The authors reported that 1 child was hospitalized for unsupervised ingestion for 
every 500 unique patients receiving buprenorphine.   
This study examined drug classes and individual drugs involved in unintentional exposure-related 
emergency hospitalizations in young children, and compared it to the drug availability at a national 
level. These estimates indicate severe drug exposures among young children but there exist a few 
limitations. First, these estimates did not include non-oral medications. Second, analyses were 
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limited to ED visits that resulted in admission hence, it did not incorporate cases that were managed 
at-home or were directly admitted. Finally, related clinical effects, scenario and reason of 
exposure, and deaths were not investigated.  
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Table 3: Literature review articles – HCRU and costs 
Study Data source(s) Sample  Methods Results 
Inocencio 
et al. 
2013(a)55 
NEDS (2009), 
NIS (2009), 
DAWN (2009) 
Visits in the NEDS and 
NIS with opioid 
poisoning ICD-9-CM 
code. Opioid poisoning 
cases from DAWN. 
Calculated direct and 
indirect costs related to 
opioid poisonings 
including heroin and 
Rx opioids in 2011 
USD 
Mean direct cost for Rx opioid poisonings was 
$4,255. Estimated mean ED treatment cost was 
$1,967 and inpatient stay cost was $9,696. Total 
direct cost of prescription opioid poisoning was 
$1.8 billion and the total indirect cost was $14.1 
billion. Absenteeism costs were estimated at $618 
per case, and mortality costs at $33,664 per case. 
Yokell et 
al. 201456 
NEDS (2010) Visit with an opioid 
poisoning ICD-9-CM 
code  
Descriptively  
examined the 
characteristics and 
mean charges in 2010 
USD 
Total 92,209 ED visits for Rx opioid poisonings. Of 
these, 4,998 ED visits were for children ≤17 years. 
Mean charges for opioid poisoning ED visit without 
admission ranged from $3,640 for Rx opioid 
poisoning, $3,692 for methadone poisoning and 
$4,121 for unspecified or multiple opioid 
poisonings. Mean charges for opioid poisoning 
inpatient stays ranged from $29,497 for Rx opioid 
poisoning, $32,647 for methadone poisoning and 
$29,669 for unspecified or multiple opioid 
poisonings in 2010 USD. Mean LOS for Rx opioid 
poisoning hospitalizations was 3.8 days.  
Xiang et 
al. 201257 
NEDS (2007) Visit with any drug 
poisoning ICD-9-CM 
code  
Estimated population 
rate of ED visits by age 
groups, and the total 
ED charges in 2007 
USD 
About 19.58% of the total drug poisoning-related 
ED visits for children ≤17 years. Compared to any 
other age group, children ≤5 years had the highest 
rate of unintentional poisonings. Among teens, 
females had a higher rate of intentional poisonings 
compared to males. Total charges for drug 
poisoning ED visits was $1,994 per visit. 
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(a)Study is described further (below). 
NEDS = Nationwide Emergency Department Sample, NIS = Nationwide Inpatient Sample, 
DAWN = Drug Abuse Warning Network, ED = Emergency Department, Rx = Prescription, ICD-
9-CM = International Classification of Diseases, 9th Revision, Clinical Modification, USD = 
United States dollar, LOS = Length of stay. 
 
Inocencio et al. 201355 
A study by Inocencio et al.55 evaluated the economic burden of opioid poisonings in the United 
States. The authors used 2009 Healthcare Cost and Utilization Project (HCUP) Nationwide 
Emergency Department Sample (NEDS) and Nationwide Inpatient Sample (NIS) databases to 
compute the mean ED and inpatient costs related to opioid poisonings, including heroin and 
prescription opioids. They computed cost for each component of care, ED, inpatient, ED physician, 
ambulance and drug costs. The total direct and indirect costs were calculated using prevalence 
estimates from Drug Abuse Warning Network (DAWN). This database consists of drug-related 
ED visits and deaths and is used to monitor the impact of drug use, misuse, and abuse across the 
nation. Cases in DAWN are categorized as suicide attempt, seeking detox, alcohol only, 
overmedication, adverse reaction, accidental ingestion, malicious poisoning, and other. Inocencio 
et al. limited their sample to those ED visits that were related to overmedication, suicide attempt, 
malicious poisoning, or other.  
The authors reported a mean direct cost of $4,255 for prescription opioid poisonings. The mean 
ED treatment costs was estimated as $1,967 and inpatient stay costs at $9,696. The total direct cost 
of prescription opioid poisoning was $1.8 billion and the total indirect cost was $14.1 billion. The 
mean costs related to absenteeism were $618 per case, and the mean costs related to mortality were 
$33,664 per case. All costs were reported in 2011 USD.  
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Inocencio et al. employed a rigorous study design to estimate the economic costs of opioid 
poisonings yet, these estimates cannot be used to gauge the costs of opioid poisonings in children 
for a number of reasons. First, the mean costs of prescription opioid poisonings estimated from 
HCUP databases were not reported by specific age groups. These estimates include opioid 
poisonings in adults and older adults. The characteristics of these population groups can vary 
significantly from children. For example, the burden of adult poisonings can be related to 
underlying abuse or addiction, while older adults may have multiple comorbidities, resulting in 
high costs of treatment following a poisoning. Second, accidental ingestions were not included in 
the authors’ poisoning case definition, this may have excluded majority of prescription opioid 
poisonings in young children.  
Summary of the literature – Prevalence and characteristics  
The distribution of age for drug exposures and poisonings is mainly found to be bimodal. The 
number of drug or opioid exposures and poisonings were found to be higher in young children, 
particularly 1 to 2 year olds, followed by adolescents.31,35,38–40,48,49,53,58 More than half of the drug 
exposures and poisonings were in boys among children less than 6 years. Among teenagers, the 
occurrence of opioid exposures and poisonings was higher among females.42 Over 90% of opioid 
exposures occurred at one’s home.38,39 Caller site for drug exposures and poisonings was 
predominantly one’s own residence however, about 20% were reported from a health care facility 
(HCF).32,38,39  
Multitude of studies have investigated pediatric exposures and poisonings to various opioid agents 
including hydrocodone, oxycodone, buprenorphine, methadone, oxymorphone, hydromorphone, 
tramadol, tapentadol, codeine, meperidine, propoxyphene, fentanyl, and morphine.38–40,42,46,49,51–
53,59,60 One study examined exposures and poisonings from acetaminophen and cough and cold 
 
 
25 
 
product combinations.48 The number of hydrocodone and oxycodone exposures and poisonings in 
children have been on the rise.38 Studies also indicated an increase in the number of methadone 
and buprenorphine exposures and poisonings.42,47 Severe outcomes were reported following 
buprenorphine or methadone exposures in children, especially among those under 6 
years.38,40,49,52,53,61,62 The number of exposures involving more than one product varied from 5% 
to 22%.39,49 
Ingestion was the most common route of drug exposures in children. Unintentional and intentional 
exposures to drugs or opioids in children were more common compared to adverse events. 
Exposures in young children under the age of 6 were unintentional, while exposures among 
adolescents were mostly intentional. Unintentional exposures due to therapeutic errors were more 
common in infants, and self-ingestions were more common in children aged 1 to 3 years.35,38,47,48,61 
Clinical effects were reported in 25% to 40% of children exposed to opioids.38,39,51 Drowsiness, 
lethargy, dizziness, nausea and vomiting were the most common symptoms. Respiratory 
depression, tachycardia, CNS depression, and seizures were reported with severe opioid 
poisonings.46,51,53,59,60 Majority of exposures were acute.51 The proportion of opioid exposures and 
poisonings resulting in moderate-to-major medical outcome varied from 5% to 13%. These 
numbers further varied by age group.31,38,39 For instance, Tormoehlen et al. reported a medical 
complication (moderate-to-major effect) rate of 4.9 per 1,000 adolescents Indiana PC cases.42  
Over one-fourth of opioid exposures in young children were associated with storage and access 
scenarios such as “stored in sight, left out, not secured”, “accessed from bag or purse”, or “drug 
stored in package other than original packaging”.39 Naloxone and decontamination procedures 
were the most common therapies performed following an opioid exposure in children.46,53,59,61 
Naloxone was also commonly used for buprenorphine exposures in young children.38,62 Nearly 
 
 
26 
 
half of the children with opioid exposures and poisonings were presented to the ED, and the 
proportion of the ED visits resulting in admission ranged from 18% to 42%. These numbers varied 
by age and the opioid agent involved. For example, Borys et al. reported that 78% of children 
exposed to tapentadol were presented to the ED. While Lovegrove et al. reported that 62.4% of 
ED visits for buprenorphine exposures, 30.5% of ED visits for hydrocodone exposures, and 26.1% 
of the ED visits for oxycodone exposures among children under 6 years resulted in 
hospitalization.31,33,49,51,63  
Prescription opioid availability was reported to be significantly associated with the number of 
opioid exposures and poisonings among children at 3-digit ZIP Code level,38 at state-level,42 and 
at national-level.31 Nguyen et al. identified 5-digit ZIP Code clusters of pediatric exposure calls, 
and examined the associated population characteristics in Pennsylvania. The authors found 
significant association between area-level characteristics including lower education, household 
size (average household size of 2.36) and Non-white race and lower odds of pediatric drug 
exposures in the area.54 Schillie et al. reported a three times higher rate of ED visits for medication 
overdoses compared to nondrug exposures among White children under the age of 19.35 Among 
the studies reviewed, no other study based in the U.S. has examined area-level characteristics 
associated with pediatric drug exposures. Two studies in Europe have examined the association of 
socioeconomic factors and childhood drug poisonings. One of these studies reported an increasing 
rate of hospital admissions for unintentional drug poisonings, including poisonings by analgesics, 
with lower socioeconomic status among children under 5 years of age. Socioeconomic status was 
examined using the Townsend scores, which is a widely used measure of deprivation or 
socioeconomic status in the United Kingdom.64 While another study found higher rates of 
unintentional drug or chemical poisonings among children under the age of 15 years to be 
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associated with lower income and lower educational level. The authors did not find a significant 
association between the rate of unintentional pediatric poisonings and crowded household.65 In 
addition, adults’ prescriptions including parents, caregivers and grandparents, are reported to be 
the common source of opioids in pediatric exposures and poisonings.39 Hence, it was interesting 
to explore the association of area-level population characteristics of adults and older adults in 
households and the number of opioid exposures and poisonings. Based on the knowledge from the 
literature reviewed above, various sociodemographic and clinical characteristics of opioid 
exposures and poisonings were examined in the current study. 
Summary of the literature – HCRU and costs 
Few studies have examined the rate of ED visits and subsequent medical admissions as described 
above.31,33,49,51,63 Although not specific to the pediatric population, some previous investigations 
have reported differences in the sociodemographic, clinical, payer and hospital characteristics 
associated with ED visits for drug or opioid poisonings.   
Drug or opioid poisoning-related ED visits differed by age group, gender, residence location and 
median area-level income. Proportion of drug poisoning-related ED visits were higher for children 
less than 6 years and children 12 to 17 years.57 Drug or opioid poisoning-related ED visits were 
more common among females, and those from areas with lower median ZIP Code level income 
and urban areas.56,57 As for race and ethnicity, rate of opioid poisoning-related ED visits per 
100,000 population did not vary much across Whites and Blacks, or Hispanics and non-
Hispanics.50  
Certain clinical characteristics were also found to be related to drug poisoning-related ED visits. 
Compared to methadone, higher proportion of ED visits were for poisonings related to other 
 
 
28 
 
prescription opioids.56 One study reported a higher rate of ED visits per 100,000 population for 
unintentional opioid poisonings.50 Mood disorders, and acute benzodiazepine and alcohol 
intoxication were the most common concurrent diagnoses among patients presenting to the ED 
with opioid poisonings.56 Two studies also found that about 20% to 30% of the total ED visits for 
opioid or drug-related poisonings involved more than one drug. Benzodiazepines were frequently 
involved in such multi-drug poisonings.55,57 Mental disorder was the most commonly recorded 
chronic condition in opioid poisoning-related ED visits.56 Kline-Simon at al. examined substance 
use disorders and co-occurring psychiatric comorbidities, medical comorbidities and chronic 
conditions in adolescents. The authors reported that about 40% of these children had 2 or more 
psychiatric comorbidities, commonly depression and anxiety. They also found a significant 
association between substance use disorders and presence of any medical comorbidities, or chronic 
conditions such as asthma.66 Mazer-Amirshahi et al. examined common procedures performed in 
poisoning-related visits. The authors found that diagnostic procedures such as blood work, 
electrocardiogram (ECG), urine studies and X-rays were most commonly recorded.67  
Literature on the common source of payment for drug or opioid poisoning-related ED visits was 
inconclusive. Two studies reported that private insurance was the more common source of 
payment,57,67 whereas another study reported a similar proportion of ED visits had Medicaid or 
private insurance.50 Hospitals in southern region had a higher proportion of opioid poisoning-
related ED visits.50,56 Similarly, urban hospitals, non-teaching institutions and non-profit hospitals 
had a higher number of poisoning-related ED visits.67  
None of these studies examined hospital trauma status or bedsize. Trauma status of the institution 
has been associated with severity of injured patients i.e., trauma centers treat more severe cases 
and have different outcomes compared to non-trauma centers.68 There is no definitive literature on 
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the relationship of hospital bed size and health outcome or HCRU. However, it is theorized that 
bed size affects the average cost per patient. Hospitals with a higher number of beds should have 
a lower cost per patient due to economies of scale.69   
The studies reviewed above did not examine the association of various characteristics with 
inpatient stays or hospital costs of drug or opioid poisonings, especially in children. Yet, these 
studies illustrate differences in sociodemographic, clinical, payer and hospital characteristics for 
drug or opioid poisoning-related ED visits. Emergency care is an important component of HCRU 
for opioid poisonings in children. Similar associations are expected for ED visits, inpatient stays 
and hospital costs of pediatric opioid poisonings hence, the association of these characteristics with 
ED visits, inpatient stays and costs was examined in the current study.  
 
2.2: Gaps in the literature  
A number of studies have examined drug exposures and poisonings in children. Few studies have 
examined the prevalence and characteristics of exposures and poisonings due to opioids. Yet, many 
of these analyses were either limited to a specific opioid agent, mostly buprenorphine or 
methadone, to single-substance opioid products or single ingestions, to a specific age group such 
as children under the age of 6 years or adolescents, or to specific population such as those 
presenting to the ED. Some of these studies have examined the association between prescription 
opioid availability among adults and opioid exposures among children. However, none of the 
studies that were reviewed has assessed the association between area-level socioeconomic status 
(SES) and opioid exposures and poisonings in children. In addition to individual characteristics, 
neighborhood factors may also influence health outcomes such as pediatric opioid exposures.  
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Another gap identified in the literature is that no study has quantified the economic burden related 
to opioid poisonings in children. A study by Inocencio et al. evaluated the economic burden of 
opioid poisonings but, it did not specifically estimate economic costs associated with opioid 
poisonings in the pediatric population.55 The epidemiology of opioid poisonings and the associated 
HCRU and costs in children can vary tremendously from that in adults.  
 
2.3: Conceptual framework  
Existing research and clinical knowledge was used to guide the conceptual framework for this 
project. McCaig and Burt (CDC, 1999) depicted the burden of poisonings nationally using the 
"Poisoning Pyramid" framework. The authors used multiple CDC data sources to delineate various 
HCRU components associated with a poisoning episode. The bottom of the pyramid corresponds 
to all exposures and poisonings, followed by poisonings that result in ED visits and subsequent 
hospitalization, and the tip of the pyramid representing deaths resulting from poisonings.70 We 
implemented this framework to guide our approach for examining pediatric opioid exposures and 
poisonings in two parts. The first part of our study (Specific Aim 1 below) examined the prevalence 
and characteristics of pediatric opioid exposures and poisonings which corresponds to the bottom 
of the pyramid. The second part of our study (Specific Aims 2 and 3 below) examined the HCRU 
and costs associated with pediatric opioid poisonings (Figure 1). 
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Source: McCaig and Burt (CDC, 1999)70  
Data from 1995 National Vital Statistics System (NVSS); 1995 National Hospital Discharge 
Survey (NHDS); 1993-96 National Hospital Ambulatory Medical Care Survey (NHAMCS), and 
1995 AAPCC Toxic Exposure Surveillance System (TESS, now known as the NPDS). 
 
Figure 1: The Poisoning Pyramid 
 
2.4: Specific Aims 
Aim 1: To examine the prevalence and characteristics of pediatric opioid exposures  
A.  To determine the prevalence of opioid exposures and poisonings in children 
B.  To characterize pediatric opioid exposures based on sociodemographic and clinical 
characteristics 
C.  To examine the factors associated with severity of opioid exposures in children  
D.  To examine opioid exposures in children at 5-digit ZIP Code level and study its 
association with area-level socioeconomic status (SES) 
Aim 2: To estimate the economic costs associated with opioid poisonings in children  
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Aim 3: To examine the characteristics associated with pediatric opioid poisoning-related 
health care resource use and costs 
A. To assess the characteristics associated with pediatric opioid poisoning ED visits 
B. To identify factors associated with ED visit costs among children with opioid 
poisonings 
C. To examine the characteristics associated with pediatric opioid poisoning inpatient 
stays 
D. To identify factors associated with inpatient stay costs among children with opioid 
poisonings 
 
2.5: Significance 
The current study provides a more comprehensive assessment of the burden of opioid exposures 
and poisonings in children. This study examined pediatric exposures and poisonings related to all 
opioid containing drugs including oral or non-oral opioids, single-substance or combination 
opioids, or prescription or OTC opioids.  
Examination of prevalence of opioid exposures and poisonings in children and the associated 
sociodemographic, clinical, and area-level characteristics can help to estimate the magnitude of 
the problem and identify vulnerable areas or subgroups. The study used national PCs data to 
quantify the prevalence of pediatric opioid exposures and poisonings, instead of health care 
encounter data, to capture pediatric opioid exposures. Use of PCs data allowed us to measure 
exposures that are not presented to HCFs as well as exposures that do present to HCFs. Although 
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cases that are not presented to the ED or admitted do not incur HCRU or costs, there is still an 
intangible burden associated with them. These cases represent the population that was at risk for 
opioid poisoning. At the same time, this study distinguished poisonings from exposures thus 
avoiding an overestimation of the prevalence of opioid poisonings since not all exposures result in 
poisoning.  
On the other hand, this study used national, administrative billing data to quantify HCRU and costs 
because these sources are probably more precise compared to using self-reported data obtained 
from PCs. Estimating the economic costs of pediatric opioid poisonings to society can aid in 
planning and prioritizing interventions. The current study examined the full-spectrum of economic 
burden associated with pediatric opioid poisonings. This included estimating direct costs for 
inpatient stays and ED visits as well as indirect productivity costs resulting from morbidity and 
mortality. Deaths associated with opioid poisonings were examined using the CDC’s National 
Vital Statistics System (NVSS) data. These data record over 99% of registered deaths nationally, 
hence providing considerable value for mortality research.  
Lastly, these analyses allowed for comparison of prevalence and HCRU related to pediatric opioid 
poisonings across two datasets, the national hospital discharge-level data and the national PCs 
data. The PCs data is obtained through a passive data collection system, and relies on individual 
reporting by patients, family, friends, or health care professionals. Although using medical 
discharge data from a different data source such as the HCUP did not allow for linking or 
comparing the same cases across the datasets, it provided rough population level comparisons. 
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Chapter 3: Specific Aim 1 
 
Aim 1: To examine the prevalence and characteristics of pediatric opioid exposures  
A.  To determine the prevalence of opioid exposures and poisonings in children 
B.  To characterize pediatric opioid exposures based on sociodemographic and clinical 
characteristics 
C.  To examine the factors associated with severity of opioid exposures in children  
D.  To examine opioid exposures in children at 5-digit ZIP Code level and study its 
association with area-level socioeconomic status (SES) 
 
3.1: Methods  
Design 
A retrospective, cross-sectional study design was implemented for this Specific Aim. 
Data 
Data from the National Poison Data System (NPDS), from January 2010 to December 2014, were 
used for this study. The American Association of Poison Control Centers’ (AAPCC) maintains the 
NPDS, a national database that logs information from approximately 55 poison centers (PCs) 
across the nation, serving the entire United States population. The PCs receive roughly 6,000 
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exposure calls per day which are managed by trained health care professionals and specialists in 
poison information (SPIs). Case records are based on self-reported calls initiated by the public 
(family member or friend) or by health care providers (HCP). The SPIs provide exposure 
management recommendations to the caller and record case related documentation in standard data 
collection fields that are abstracted into the NPDS every few minutes. The PCs also attempt to 
follow-up on cases post-exposure, to determine and record medical outcomes associated with the 
exposure. The NPDS data is captured in near real-time and provides an actual count of 
exposures.27,32 NPDS has been validated as a potential pharmaceutical poisoning surveillance 
system and it has been widely used in drug poisoning studies.71,72   
Population estimates were obtained at state- and national-level, by single year of age, from the 
2010 United States Census. For area-level analyses, SES data were obtained at 5-digit ZIP Code 
level from ESRI Updated Demographics 2010 United States Census data. 
Sample 
NPDS data were extracted for opioid exposure-related calls involving children less than 18 years 
of age. Closed cases with a suspected exposure to 1 or more opioid containing product were 
included. Cases that were initially recorded as a suspected opioid exposure but confirmed as non-
exposure during follow-up were excluded. This was used as the final sample for examining the 
prevalence and characteristics of opioid exposures. Further exclusions were made for subsequent 
sub-aims as follows. Figure 2 depicts the final sample size for each of the sub-aims. 
A. Cases without a record of 1 or more clinical effect following an opioid exposure were excluded 
from the opioid poisoning analyses (Specific Aim 1A). 
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B. Cases with exposure to more than 1 opioid or non-opioid product were excluded for examining 
the factors associated with severity of opioid exposures. This was done to eliminate any 
confounding in the association between severity of opioid exposure and various exposure 
characteristics, due to involvement of additional products. Such an approach has also been 
implemented in the NPDS annual report analyses (Specific Aim 1C).  
C. Cases were excluded if the recorded exposure site and caller site was not one’s own residence 
for area-level analyses (Specific Aim 1D). This was done in an attempt to restrict pediatric 
opioid exposures that occurred in one’s own area, in order to examine area-level factors that 
may be associated with pediatric opioid exposures. Such exclusion criteria also helped to limit 
the analyses to cases that were reported by public and not by a health care facility (HCF).  
However, this led to exclusion of nearly 47.6% of total pediatric opioid exposures. The sample 
for Specific Aim 1D was compared to the total sample as shown in Appendix H. Compared to 
the total pediatric opioid exposures, the sample for Specific Aim 1D had a lower proportion of 
teenagers (14% vs. 27.9%) and more unintentional exposures (89.2% vs. 73.3%), less 
involvement of HCF care (39.3% vs. 63.2%), and a smaller proportion of exposures resulted 
in moderate-to-major outcomes (2.3% vs. 10.9%).   
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a, bindicates the final sample used for analyses of pediatric opioid exposures (Aims 1A and B) 
a*indicates the final sample used for analyses of pediatric opioid poisonings (Aim 1A) 
cindicates the final sample used for analyses of severity of pediatric opioid exposures (Aim 1C) 
dindicates the final sample used from the NPDS for area-level analyses of pediatric opioid 
exposures (Aim 1D) 
*Cases represent unique exposures and not unique patients.  
 
Figure 2: Sample flow chart for Specific Aim 1 
 
 
 
 
 
 
 
 
 
Reported closed cases of children <18 years with a suspected exposure to ≥1 opioid 
in NPDS from January 2010 to December 2014 (N = 84,954)* 
Excluded 1,536 (1.81%) cases that were later confirmed as non-exposure  
(N = 83,418)a, b  – Aims 1A and 1B 
Excluded 39,915 (47.85%) cases that did not result in a 
poisoning (n = 43,503)a*  – Aim 1A 
Excluded 19,373 (23.22%) cases with exposure to >1 product   
(n = 64,045)c  – Aim 1C 
Excluded 39,717 (47.61%) cases because exposure site and caller site were not 
one’s own residence (n = 43,701)d  – Aim 1D 
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Variables 
Clinical variables 
Opioids constituted the entire family of opioid-containing medicinal drugs including OTC and 
prescription opioid analgesics and opioid containing antidiarrheal and cough preparations. Opioids 
were identified using generic codes maintained by the AAPCC and comprised single substance 
opioids (or single-opioids), such as oxycodone, buprenorphine and hydrocodone, and combination 
opioids including combinations with acetaminophen (APAP), acetylsalicylic acid (ASA), and anti-
inflammatory drugs (NSAIDs), gastrointestinal agents (GI) and cough and cold products (CNC). 
Detailed list of all opioids can be found in Appendix A.  
Exposure comprised any suspected opioid exposure, while poisoning was operationalized as any 
opioid exposure that resulted in 1 or more clinical effect. Hence, every exposure to an opioid did 
not represent opioid poisoning but opioid poisonings were a subset of opioid exposures. Poisonings 
were identified using the medical outcome and clinical effects variables in the NPDS. Medical 
outcome is categorized in the NPDS as follows, 
▪ No effect was defined as no development of symptoms as a result of the exposure 
▪ Minor effect was defined as some minimally bothersome symptoms as a result of the exposure 
(e.g., drowsiness, nausea) 
▪ Moderate effect was for more pronounced, prolonged or systemic symptoms that required 
some treatment but was not life threatening (e.g., high fever, single seizure) 
▪ Major effect was any life-threatening symptoms which resulted in significant residual 
disability (e.g., cardiac arrest, respiratory depression) 
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▪ Death if the patient died due to an exposure 
▪ Not followed, judged as nontoxic exposures (clinical effects not expected) 
▪ Not followed, minimal clinical effects possible (no more than minor effect possible) 
▪ Unable to follow, judged as potentially toxic exposure 
▪ Unrelated effect, the exposure was probably not responsible for the effect(s) 
When medical outcome is observed and such data is obtained on the call at the PC, it is classified 
under none, minor, moderate, major effect, or death categories. However, when such information 
is not obtained during the initial or the follow-up call, outcome is recorded in one of the other four 
categories listed above, based on the SPI’s judgment of anticipated outcome. Further, information 
on specific clinical effects or symptoms is recorded in the NPDS as related, not related, or unknown 
if related. Information was combined from these two variables to identify poisonings: (1) Cases 
were reclassified as no outcome (‘no effect’, ‘not followed but judged as nontoxic’ or ‘unrelated 
effect’, and had no related clinical effects recorded), minor outcome (‘minor effect’ or ‘not 
followed but minimal clinical effects possible’), moderate outcome (‘moderate effect’), major 
outcome (‘major effect’) or death. Based on this grouping, medical outcome was unknown for 
about 8,843 (10.6%) of the total opioid exposures cases of which, 8,811 cases were ‘unable to be 
followed but judged as potentially toxic exposure’. (2) Poisonings were operationalized as those 
cases that had minor, moderate, major outcome or death (based on our outcome classification in 
(1) above), or those that had an unknown outcome but had one or more related clinical symptom.  
Additionally, related clinical symptoms were categorized under six system organ classes (SOC) 
including cardiovascular and lymphatic, ocular, gastrointestinal, neurological, respiratory, and 
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others (combined all others due to low number of cases), based on Medical Dictionary for 
Regulatory Activities (MedDRA) and the AAPCC symptoms classification.73 Symptoms related 
to an exposure were not recorded for 55,572 (66.62%) cases. The medical outcome variable 
described above was also used to identify severity (i.e., severe outcome) following an opioid 
exposure. Cases were operationalized as severe (moderate, major or death outcome) or non-severe 
(none or minor outcome). 
Other exposure related clinical variables were reason, route, chronicity and scenario of exposures, 
performed therapies and level of health care received following an exposure. AAPCC’s standard 
definitions were used for operationalizing these variables. The AAPCC defines reason for an 
exposure primarily based on the intent as intentional, unintentional, adverse reaction, or other. An 
exposure is classified as intentional “if a purposeful action resulted in an exposure” and included 
suspected suicidal, intentional abuse and misuse. An unintentional exposure results from an 
unforeseen event for instance, “a child gaining inappropriate access to an opioid without adult 
supervision and without realizing the danger of the action”, and it included general accidental 
exposure, therapeutic error, unintentional misuse or unintentional other. Exposure due to an 
adverse reaction was recorded “when unwanted effects develop with normal or recommended use 
of the product”. Exposure due to other reasons included tampering, malicious or withdrawal 
attempts.  
Recorded routes of exposures were categorized as ingestion or other route including inhalation, 
aspiration, dermal, ocular, otic, parenteral, rectal, or any other routes. Chronicity was classified as 
acute if any single, repeated or continuous exposure occurred over a period of 8 hours or less, and 
non-acute if it lasted more than 8 hours.  
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Scenarios related to opioid exposures were grouped as storage or access (for e.g., child resistant 
closures not secured), therapeutic error (for e.g., confused units of measure), others (for e.g., 
inhalation abuse) or unknown. Therapies were recorded in the NPDS as performed, recommended 
and performed, not performed, and recommended but not performed. Only therapies that were 
recorded as performed or recommended and performed were examined. Performed therapies were 
grouped under decontamination (e.g., charcoal use), therapeutic intervention (e.g., ventilator use) 
and naloxone (recommended antidote for opioid poisoning). Categorization of scenarios and 
performed therapies was similar to that adopted in the annual AAPCC reports and in past 
research.32,39 Exposure scenario was unknown or not recorded for 64,458 (70.27%) cases and 
performed therapies were not recorded for 50,698 (60.78%) cases.  
The AAPCC provides information on level of HCF used and management site. Data was combined 
from these two elements to identify the level of HCF involved.  Level of HCF was recorded in the 
NPDS as treated, evaluated and released (T/E & R), admitted for critical care, non-critical care or 
psychiatric care. For cases that were recorded as no HCF treatment received with management on 
site or other were reclassified as no HCF involved, while those with a record of no HCF treatment 
with unknown management site were reclassified as unknown. Cases wherein the patient refused 
referral or left against medical advice (AMA) were reclassified as other HCF involved, since they 
were either in (or en route to) a HCF, or were referred to a HCF. Additionally, there were 8 records 
of children aged less than 5 years that had a psychiatric care admission. After manual inspection, 
level of HCF was recoded as unknown for these 8 cases.  
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Sociodemographic variables 
As for sociodemographics, age was categorized into ≤5 (young children), 6 to 12 (middle-aged 
children), and 13 to 17 (teenagers) years groups. This age grouping is consistent with previous 
child developmental research.74,75 The AAPCC also provided information on child’s gender, 
exposure site and caller site, and the caller’s residential 5-digit ZIP Code and state. It was assumed 
that caller’s residential information represented patient’s residential location. This may be a 
reasonable assumption since over 90% of exposures occur at one’s own home, and are mostly 
reported by the patient’s (child’s) family member.32 Exposure and caller sites were identified as 
residence (own/other), HCF, school, or other which included public area, restaurant, workplace, 
or others. The operational definitions of the variables listed above were reviewed by the clinical 
expert on the team (Table 4). 
Table 4: NPDS variables considered for Specific Aim 1 
Clinical variables 
Exposures and Poisonings 
Opioid drug involveda 
Severity  
Medical 
outcome 
None 
Minor 
Moderate 
Major 
Death 
Related effects  
CVS/lymphatic 
Ocular 
GI 
Neurological 
Respiratory 
Others 
Reason   
Intentional 
Unintentional 
ADR 
Others  
Route 
Ingestion 
Others  
Chronicity 
Acute 
Non-acute 
Scenario 
Therapeutic 
error 
Storage/Access 
Others 
Performed therapy 
Decontamination 
Naloxone 
Others 
Level of HCF care  
None 
T/E & R 
Non-critical care  
Critical care 
Psychiatric care 
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Others 
Sociodemographic variables 
Age group 
(years) 
0-5 (0<1, 1-2, 
3-5) 
6-12 
13-17  
Gender 
 Male 
Female 
Exposure site 
Residence 
(own/other) 
School 
Other 
Caller site 
Own residence 
HCF 
Other 
5-digit ZIP 
Code  
and 
State 
aOpioids constituted all opioid-containing medicinal (prescription and OTC) drugs.  
CVS = Cardiovascular; GI = Gastrointestinal; ADR = Adverse drug reaction; HCF = Health 
care facility; T/E & R = Treated/evaluated and released. 
 
Area-level socioeconomic status (SES) variables 
For SES analyses at 5-digit ZIP Code level, the final sample obtained in the NPDS (n = 43,701) 
after applying the selection criteria, was aggregated at 5-digit ZIP Code level. This resulted in 
13,751 unique 5-digit ZIP Code areas that had one or more pediatric opioid exposures in the 5-
year study period. These data were merged to the 2010 Census 5-digit ZIP Code file. Areas that 
did not have corresponding Census information, or areas with total or persons under 18 years 
population of zero were excluded from further analyses. A total of 12,821 unique 5-digit ZIP Code 
areas was used in the final analyses (Specific Aim 1D).  
Census data on total population of adults, minority, males and females, different racial and ethnic 
groups were examined. Proportion of pediatric opioid exposures in a 5-digit ZIP Code area was 
calculated using the number of pediatric exposures reported in the NPDS and the total Census 
population of children (<18 years of age) in that area. Population of children in a 5-digit ZIP Code 
area was calculated from the total population and the total adult population in that area. Proportions 
of adults, minority, males and females in a 5-digit ZIP Code area were calculated using the total 
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area-level population, while the proportions of different race and ethnic groups were calculated 
using the total race base population denominator reported in the Census.                                       
Additionally, area-level household variables for median household income, average household and 
family size, and older adults population (>65 years of age) in households and family households, 
were also included. Proportions of older adults in households and family households in an area 
were calculated using the total population in households and family households in that area, 
respectively. For median household income, the variable was used as defined in the Census data. 
Area-level median household income data was missing for 12 observations or areas, and 11 of 
these observations had information on area-level per capita income. Median household income for 
these 11 areas was imputed using the corresponding per capita income. 
Statistical Analyses   
Prevalence rate of opioid exposures and poisonings was calculated using the number of cases 
reported in the NPDS and the United States Census Annual Estimates of the Resident Population 
by Single Year of Age and Sex for the United States: April 1, 2010 to July 1, 2014 file. Total 5-
year and annual prevalence rates were calculated for pediatric opioid exposures and poisonings. 
Annual prevalence rates were compared to study the trend of pediatric opioid exposures and 
poisonings. We further adjusted annual prevalence estimates of opioid exposures for the number 
of child exposure calls reported in the AAPCC Annual Report in the respective year. This approach 
was undertaken to account for differences in the annual number of exposures calls made to the 
PCs. Total (5-year) and annual case fatality rates were calculated using the number of cases of 
opioid exposures and number of deaths among these cases, reported in the NPDS.  
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Age specific prevalence rates of opioid exposures were computed to account for population level 
changes that may have affected the number of exposure cases reported to the PCs. We further 
examined prevalence by regrouping the young children (≤5 years age group) into 0 to <1 year 
(infants), 1 to 2 years (toddlers) and 3 to 5 years (preschoolers). This was done to examine if the 
prevalence of opioid exposures was different among infants and toddlers.  
Prevalence rates of opioid exposures were also calculated at state-level using the number of cases 
reported in NPDS for each state and the United States Census Annual Estimates of the Resident 
Population: April 1, 2010 to July 1, 2014 state-level file. A generalized linear mixed model 
(GLMM) using PROC GLIMMIX with Poisson distribution and log-link function was used to 
examine the statistical significance of the trend of pediatric opioid exposures, from 2010 to 2014, 
and the state-level differences. The log of population of children (<18 years of age) in the state for 
the respective year, was used as an offset in this model. In linear models, the error term is assumed 
to be independently and identically distributed with constant variance (i.i.d.). However, this 
assumption is violated in mixed models. Mixed effects model with fixed and random effects can 
be used when the dependent variable is correlated. For example, number of opioid exposures 
(dependent variable) may be correlated within a state (random-effect variable). Mixed effects 
allow the effect of the year of exposure (fixed-effect independent variable) to vary randomly by 
states. GLMMs are considered as an extension of generalized linear models (GLMs) by 
incorporating random effects or correlations in the data.76,77 SAS provides few procedure options 
for estimating such mixed models including PROC MIXED, PROC NLMIXED and PROC 
GLIMMIX. PROC MIXED is commonly used to model linear data whereas PROC NLMIXED 
models non-linear data, but it is reported to be programmatically complex. PROC GLIMMIX is a 
newer procedure and is used to model non-linear data.  
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Descriptive statistics (frequency, %, mean, SD) were calculated to describe the sociodemographic 
and clinical characteristics of children with opioid exposures. Separate analyses were done for 
children with any opioid exposure, those with one opioid product exposure and those with more 
than one product (at least one opioid) exposure. Chi-square tests were used to examine the 
association of various characteristics by age group and reason (or intent) of exposure. 
Bivariate analyses using Chi-square tests and multivariable analyses using logistic regression 
(PROC LOGISTIC) were performed to estimate the association between severity of opioid 
exposures and various sociodemographic, drug and clinical characteristics. These analyses were 
limited to cases with one opioid, either single or combination, exposure (64,045 cases). Bivariate 
analyses were exploratory and examined all sociodemographic, drug and clinical factors described 
above. The logistic regression model was intended to be parsimonious, hence predictor variables 
were chosen based on practical significance and knowledge from literature. These included age, 
gender, chronicity, reason, type of opioid (single or combination) and specific opioid drug 
(buprenorphine or methadone). Interaction terms were also tested in the model.  Roughly 2.7% 
cases had no information (unknown) recorded for age, gender, reason and chronicity. These 
observations were set as missing (i.e., excluded) in the logistic model analyses. 
Based on our initial operationalization of medical outcome and severity, about 11% cases had no 
data on severity (i.e., unknown outcome). These cases were excluded in the initial logistic model. 
Sensitivity analysis was performed to avoid biases due to missing data. Severity was recoded by 
reclassifying unknown outcome cases that were unable to be followed, but judged as potentially 
toxic exposure by the SPI, as severe cases (these cases were grouped as unknown and excluded in 
the initial model).  
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For SES analyses, 5-digit ZIP Code level pediatric opioid exposures data from the NPDS was 
merged with 2010 Census 5-digit ZIP Code data. Further, centroid information (latitude and 
longitude) for each of these 5-digit ZIP Code areas was obtained from SAS Maps. The final sample 
of 5-digit ZIP Code areas consisted of areas that had 1 or more pediatric opioid exposures from 
2010 to 2014 with exposure and caller site as one’s own residence, and had corresponding Census 
information. Univariate analyses were performed, and the top and bottom 1% of the values of each 
of the Census variables were examined to identify outliers. There were 12 observations or areas 
with the rate of opioid exposures in children greater than 1 (or proportion >100%). After manually 
inspecting, these observations were excluded from further analyses.  
Next, Spearman correlation tests were used to examine the unadjusted correlation between the 
proportion of pediatric opioid exposures in a 5-digit ZIP Code area and the corresponding SES 
variables. Covariates that were found to be significant and not highly multicollinear with other 
factors were chosen for adjusted analyses. Multicollinearity was assessed using a correlation 
matrix. Adjusted Poisson regression with log link function was performed initially to obtain the 
residuals for testing spatial autocorrelation as explained below. The log of population of children 
(<18 years of age) in an area was used as an offset in the Poisson model, since it represented the 
pediatric population at risk in a 5-digit ZIP Code area. 
Moran’s I test using PROC VARIOGRAM was then performed to examine the spatial 
autocorrelation in these data. Spatial autocorrelation is based on the premise that observations in 
closer locations are correlated, and this correlation decreases with increasing distance. Existence 
of spatial autocorrelation, if not accounted for, can distort the standard errors and mean estimates 
from the regression model. Moran’s I is a frequently used global test for detecting such spatial 
autocorrelation in continuous data. The Moran’s I index varies from -1 to +1, with zero indicating 
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no spatial autocorrelation. A positive test value denotes positive spatial autocorrelation and 
indicates clustering (i.e., similar observations are clustered), while a negative value denotes 
dispersion (i.e., dissimilar observations are clustered).   
Moran’s I tests the hypothesis (Ho) that there is zero spatial autocorrelation in the data. Hence, 
rejection of the null hypothesis (Z-score >|1.96| and p-value <.05) denotes that positive or negative 
(depending on the index value) spatial autocorrelation exist. Moran’s I was performed by varying 
the width of distance bins (from 1 to .01) on both the number of opioid exposures in a 5-digit ZIP 
Code area (dependent variable) and on the raw residuals obtained from an adjusted Poisson 
regression model described above (residual spatial autocorrelation).78,79  Multilevel model using 
GLMM (PROC GLIMMIX) was attempted to examine the association of number of pediatric 
opioid exposure and SES variables, adjusting for random effects at 5-digit ZIP Code level and 
accounting for any spatial autocorrelation in the data. The log of population of children (<18 years 
of age) in an area was used as an offset in this model.  
PROC GLIMMIX is an iterative procedure and due to large size of the ZIP Code level data, certain 
strategies had to be adopted to ensure the convergence of the statistical model. After attempting 
various strategies, the likelihood-based estimation method (METHOD = LAPLACE), instead of 
the default pseudo-likelihood, was used in combination with PARMS statement. PARMS assigns 
a starting value to the covariance parameter based on the value(s) specified by the programmer 
(instead of the default value). It is one of the recommended techniques for addressing convergence 
failures in mixed models. Values from 0.1 to 1 with increments of 0.1 were specified with the 
PARMS statement. When a set of initial values is supplied in the PARMS statement, PROC 
GLIMMIX performs a grid search and uses the best point on the grid for further analyses.80,81  
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All statistical tests were performed with a two-sided significance level of 0.05. All analyses were 
done in SAS version 9.4, Microsoft Excel 2013 and ArcGIS version 10.3.1. The study was 
approved under exempt status by the Virginia Commonwealth University Institutional Review 
Board (IRB) (ID: HM20004393). 
 
3.2: Results 
Aim 1A: To determine the prevalence of opioid exposures and poisonings in children  
There were a total of 83,418 pediatric opioid exposures over the 5-year period and nearly half of 
them (52.15%) resulted in poisoning. Total (5-year) prevalence rates of opioid exposures and 
opioid poisonings were 22.6 and 11.8 per 100,000 children, respectively. Total prevalence rates of 
opioid exposures and poisonings were higher among children under 6 years, especially those 1 to 
2 years of age. Total prevalence rate of opioid exposures was 42.4 per 100,000 children in ≤5 year 
olds, 6.1 per 100,000 children in 6 to 12 years and 22.2 per 100,000 children in 13 to 17 years. 
Total prevalence rate of opioid exposures among infants was found to be 25.6 per 100,000 children, 
among toddlers was 80.9 per 100,000 children, and among preschoolers was 22.6 per 100,000 
children (Figure 3).  
Total prevalence of pediatric opioid exposures varied by state. There was some clustering observed 
in the western states. Alabama, Arizona, Maine, New Mexico, Oklahoma, Oregon, South Dakota, 
Utah, West Virginia and Wyoming had a higher number of pediatric opioid exposures per 100,000, 
compared to other states (Figure 4). Total case fatality rate was 0.13%. It was higher among 13 to 
17 year olds (0.27%) compared to ≤5 year olds (0.08%) and 6 to 12 year olds (0.09%).  Annual 
case fatality rate did not vary much across years. 
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The annual prevalence rate of pediatric opioid exposures decreased from 25.5 to 20 per 100,000 
children from 2010 to 2014. Decline in the annual prevalence rate was greater among 1 to 2 year 
olds compared to other age groups (94.4 to 70.8 per 100,000 children from 2010 to 2014). The 
annual prevalence rate of pediatric opioid poisonings decreased from 13.1 to 10.7 per 100,000 
children from 2010 to 2014 (Figures 5 and 6). Decline in pediatric opioid exposures was found to 
be statistically significant. The overall mean number of pediatric opioid exposures decreased 
significantly from 2010 to 2014, after adjusting for random effects of states (28 to 22 per 100,000 
children respectively, p<.0001). There was a significant amount of variability in the rate of 
pediatric opioid exposures across states (Covariance parameter estimate = 0.077, p<.0001). There 
were statistically significant differences in the random effects by state in this adjusted model. The 
state-level relative rates (obtained from exponentiated state-level random effects) exhibited in 
Figure 8 help to examine which particular states had significant random effects (i.e., variability in 
pediatric opioid exposure rates) from 2010 to 2014. In addition to the states listed above, Arkansas, 
Delaware, Idaho, Indiana, Kentucky, Louisiana, Maryland, Missouri and Vermont had a 
significantly higher relative rate (Table 5, Figures 7 and 8). This indicates that after controlling for 
trend, there are certain state-level factors that may be associated with the number of pediatric 
opioid exposures. Residual analysis showed that the GLMM for trend fits the data well. Test for 
covariance parameters in the model was significant, indicating that random effects of states cannot 
be eliminated from the model (Chi-square = 5930.81, p<.0001). 
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Note: 364 cases with unknown age were included in total prevalence analyses. 
 
Figure 3: Prevalence of pediatric opioid exposures by age, 2010-2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Prevalence of pediatric opioid exposures by state, 2010-2014 (per 100,000 
children) 
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Figure 5: Annual prevalence of pediatric opioid exposures, 2010-2014 
 
 
Note: 364 cases with unknown age were included in total prevalence analyses (above). 
 
Figure 6: Age-specific annual prevalence of pediatric opioid exposures, 2010-2014 
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Table 5: Trend analysis of pediatric opioid exposures, 2010-2014 
Variable Estimate SE Mean per 100,000 
(95% CI) 
t-value  p-value  
Covariance parameter estimate   
Intercept  
(Subject = State)* 
0.077 0.016 -- --  
Solutions for fixed effects   
Intercept -8.181 0.040 -- -206.49 <.0001 
2010 (reference)a -- -- 28.0 (25.9 - 30.3) --  
2011a -0.071 0.011 26.1 (24.1 - 28.2) -6.72 <.0001 
2012a -0.114 0.011 25.0 (23.1 - 27.0) -10.72 <.0001 
2013a -0.201 0.011 22.9 (21.2 - 24.8) -18.39 <.0001 
2014a -0.242 0.011 22.0 (20.3 - 23.8) -21.94 <.0001 
 
*Z-value = 4.92; p<.0001. Generalized Chi-square/degrees of freedom = 1.36 indicates no 
overdispersion. aType III tests of fixed effects (year): F-value = 157.27, p<.0001. 
 
 
 
p<.0001. Least Square (LS) means with 95% CI.  
Figure 7: Trend analysis of pediatric opioid exposures, 2010-2014 
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Figure 8: Relative rate of pediatric opioid exposures by state, 2010-2014 
 
 
Aim 1B: To characterize pediatric opioid exposures based on sociodemographic and clinical 
characteristics 
Sociodemographic and clinical characteristics were examined for total number of reported cases 
of pediatric opioid exposures (83,418), one product (opioid) exposures (64,045), and more than 
one product (at least one opioid) exposures (19,373). Separate analyses were performed for cases 
with single-opioid exposures (31,775) and combination opioid exposures (32,270), within the 
category of one product exposures. The results are summarized in tables 6 and 7 as follows.  
Of the total 83,418 exposure cases identified, 61.1% were under 6 years of age and 27.9% were 
teenagers. The median age was 3 years. Over 90% of exposures occurred at home, involved 
ingestion, and were acute in nature. Nearly half of the total cases involved single-opioid exposures 
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(48.7%). The number of products involved in an exposure ranged from 1 to 36, while the number 
of opioids involved ranged from 1 to 5. About 73.4% of total opioid exposure cases were 
unintentional and 18.8% resulted from a therapeutic error. At least one related clinical effect was 
recorded in 33.4% of exposures, mainly neurological (25.8%), gastrointestinal (9.3%), cardiac 
(6.2%), ocular (3.8%), and respiratory (3.4%) effects. One-third (31.2%) of these exposure cases 
were treated in an ED and 20.2% were admitted for medical care, including psychiatric and critical 
care. Almost half of the total cases had a negative outcome following an opioid exposure of which 
22.1% had a moderate-to-major outcome (including death).  
Among one opioid product exposure cases, median age was lower among those exposed to single-
opioids compared to those exposed to combination opioids (2 vs. 3 years, respectively). Exposures 
in younger children had a higher involvement of single-opioids whereas exposures in teenagers 
had a higher involvement of combination opioids. Tramadol, oxycodone, buprenorphine and 
codeine were the most common single-opioid exposures while acetaminophen with hydrocodone, 
acetaminophen with oxycodone and acetaminophen with codeine were the most common 
combination-opioid exposures (Figure 9). 
Combination opioids were involved in a slightly higher number of intentional exposures compared 
to single-opioid exposures (16.6% vs. 13.0%, respectively). Related clinical effects were recorded 
for a higher proportion of single-opioid exposures compared to combination opioid exposures 
(33.1% vs. 21.3%), especially neurological (27.1% vs. 15.2%), ocular (5.1% vs. 1.1%) and 
respiratory (4.9% vs. 0.8%) effects, respectively. Poisonings (50.9% vs. 45.6%) and naloxone 
treatment (9.1% vs. 1.7%) were more common among cases with single-opioid exposures 
compared to combination-opioid exposures, respectively. Similarly, proportion of hospital 
admissions was higher among cases with single-opioid exposures (20% vs. 7.8%). Moderate-to-
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major outcomes were recorded for 11.1% and 3% of cases following a single-opioid and a 
combination opioid exposure, respectively.  
One-fourth of total exposure cases involved co-ingestants or multiple opioid and non-opioid 
products. More than one product (at least one of these products was an opioid) exposures were 
mostly among teenagers (median age = 14 years) and females (56.4%). Most of these cases were 
reported from a HCF (62.9%). Exposures to opioid combinations with APAP were most common 
(55.8%), followed by single-opioids (45.8%). Over half of these exposure cases were intentional 
(54.5%), and had at least one related clinical effect (54%). Nearly 75.3% were treated in the ED 
or admitted for medical care, 24.2% had moderate-to-major outcomes (including death), and 
65.1% of these exposures resulted in poisoning (Tables 6 and 7). 
Exposures were further examined by age group and reason (or intent) of exposure. Tables 8 and 9 
summarize sociodemographic and clinical characteristics of opioid exposures by age group. 
Opioid exposures commonly occurred in boys among the younger children (52.7% to 55.2%). 
However, they were more common among teenage girls (60.5%). Although majority of the 
exposures occurred at one’s own residence across all age groups, teenagers had a higher proportion 
of exposures at school compared to the younger children (3.5% vs. 0.1% to 1%). Exposures among 
younger children were mostly reported from one’s own residence (63% to 74.7%), while exposures 
among teenagers were mostly reported by a HCF (61.3%). About 48.8% of exposures among teens 
had more than one product involvement, 6.2% had more than one opioid involvement, 4.4% were 
through non-ingestion routes and 11% were non-acute. Single-opioid exposures were more 
common among children under 6 years of age, while exposure to opioid combinations with APAP 
were more common among teenagers.  
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Majority of exposures among young children were unintentional (98.7%). Over one-fifth of 
exposures in children under 6 years of age had one or more related effect recorded (21.5%), 35% 
were treated in an ED and 13.1% were admitted for medical care. About 41.2% of these exposures 
resulted in poisoning and 5.8% were treated with naloxone. On the contrary, nearly 81% of 
exposures in teenagers were intentional. At least one related clinical effect was recorded for 62.6% 
of opioid exposures in teenagers and about 69% were treated in the ED or admitted for medical 
care, particularly critical or psychiatric care. Nearly three-fourths of these exposures resulted in 
poisoning and 23.5% had a moderate-to-major outcome (including death). A total of 9.3% of 
opioid exposures in teenagers were treated with naloxone (Tables 8 and 9).  
Tables 10 and 11 summarize the sociodemographic and clinical characteristics of pediatric opioid 
exposures by reason (or intent). Intentional opioid exposures were more common among 
teenagers, whereas unintentional exposures were more common among children under 6 years of 
age. The sociodemographic and clinical characteristics associated with intentional and 
unintentional exposures were similar to those described above for exposures in teenagers and 
young children (≤5 years), respectively. Unintentional exposures mostly involved single-opioids 
(50.5%) and over two-fifths of these exposures were treated in the ED or admitted for medical care 
(43.2%). On the contrary, intentional exposures mostly involved opioid APAP combinations 
(57.3%), and nearly 77.4% of those involved in an intentional exposure were treated in the ED or 
admitted (Tables 10 and 11).
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Table 6: Sociodemographic characteristics of pediatric opioid exposures 
Characteristic, n (%) 
Total opioid 
exposures 
(N = 83,418) 
One opioid product exposures (n = 64,045) >1 opioid product 
exposuresb 
(n = 19,373) Single-opioid
a 
(n = 31,775) 
Combination opioida 
(n = 32,270 ) 
Age, years (range) 
Mean  
Median  
 
6.42  (0-17) 
    3  (0-17) 
 
4.72  (0-17) 
2  (0-17) 
 
5.67  (0-17) 
3  (0-17) 
 
10.44  (0-17) 
14  (0-17) 
Age group 
0 < 1  
1 - 2 
3 - 5 
6 - 12 
13 - 17 
Unknown (child) 
 
5,042  (6.04)c 
32,204  (38.61) 
13,744  (16.48) 
8,819  (10.57) 
23,245  (27.87) 
364  (0.44) 
 
2,388  (7.52) 
14,771  (46.49) 
5,994  (18.86) 
3,463  (10.9) 
4,982  (15.68) 
177  (0.56) 
 
2,163  (6.7) 
12,987  (40.24) 
6,052  (18.75) 
4,031  (12.49) 
6,912  (21.42) 
125  (0.39) 
 
491  (2.53) 
   4,446  (22.95) 
1,698  (8.76) 
1,325  (6.84) 
11,351  (58.59) 
62  (0.32) 
Gender 
Female 
Male 
Unknown 
 
42,022 (50.38) 
41,081 (49.25) 
315  (0.38) 
 
15,117  (47.58) 
16,505  (51.94) 
153  (0.48) 
 
15,973  (49.5) 
 16,183  (50.15) 
114  (0.35) 
 
10,932  (56.43) 
8,393  (43.32) 
48  (0.25) 
Exposure site 
Own residence 
Other residence 
School 
Other 
Unknown 
 
76,577  (91.80) 
3,518  (4.22) 
949  (1.14) 
1,131  (1.36) 
1,243  (1.49) 
 
29,057  (91.45) 
1,467  (4.62) 
325  (1.02) 
477  (1.5) 
 449  (1.41) 
 
30,110  (93.31) 
1,236  (3.83) 
 319  (0.99) 
 329  (1.02) 
 276  (0.86) 
 
17,410  (89.87) 
815  (4.21) 
305  (1.57) 
325  (1.68) 
518  (2.67) 
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Caller site 
Own residence 
HCF 
Other 
Unknown 
 
45,693  (54.78) 
29,749  (35.66) 
7,699  (9.23) 
277   (0.33) 
 
18,327  (57.68) 
10,148  (31.94) 
3,170  (9.98) 
130  (0.41) 
 
21,791  (67.53) 
7,415  (22.98) 
2,961  (9.18) 
 103  (0.32) 
 
 5,575  (28.78) 
     12,186  (62.9) 
1,568  (8.09) 
44  (0.23) 
 
aAnalyses within single opioid and combination opioid were limited to cases with one product (opioid) exposures.  
bAt least one of the products was an opioid. 
cNone of these children had scenario recorded as “exposure through breastmilk”.  
  
 
Table 7: Clinical characteristics of pediatric opioid exposures 
Characteristic, n (%) 
Total opioid 
exposures 
(N = 83,418) 
One opioid product exposures (n = 64,045) 
>1 Product exposuresb 
(n = 19,373) Single-opioida 
(n = 31,775) 
Combination opioida 
(n = 32,270 ) 
Opioid type involved 
Single substance 
APAP combinations 
CNC combinations 
Other combinations 
 
40,651  (48.73) 
37,472  (44.92) 
5,406  (6.48) 
1,028  (1.23) 
 
31,775  (100) 
-- 
-- 
-- 
 
-- 
26,657  (82.61) 
 4,825  (14.95) 
 788  (2.44) 
 
8,876  (45.82) 
10,815  (55.83) 
        581  (3) 
240  (1.24) 
No. of products b (range) 
Mean  
Median 
 
1.48  (1-36) 
1  (1-36) 
 
-- 
-- 
 
-- 
-- 
 
3.07  (2-36) 
2  (2-36) 
No. of opioid products (range) 
Mean  
Median 
 
1.03  (1-5) 
1  (1-5) 
 
-- 
-- 
 
-- 
-- 
 
1.03  (1-5) 
1  (1-5) 
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Route 
Ingestion 
Other 
Unknown 
 
82,322  (98.69) 
1,602  (1.92) 
375  (0.45) 
 
31,151  (98.04) 
541  (1.7) 
153  (0.48) 
 
32,089  (99.44) 
189  (0.59) 
37  (0.11) 
 
19,082  (98.5) 
872  (4.5) 
185  (0.95) 
Chronicity 
Acute 
Non-acute 
Unknown 
 
77,602  (93.03) 
4,609  (5.53) 
1,207  (1.45) 
 
30,389  (95.64) 
1,049  (3.3) 
  337  (1.06) 
 
30,255  (93.76) 
1,770  (5.48) 
 245  (0.76) 
 
16,958  (87.53) 
1,790  (9.24) 
625  (3.23) 
Reason 
Unintentional 
Intentional 
Adverse reaction 
Other 
Unknown 
 
61,206  (73.37) 
20,064  (24.05) 
1,088  (1.3) 
227  (0.27) 
833  (1) 
 
26,925  (84.74) 
4,143  (13.04) 
223  (0.7) 
132  (0.42) 
352  (1.11) 
 
26,137  (80.99) 
5,361  (16.61) 
495  (1.53) 
 36  (0.11) 
241  (0.75) 
 
8,144  (42.04) 
10,560  (54.51) 
370  (1.91) 
59  (0.3) 
240  (1.24) 
Scenario 
Therapeutic error 
Storage/Access 
Other 
Unknown 
 
15,666  (18.78) 
2,917  (3.5) 
778  (0.93) 
64,458  (77.27) 
 
6,258  (19.69) 
1,282  (4.03) 
342  (1.08) 
24,086  (75.8) 
 
 7,676  (23.79) 
1,248  (3.87) 
 267  (0.83) 
23,237  (72.01) 
 
1,732  (8.94) 
387  (2) 
169 (0.87) 
17,135  (88.45) 
Related effect 
Any 
Neurological 
Gastrointestinal 
Cardiovascular 
Ocular 
Respiratory 
Other 
 
27,846  (33.38) 
21,544  (25.83) 
7,751  (9.29) 
5,136  (6.16) 
3,126  (3.75) 
2,863  (3.43) 
4,275  (5.12) 
 
10,527  (33.13) 
8,601  (27.07) 
2,793  (8.79) 
1,169  (3.68) 
1,625  (5.11) 
1,563  (4.92) 
1,461  (4.6) 
 
6,868  (21.28) 
4,911  (15.22) 
2,137  (6.62) 
443  (1.37) 
357  (1.11) 
243  (0.75) 
904  (2.8) 
 
10,451  (53.95) 
8,032  (41.46) 
2,821  (14.56) 
3,524  (18.19) 
1,144  (5.91) 
1,057  (5.46) 
1,910  (9.86) 
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Performed therapy 
Decontamination 
Naloxone 
Other therapy 
 
19,571  (23.46) 
5,300  (6.35) 
14,591  (17.49) 
 
7,247  (22.81) 
2,884  (9.08) 
4,831  (15.2) 
 
8,162  (25.29) 
549  (1.7) 
2,807  (8.7) 
 
4,162  (21.48) 
1,867  (9.64) 
6,953  (35.89) 
HCF 
None 
T/E and R 
Critical care 
Non-critical care 
Psychiatric care 
Other 
Unknown 
 
30,093  (36.07) 
25,983  (31.15) 
7,097  (8.51) 
6,122  (7.34) 
3,658  (4.39) 
9,836  (11.79) 
629  (0.75) 
 
10,830  (34.08) 
10,089  (31.75) 
3,012  (9.48) 
2,869  (9.03) 
 459  (1.44) 
4,259  (13.4) 
 257  (0.81) 
 
16,114  (49.93) 
9,316  (28.87) 
662  (2.05) 
895  (2.77) 
975  (3.02) 
4,021  (12.46) 
287  (0.89) 
 
3,149  (16.25) 
6,578  (33.95) 
3,423  (17.67) 
2,358  (12.17) 
2,224  (11.48) 
        1,556  (8.03) 
85  (0.44) 
Outcome 
No effect 
Minor 
Moderate 
Major 
Death 
Unknown 
 
32,944  (39.49) 
32,443  (38.89) 
7,709  (9.24) 
1,368  (1.64) 
111  (0.13) 
8,843  (10.6) 
 
12,478  (39.27) 
11,820  (37.2) 
2,900  (9.13) 
581  (1.83) 
46  (0.14) 
3,950  (12.43) 
 
14,599  (45.24) 
13,120  (40.66) 
888  (2.75) 
81  (0.25) 
7  (0.02) 
3,575  (11.08) 
 
5,867  (30.28) 
7,503  (38.73) 
3,921  (20.24) 
706  (3.64) 
58  (0.3) 
    1,318  (6.8) 
Poisoning 43,503  (52.15) 16,180  (50.92) 14,714  (45.60) 12,609  (65.09) 
 
APAP = Acetaminophen, CNC = Cough and cold products, T/E and R = Treated/evaluated and released, HCF = Healthcare facility.  
aAnalyses within single opioid and combination opioid were limited to cases with one product (opioid) exposures.  
bAt least one of the products was an opioid. 
Other opioid combinations include combinations with acetylsalicylic acid (ASA), nonsteroidal anti-inflammatory drugs (NSAIDs), 
and gastrointestinal agents (GI). 
There can be more than 1 opioid type involved, route, scenario, clinical effect and therapies recorded hence, the sub-categories under 
each of these variables are not mutually exclusive. Also, scenarios, related effect and performed therapy are missing for 60-70% of 
cases. 
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APAP = acetaminophen; PPA = phenylpropanolamine; D = Decongestant; w/o = without. 
 
Figure 9: Opioids commonly involved in pediatric exposures 
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Table 8: Sociodemographic characteristics of pediatric opioid exposures by age 
Characteristic, n (%) 
Age Group 
≤5 years a  
(n = 51,072) 
6 to 12 years 
(n = 8,819) 
13 to 17 years 
(n = 23,245) 
Gender* 
Female 
Male 
Unknown 
 
23,919  (46.83) 
26,935  (52.74) 
218  (0.43) 
 
3,933  (44.60) 
4,866  (55.18) 
20  (0.23) 
 
14,056  (60.47) 
9,159  (39.40) 
30  (0.13) 
Exposure site* 
Own residence 
Other residence 
School 
Other 
Unknown 
 
47,578  (93.16) 
2,660  (5.21) 
50  (0.10) 
543  (1.06) 
241  (0.47) 
 
8,253  (93.58) 
290  (3.29) 
89  (1.01) 
130  (1.47) 
57  (0.65) 
 
20,510  (88.23) 
552  (2.37) 
805  (3.46) 
452  (1.94) 
926  (3.98) 
Caller site* 
Own residence 
HCF 
Other 
Unknown 
 
32,192  (63.03) 
14,025  (27.46) 
4,728  (9.26) 
127  (0.25) 
 
6,584  (74.66) 
1,449  (16.43) 
755  (8.56) 
31  (0.35) 
 
6,725  (28.93) 
14,246  (61.29) 
2,167  (9.32) 
107  (0.46) 
 
*Chi-square p<.05.  Unknown age group not shown here.  
Unknown category for characteristics was included in Chi-square tests. 
aNumber of opioid exposures in ≤5 in Tables 6 and 10 do not add up to the number in this table. 
Exposures recorded as unknown age but ≤5 years in the NPDS were added to the ≤5 years 
subgroup here, but these exposures were set as unknown for analyses in other tables.  
 
Table 9: Clinical characteristics of pediatric opioid exposures by age 
Characteristic, n (%) 
Age Group 
≤5 yearsa 
(n = 51,072) 
6 to 12 years 
(n = 8,819) 
13 to 17 years 
(n = 23,245) 
Opioid type involved* 
Single substance 
APAP combinations 
CNC combinations 
Other combinations 
 
26,752  (52.38) 
20,544  (40.23) 
3,442  (6.74) 
695  (1.36) 
 
3,970  (45.02) 
3,564  (40.41) 
1,235  (14.00) 
99  (1.12) 
 
9,765  (42.01) 
13,249  (57.00) 
724  (3.11) 
230  (0.99) 
No. of products* 
1  
≥2 
 
44,431  (87.00) 
6,641  (13.00) 
 
7,494  (84.98) 
1,325  (15.02) 
 
11,894  (51.17) 
11,351  (48.83) 
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No. of opioid products*  
1  
≥2 
 
50,322  (98.53) 
750  (1.47) 
 
8,708  (98.74) 
111  (1.26) 
 
21,796  (93.77) 
1,449  (6.23) 
Route* 
Ingestion 
Other 
Unknown 
 
50,599  (99.07) 
447  (0.88) 
161  (0.32) 
 
8,708  (98.74) 
126  (1.43) 
23  (0.26) 
 
22,742  (97.84) 
1,017  (4.38) 
188  (0.81) 
Chronicity* 
Acute 
Non-acute 
Unknown 
 
49,646  (97.21) 
1,285  (2.52) 
141  (0.28) 
 
8,018   (90.92) 
738   (8.37) 
63     (0.71) 
 
19,702  (84.76) 
2,561  (11.02) 
982  (4.22) 
Reason* 
Unintentional 
Intentionalb 
Adverse reaction 
Other 
Unknown 
 
50,390  (98.66) 
118  (0.23) 
253  (0.50) 
127  (0.25) 
184  (0.36) 
 
7,283  (82.58) 
1,035  (11.74) 
258  (2.93) 
23  (0.26) 
220  (2.49) 
 
3,361  (14.46) 
18,829  (81.00) 
560  (2.41) 
74  (0.32) 
421  (1.81) 
Scenario* 
Therapeutic error 
Storage/Access 
Other 
Unknown 
 
7,904  (15.48) 
2,766  (5.42) 
604  (1.18) 
40,112  (78.54) 
 
5,295  (60.04) 
108  (1.22) 
71  (0.81) 
3,393 (38.47) 
 
2,436  (10.48) 
29  (0.12) 
91  (0.39) 
20,718  (89.13) 
Related effect* 
Any 
Neurological 
Gastrointestinal 
Cardiovascular 
Ocular 
Respiratory 
Other 
 
10,975  (21.49) 
9,069  (17.76) 
2,450  (4.80) 
827  (1.62) 
1,751  (3.43) 
1,534  (3.00) 
1,370  (2.68) 
 
2,271  (25.75) 
1,719  (19.49) 
708  (8.03) 
232  (2.63) 
153  (1.73) 
111  (1.26) 
354  (4.01) 
 
14,546  (62.58) 
10,722  (46.13) 
4,577  (19.69) 
4,075  (17.53) 
1,220  (5.25) 
1,216  (5.23) 
2,539  (10.92) 
Performed therapy* 
Decontamination 
Naloxone 
Other therapy 
 
13,633  (26.69) 
2,939  (5.75) 
5,225  (10.23) 
 
2,042  (23.15) 
188  (2.13) 
892  (10.11) 
 
3,883  (16.70) 
2,171  (9.34) 
8,462  (36.40) 
HCF* 
None 
T/E and R 
Critical care 
Non-critical care 
Psychiatric care 
Other 
 
20,541  (40.22) 
17,888  (35.03) 
3,257  (6.38) 
3,415  (6.69) 
--         
5,635  (11.03) 
 
5,595  (63.44) 
1,539  (17.45) 
283  (3.21) 
315  (3.57) 
105  (1.19) 
899  (10.19) 
 
3,871  (16.65) 
6,538  (28.13) 
3,551  (15.28) 
2,392  (10.29) 
3,550  (15.27) 
3,154  (13.57) 
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Unknown 336  (0.66) 83  (0.94) 189  (0.81) 
Outcome* 
None 
Minor 
Moderate 
Major 
Death 
Unknown 
 
25,441  (49.81) 
17,188  (33.65) 
2,727  (5.34) 
499  (0.98) 
40  (0.08) 
5,177  (10.14) 
 
2,926  (33.18) 
4,651  (52.74) 
376  (4.26) 
63  (0.71) 
8  (0.09) 
795  (9.01) 
 
4,532  (19.50) 
10,536  (45.33) 
4,601  (19.79) 
805  (3.46) 
63  (0.27) 
2,708  (11.65) 
Poisoning* 21,037  (41.19) 5,237  (59.38) 17,128  (73.68) 
 
*Chi-square p<.05.  Unknown age group not shown here. 
aNumber of opioid exposures in ≤5 in Tables 6 and 10 do not add up to the number in this table. 
Exposures recorded as unknown age but ≤5 years in the NPDS were added to the ≤5 years 
subgroup here, but these exposures were set as unknown for analyses in other tables.  
bChildren ≤5 years can be coded as intentional if someone intentionally gave the child a wrong 
drug or dose. 
Unknown category for characteristics was included in Chi-square tests. 
APAP = Acetaminophen, CNC = Cough and cold products, T/E and R = Treated/evaluated and 
released, HCF = Healthcare facility.   
Other opioid combinations include combinations with acetylsalicylic (ASA), nonsteroidal anti-
inflammatory drugs (NSAIDs), and gastrointestinal agents (GI). 
There can be more than 1 opioid type involved, route, scenario, clinical effect and therapies 
recorded hence, the sub-categories under each of these variables are not mutually exclusive. 
 
 
Table 10: Sociodemographic characteristics of pediatric opioid exposures by intent 
Characteristic, n (%) 
Intent of exposure 
Unintentional 
(n = 61,206) 
Intentional 
(n = 20,064) 
Age group* 
0 < 1  
1 - 2 
3 - 5 
6 - 12 
13 - 17 
Unknown (child) 
 
4,800   (7.84) 
31,978  (52.25) 
13,534  (22.11) 
7,283  (11.90) 
3,361  (5.49) 
250  (0.41) 
 
17  (0.08) 
59  (0.29) 
41  (0.20) 
1,035  (5.16) 
18,829  (93.84) 
83  (0.41) 
Gender* 
Female 
Male 
Unknown 
 
28,653  (46.81) 
32,296  (52.77) 
257  (0.42) 
 
12,290  (61.25) 
7,745  (38.60) 
29  (0.14) 
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Exposure site* 
Own residence 
Other residence 
School 
Other 
Unknown 
 
57,285  (93.59) 
2,910  (4.75) 
138  (0.23) 
641  (1.05) 
232  (0.38) 
 
17,546  (87.45) 
540  (2.69) 
768  ( 3.83) 
356  (1.77) 
854  (4.26) 
Caller site* 
Own residence 
HCF 
Other 
Unknown 
 
40,331  (65.89) 
15,117  (24.70) 
5,604  (9.16) 
154  (0.25) 
 
4,265  (21.26) 
13,822  (68.89) 
1,888  (9.41) 
 89  (0.44) 
 
*Chi-square p<.05.  Exposures due to adverse reaction, others reasons or unknown shown here. 
Unknown category for characteristics was included in Chi-square tests. 
 
 
Table 11: Clinical characteristics of pediatric opioid exposures by intent 
Characteristic, n (%) 
Intent of exposure   
Unintentional 
(n = 61,206) 
Intentional 
(n = 20,064) 
Opioid type involved* 
Single substance 
APAP combinations 
CNC combinations 
Other combinations 
 
30,936  (50.54) 
25,003  (40.85) 
4,866  (7.95) 
812  (1.33) 
 
8,635  (43.04) 
11,493  (57.28) 
441  (2.20) 
194  (0.97) 
No. of products* 
1  
≥2 
 
53,062  (86.69) 
8,144  (13.31) 
 
9,504  (47.37) 
10,560  (52.63) 
No. of opioid products*  
1  
≥2 
 
60,334  (98.58) 
872  (1.42) 
 
18,699  (93.20) 
1,365  (6.80) 
Route* 
Ingestion 
Other 
Unknown 
 
60,746  (99.25) 
486  (0.79) 
126  (0.21) 
 
19,636  (97.87) 
939  (4.68) 
155  (0.77) 
Chronicity* 
Acute 
Non-acute 
Unknown 
 
58,817  (96.10) 
2,274  (3.72) 
115  (0.19) 
 
17,203  (85.74) 
1,954  (9.74) 
907  (4.52) 
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Scenario* 
Therapeutic error 
Storage/Access 
Other 
Unknown 
 
15,649  (25.57) 
2,902  (4.74) 
695  (1.14) 
42,359  (69.21) 
 
4  (0.02) 
10  (0.05) 
71  (0.35) 
19,979  (99.58) 
Related effect* 
Any 
Neurological 
Gastrointestinal 
Cardiovascular 
Ocular 
Respiratory 
Other 
 
13,302  (21.73) 
10,823  (17.68) 
3,320  (5.42) 
894  (1.46) 
1,813  (2.96) 
1,511  (2.47) 
1,642  (2.68) 
 
13,310  (66.34) 
9,924  (49.46) 
4,085  (20.36) 
4,053  (20.20) 
1,208  (6.02) 
1,192  (5.94) 
2,232  (11.12) 
Performed therapy* 
Decontamination 
Naloxone 
Other therapy 
 
16,121  (26.34) 
2,972  (4.86) 
5,852  (9.56) 
 
3,263  (16.26) 
2,160  (10.77) 
8,140  (40.57) 
HCF* 
None 
T/E and R 
Critical care 
Non-critical care 
Psychiatric care 
Other 
Unknown 
 
27,802  (45.42) 
19,473  (31.82) 
3,315  (5.42) 
3,564  (5.82) 
 83  (0.14) 
6,539  (10.68) 
430  (0.70) 
 
1,529  (7.62) 
6,116  (30.48) 
3,537  (17.63) 
2,329  (11.61) 
3,543  (17.66) 
2,880  (14.35) 
130  (0.65) 
Outcome* 
None 
Minor 
Moderate 
Major 
Death 
Unknown 
 
28,819  (47.09) 
22,945  (37.49) 
2,960  (4.84) 
485  (0.79) 
22  (0.04) 
5,975  (9.76) 
 
3,813  (19.00) 
8,485  (42.29) 
4,409  (21.97) 
786  (3.92) 
61  (0.30) 
2,510  (12.51) 
Poisoning* 27,137  (44.34) 14,749  (73.51) 
 
*Chi-square p<.05.  Exposures due to adverse reaction, others reasons or unknown shown here. 
Unknown category for characteristics was included in Chi-square tests. 
APAP = Acetaminophen, CNC = Cough and cold products, T/E and R = Treated/evaluated and 
released, HCF = Healthcare facility.   
Other opioid combinations include combinations with acetylsalicylic acid (ASA), nonsteroidal 
anti-inflammatory drugs (NSAIDs), and gastrointestinal agents (GI). 
There can be more than 1 opioid type involved, route, scenario, clinical effect and therapies 
recorded. Hence, the sub-categories under each of these variables are not mutually exclusive. 
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Aim 1C: To examine the factors associated with severity of opioid exposures in children 
Bivariate and multivariable analyses were performed to examine the sociodemographic, drug and 
clinical characteristics associated with severity (i.e., severe medical outcome) following an opioid 
exposure. These analyses were limited to cases with one opioid exposure, either single or 
combination. Of the total 64,045 cases, 7% had a severe outcome. All factors, except gender, were 
found to be statistically significant in the bivariate analyses. Table 12 summarizes the results from 
bivariate analyses. Compared to those with non-severe outcomes, cases with severe outcomes were 
more likely to be older (37.9% vs. 15.8%) and have a single-opioid (78.3% vs. 46.7%), especially 
buprenorphine (21.7% vs. 5.7%) or methadone (10.9% vs. 1.8%) involved in an exposure. Nearly 
34.6% of severe cases were intentional, 96.8% had at least one related clinical effect, largely 
neurological (83.7%) or respiratory effects (37%), and were commonly treated with naloxone 
(45.8%). Majority of cases with severe outcomes following an opioid exposure were either treated 
in the ED or admitted for medical care, especially for critical care (94.1%) (Table 12).  
Table 12: Characteristics associated with severe pediatric opioid exposures (bivariate 
analyses) 
Characteristics, n (%) 
Totala 
(N = 64,045 ) 
Non-severe 
outcome 
(n = 52,017) 
Severe outcome 
(n = 4,503) 
Sociodemographic 
Age group* 
0 ≤ 5 
6 ≤ 12 
13 ≤ 17 
Unknown 
 
44,431  (69.37) 
7,494  (11.7) 
11,894  (18.57) 
226  (0.35) 
 
37,161  (71.44) 
6,531  (12.56) 
8,240  (15.84) 
85  (0.16) 
 
2,555  (56.74) 
236  (5.24) 
1,708  (37.93) 
4  (0.09) 
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Gender 
Female 
Male 
Unknown 
 
31,090  (48.54) 
32,688  (51.04) 
267  (0.42) 
 
25,414  (48.86) 
26,509  (50.96) 
94  (0.18) 
 
2,184  (48.50) 
2,308  (51.25) 
11  (0.24) 
Exposure site* 
Own residence 
Other residence 
School 
Other 
Unknown 
 
59,167  (92.38) 
2,703  (4.22) 
644  (1.01) 
806  (1.26) 
725  (1.13) 
 
48,512  (93.26) 
2,105  (4.05) 
474  (0.91) 
599  (1.15) 
327  (0.63) 
 
4,042  (89.76) 
157  (3.49) 
77  (1.71) 
96  (2.13) 
131  (2.91) 
Caller site* 
Own residence 
HCF 
Other 
Unknown 
 
40,118  (62.64) 
17,563  (27.42) 
6,131  (9.57) 
233  (0.36) 
 
33,686  (64.76) 
13,615  (26.17) 
4,640  (8.92) 
76  (0.15) 
 
841  (18.68) 
3,258  (72.35) 
395  (8.77) 
9  (0.20) 
Drug 
Combination opioid*b 32,270  (50.39) 27,719  (53.29) 976  (21.67) 
Opioid type involved* 
Single-substance 
APAP combination 
CNC combination 
Other combination 
 
31,775  (49.61) 
26,657  (41.62) 
4,825  (7.53) 
788  (1.23) 
 
24,298  (46.71) 
22,603  (43.45) 
4,485  (8.62) 
631  (1.21) 
 
3,527  (78.33) 
809  (17.97) 
119  (2.64) 
48  (1.07) 
Buprenorphine* 4,602  (7.19) 2,982  (5.73) 977  (21.70) 
Methadone* 1,715  (2.68) 937  (1.80) 492  (10.93) 
Hydrocodone* 1,559  (2.43) 1,319  (2.54) 47  (1.04) 
Oxycodone* 4,722  (7.37) 3,379  (6.50) 445  (9.88) 
Tramadol* 9,175  (14.33) 7,649  (14.70) 683  (15.17) 
Clinical 
Route* 
Ingestion 
Other 
Unknown 
 
63,240  (98.74) 
730  (1.14) 
190  (0.3) 
 
51,486  (98.98) 
531  (1.02) 
80  (0.15) 
 
4,353  (96.67) 
105  (2.33) 
69  (1.53) 
Chronicity* 
Acute 
Non-acute 
Unknown 
 
60,644  (94.69) 
2,819  (4.4) 
582  (0.91) 
 
49,420  (95.01) 
2,311  (4.44) 
246  (0.47) 
 
4,109  (91.25) 
269  (5.97) 
125  (2.78) 
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Reason* 
Unintentional 
Intentional 
Adverse reaction 
Other 
Unknown 
 
53,062  (82.85) 
9,504  (14.84) 
718  (1.12) 
168  (0.26) 
593  (0.93) 
 
44,936  (86.39) 
6,167  (11.86) 
564  (1.08) 
98  (0.19) 
252  (0.48) 
 
2,691  (59.76) 
1,560  (34.64) 
80  (1.78) 
47  (1.04) 
125  (2.78) 
Scenario* 
Therapeutic error 
Storage/Access 
Other 
Unknown 
 
13,934  (21.76) 
2,530  (3.95) 
609  (0.95) 
47,323  (73.89) 
 
13,132  (25.25) 
2,114  (4.06) 
509  (0.98) 
36,549  (70.26) 
 
276  (6.13) 
149  (3.31) 
38  (0.84) 
4,071  (90.41) 
Related effect* 
Any 
Neurological 
Gastrointestinal 
Cardiovascular 
Ocular 
Respiratory 
Other 
 
17,395  (27.16) 
13,512  (21.1) 
4,930  (7.7) 
1,612  (2.52) 
1,982  (3.09) 
1,806  (2.82) 
2,365  (3.69) 
 
11,585  (22.27) 
8,708  (16.74) 
3,504  (6.74) 
373  (0.72) 
919  (1.77) 
90  (0.17) 
1,269  (2.44) 
 
4,359  (96.80) 
3,770  (83.72) 
1,020  (22.65) 
1,184  (26.29) 
1,000  (22.21) 
1,664  (36.95) 
878  (19.50) 
Performed therapy* 
Decontamination 
Naloxone 
Other therapy 
 
15,409  (24.06) 
3,433  (5.36) 
7,638  (11.93) 
 
14,346  (27.58) 
1,336  (2.57) 
4,699  (9.03) 
 
628  (13.95) 
2,060  (45.75) 
2,706  (60.09) 
HCF* 
None 
T/E and R 
Critical care 
Non-critical care 
Psychiatric care 
Other 
Unknown 
 
26,944  (42.07) 
19,405  (30.3) 
3,674  (5.74) 
3,764  (5.88) 
1,434  (2.24) 
8,280  (12.93) 
544  (0.85) 
 
26,219  (50.40) 
18,035  (34.67) 
1,749  (3.36) 
2,675  (5.14) 
1,225  (2.35) 
1,928  (3.71) 
186  (0.36) 
 
135  (3.00) 
1,127  (25.03) 
1,869  (41.51) 
1,036  (23.01) 
203  (4.51) 
127  (2.82) 
6  (0.13) 
 
*Chi-square p<.05. HCF = Health care facility; T/E and R = Treated, evaluated and released.  
aNumbers in severe and non-severe outcome columns do not add up to the total since severity 
was unknown (i.e., unknown medical outcome) for 7,525 (11.8%) of the cases. 
bCombination opioid indicated if the child was exposed to one of the combination opioid 
products or a single-opioid product.   
 
 
As stated earlier, covariates for the adjusted regression model of severity following an opioid 
exposure were chosen based on practical significance and prior knowledge. These included age, 
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gender, chronicity, reason, type of opioid (single or combination) and specific opioid drug. 
Previous literature has shown differences in drug exposures in children by age and gender, 
chronicity, reason of exposure and characteristics of the drug involved. Drug characteristics in the 
current adjusted model were limited to the type of opioid drug involved (single or combination), 
and involvement of buprenorphine or methadone since these two agents have been associated with 
severe or fatal outcomes following an exposure in children (refer to Literature Review chapter).  
Table 13 summarizes the results from adjusted analyses of severity of pediatric opioid exposures 
and poisonings. All covariates were found to be significantly associated with severity in the initial 
adjusted model. However, this model exhibited poor fit (Hosmer and Lemeshow test: Chi-square 
= 66.01, p-value <.0001). Different models, with inclusion and exclusion of the interaction terms 
of age and reason with various predictors, were then compared based on the log-likelihood (-2 Log 
L) and Akaike Information Criterion (AIC) model fit statistics. The model with the best fit was 
selected for the final results. The final model included all the covariates listed above and the 
interaction terms of age x type of opioid, age x buprenorphine, age x methadone, age x reason and 
age x chronicity.  
Holding other variables constant, older age, non-accidental intent (i.e., intentional exposure or 
exposure resulting from an adverse reaction), involvement of a single-substance opioid and 
presence of buprenorphine or methadone were significantly associated with severity following 
pediatric opioid exposures. Among unintentional and non-acute exposures involving combination 
opioids, non-buprenorphine or non-methadone opioids, exposures involving children aged 6 to 12 
years and 13 to 17 years were 1.72 (95% CI = 1.02 - 2.91) times and 2.34 (95% CI = 1.57 - 3.48) 
times more likely to be severe compared to those involving children under 6 years of age. Other 
things constant, males had 15% (95% CI = 8% - 23%) higher odds of a severe opioid exposure 
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compared to females. Among exposures involving children under 6 years of age, intentional 
exposures or adverse reactions were 2.66 (95% CI = 1.29 - 5.47) to 4.25 (95% CI = 2.63 - 6.86) 
times more likely to be severe than unintentional exposures.  Exposures to single-opioids were 
4.34 (95% CI = 3.79 - 4.96) times more likely to be severe than exposures to combination opioids 
among children under 6 years of age. Similarly, exposures to buprenorphine or methadone 
involving young children were 5.15 (95% CI = 4.66 - 5.69) to 6.44 (95% CI = 5.54 -7.48) times 
more likely to be severe.  
Association of these factors with severity varied by age. The odds of a severe outcome following 
single-opioid exposures were not significantly different in children 6 to 12 years of age compared 
to the young children. However, single-opioid exposures among teenagers had 1.5 (95% CI = 1.02 
- 2.21) times higher odds of severity compared to exposures among children less than 6 years of 
age. Buprenorphine exposures were 62% (95% CI = 33% - 78%) less likely to be severe in 
teenagers compared to children under 6 years. Severity for methadone exposures was not 
significantly different among teenagers compared to the young children. However, exposures 
involving methadone were 2.51 (95% CI = 1.18 - 5.34) times more likely to be severe in children 
6 to 12 years of age compared to their younger counterparts. Exposures involving teenagers had 
4.02 (95% CI = 1.81 - 8.93) times higher odds of a severe outcome following an intentional 
exposure while exposures among children 6 to 12 years of age had 4.48 (95% CI = 2.17 - 9.27) 
times higher odds of severity following an adverse reaction, compared to exposures in children 
under 6 years. The odds of a severe outcome following an adverse reaction exposure were not 
significantly different among teenagers compared to the young children. Lastly, exposures among 
teenagers had 2.24 (95% CI = 1.78 - 2.83) times higher odds of a severe outcome after an acute 
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opioid exposure than exposures in children under 6 years. These odds were not significantly 
different for exposures involving 6 to 12 year olds compared those in young children (Table 13).  
Goodness-of-fit test, model fit statistics and residual analysis showed that the model fits the data 
well. Three observations were found to be highly influential. The logistic regression model was 
rerun after removing these influential points and the results did not change much. These 
observations were included in the final analyses. As part of the sensitivity analysis, adjusted 
analyses were performed after imputing the response variable (severity) as described in methods. 
In this logistic regression model, older age was no longer associated with severity however, acute 
exposures were found to be associated with higher odds of severity.  
Table 13: Characteristics associated with severe pediatric opioid exposures (multivariable 
analyses) 
Characteristic   
(N = 64, 045)a 
Estimate 
(β) 
SE AOR (95% CI) 
Chi-
square 
p-value 
Intercept* -4.207 0.159 -- 703.02 <.0001 
Age group (years)* 
≤ 5 
 6-12  
13-17  
 
-- 
0.544 
0.849 
 
-- 
0.267 
0.204 
 
-- 
1.72  (1.02 - 2.91) 
2.34  (1.57 - 3.48) 
 
-- 
4.16 
17.41 
 
-- 
0.0413 
<.0001 
Gender* 
Female 
Male 
 
-- 
0.140 
 
-- 
0.034 
 
-- 
1.15  (1.08 - 1.23) 
 
-- 
16.54 
 
-- 
<.0001 
Chronicity  
Non-acute 
Acute 
 
-- 
-0.083 
 
-- 
0.150 
 
-- 
0.92  (0.69 - 1.24) 
 
-- 
0.30 
 
-- 
0.5833 
Reason* 
Unintentional  
Intentional  
ADR  
Other  
 
-- 
0.976 
1.446 
1.348 
 
-- 
0.369 
0.245 
0.280 
 
-- 
2.66  (1.29 - 5.47) 
4.25  (2.63 - 6.86) 
3.85  (2.23 - 6.66) 
 
-- 
7.00 
34.83 
23.27 
 
-- 
0.0081 
<.0001 
<.0001 
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Type of opioid* 
Combination opioid 
Single 
 
-- 
1.467 
 
-- 
0.068 
 
-- 
4.34  (3.79 - 4.96) 
 
-- 
459.92 
 
-- 
<.0001 
Buprenorphine* 
No 
Yes 
 
-- 
1.639 
 
-- 
0.051 
 
-- 
5.15  (4.66 - 5.69) 
 
-- 
1032.37 
 
-- 
<.0001 
Methadone* 
No 
Yes 
 
-- 
1.862 
 
-- 
0.077 
 
-- 
6.44  (5.54 -7.48) 
 
-- 
586.18 
 
-- 
<.0001 
Interaction termsb 
Age group (years) x single 
opioid* 
6-12 x single opioid  
13-17 x single opioid  
 
 
-0.588 
-0.444 
 
 
0.178 
0.091 
 
 
-- 
-- 
 
 
10.95 
23.75 
 
 
0.0009 
<.0001 
Age group (years) x 
buprenorphine* 
6-12 x buprenorphine 
13-17 x buprenorphine 
 
 
 0.041 
-1.807 
 
 
0.287 
0.191 
 
 
-- 
-- 
 
 
0.02 
89.51 
 
 
0.8863 
<.0001 
Age group (years) x 
methadone* 
6-12 x methadone 
13-17 x methadone 
 
 
  0.374 
-0.814 
 
 
0.273 
0.160 
 
-- 
-- 
 
 
1.87 
25.98 
 
 
0.1712 
<.0001 
Age group (years) x reason* 
6-12 x Intentional 
6-12 x ADR 
6-12 x Other 
 
 13-17 x Intentional 
13-17 x ADR  
13-17 x Other 
 
 0.317 
 0.956 
-0.474 
 
 0.542 
-0.787 
0.121 
 
0.416 
0.344 
1.183 
 
0.382 
0.333 
0.459 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
 
0.58 
7.74 
0.16 
 
2.01 
5.58 
0.07 
 
0.4468 
0.0054 
0.6888 
 
0.1558 
0.0182 
0.7923 
Age group x chronicity* 
6-12 x acute  
13-17 x acute 
 
-0.808 
-0.042 
 
0.259 
0.178 
 
-- 
-- 
 
9.74 
0.05 
 
0.0018 
0.8153 
 
*p<.05. ADR = Adverse drug reaction; AOR = Adjusted odds ratio. Goodness-of-fit tests showed 
that the model fits the data well (p=0.8248). AIC = 24965.93 and -2 Log L = 24915.93.  
Buprenorphine and methadone add up to ≤10% of all opioid exposures so there were included as 
covariates.  
a8382 observations were deleted due to missing values for the response or explanatory variables. 
bAOR for each interaction term in comparison to those under 6 years of age were calculated by 
using a combination of parameter estimates from the table. For example, AOR of severity 
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associated with buprenorphine exposures among teenagers compared to the young children was 
calculated as follows, 
 
AOR = Exp (β1 (13-17) + β9 (13-17 x buprenorphine)) = Exp (0.849 + (-1.807)) = 0.384 
 
where, β1 is the parameter estimate of age group (13-17 years group) and β9 is the parameter 
estimate of age group (13-17 years group) x buprenorphine.  
 
 
Aim 1D: To examine opioid exposures in children at 5-digit ZIP Code level and study its 
association with area-level socioeconomic status (SES)  
Table 14 summarizes bivariate analyses of the proportion of pediatric opioid exposures in a 5-digit 
ZIP Code area and the corresponding area-level characteristics. ZIP Code areas with pediatric 
opioid exposures were descriptively compared to all the ZIP Code areas in the Census data. This 
was done to explore how areas in our study sample compared to all the ZIP Codes areas. A total 
of 12,809 5-digit ZIP Code areas were identified that had one or more pediatric opioid exposure 
(mean number of exposures at area-level = 3.1). The mean proportion of adults in these areas was 
76.2%, which was similar to the average proportion of adults across all United States ZIP Codes. 
The mean proportion of minorities was 28.1%, which was higher compared to the mean proportion 
of minorities across all ZIP Codes. There was a higher proportion of Non-Hispanic Whites in areas 
with one or more pediatric opioid exposures. However, compared to the average racial composition 
across all ZIP Code areas, areas with one or more pediatric opioid exposure had a lower proportion 
of Non-Hispanic Whites (71.9%), and a slightly higher proportion of Hispanic Whites (6.2%), 
Blacks (10.4%), and other races (8.9%). The median household income in these areas was $50,330, 
which was higher compared to the average across all ZIP Codes. The average household size of 
2.6 did not differ much from the average household size across all ZIP Codes. However, ZIP Code 
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areas with one or more pediatric opioid exposure had a lower proportion of older adults in 
households compared to the average across all ZIP Codes (13.8%).  
Bivariate analyses of pediatric opioid exposures at 5-digit ZIP Code level showed statistically 
significant associations between SES characteristics and the area-level proportion of pediatric 
opioid exposures among 5-digit ZIP Code areas with one or more pediatric opioid exposure. 
Positive correlations were observed for proportion of adults, males, Non-Hispanic Whites and 
older adults in households and family households (Table 14).  
Table 14: Pediatric opioid exposure and SES characteristics (bivariate analyses) 
Characteristic 
Total ZIP Code 
areas, mean (SD) 
(N = 32,086)a 
Sample ZIP Code 
areas, mean (SD) 
(N = 12,809)b, c 
Spearman 
correlation 
(r)c 
Pediatric opioid exposures 
Number 
% 
 
-- 
-- 
 
3.07  (3.46) 
0.29  (2.47) 
 
-- 
-- 
% Adults 76.97  (5.04) 76.24  (4.85)  0.217* 
% Minority  21.28  (23.87) 28.06  (24.92) -0.392* 
Gender 
% Males 
% Females 
 
50.18  (3.50) 
49.84  (3.51) 
 
49.48  (2.72) 
50.52  (2.72) 
 
 0.270* 
-0.270* 
Race and Ethnicity 
% Non-Hispanic Whites 
% Hispanic Whites 
% Blacks 
% Other races 
 
78.77  (23.90) 
4.56  (9.11) 
7.62  (15.39) 
6.91  (11.73) 
 
71.95  (24.93) 
6.25  (10.32) 
10.41  (16.78) 
8.85  (11.33) 
 
 0.393* 
-0.367* 
-0.323* 
-0.380* 
Median HH income (in $000s)d 46.65  (19.75) 50.33  (20.60) -0.267* 
Average HH size 2.56  (3.14) 2.58   (0.98) -0.273* 
Average FHH size 3.04  (4.46) 3.08   (0.56) -0.381* 
% Population >65 in HHs 15.30  (5.47) 13.79  (5.03)  0.312* 
% Population >65 in FHHs 12.68  (4.89) 11.32  (4.34)  0.315* 
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aRepresents all 5-digit ZIP code areas from the U.S. Census 2010 file (Total). 
bRepresents all 5-digit ZIP Code areas with ≥1 pediatric opioid exposure (Sample). 
cSpearman correlations computed for 5-digit ZIP Code areas with ≥1 pediatric opioid exposures. 
dMedian household income was imputed using the corresponding per capita income to the 
extent possible. 
*p<.0001. HH = Household. FHH = Family household. 
Other races = American Indians, Pacific Islanders, Asians and others. 
 
 
Adjusted analyses of pediatric opioid exposures and SES characteristics included proportion of 
adults, males, Non-Hispanic Whites, Hispanic Whites and Blacks, median household income, 
average household size and proportion of older adults in households. Moran’s I test on the residuals 
obtained from the adjusted Poisson model was found to be significant (Moran’s I value = 0.175, 
Z-statistic = 28.83, p <.0001) (Semivariogram is shown in Appendix B). This indicated presence 
of positive spatial autocorrelation in the data. Hence, GLMM was used for the final analyses, 
adjusting for spatial autocorrelation.  
Table 15 summarizes the results of adjusted analyses performed at 5-digit ZIP Code level. All 
covariates, except proportion of Blacks, were found to be significantly associated with the rate of 
pediatric opioid exposures in a 5-digit ZIP Code area. Higher rates of pediatric opioid exposures 
in an area were associated with the area-level proportion of males, Non-Hispanic Whites and older 
adults in a household.  Holding other variables constant, the rate of pediatric opioid exposures was 
found to increase by 10% for every 1% increase in the proportion of males in an area, by 1% for 
every 1% increase in the proportion of Non-Hispanic Whites, and by 1% for every 1% increase in 
the proportion of older adults in households. Interestingly, an increase in the proportion of adults 
and Hispanic Whites, median household income and average household size was found to be 
associated with a decline in the rate of pediatric opioid exposures in an area. Test for covariance 
parameters in the model was significant, indicating that random effects of 5-digit ZIP Code cannot 
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be eliminated from the model (Chi-square = 6120.46, p<.0001). Also, Moran’s I test on the 
residuals obtained from the adjusted GLMM model was no longer significant (Moran’s I value = 
9.49E-06, Z-statistic = 0.0214, p = 0.9829), indicating that the spatial autocorrelation in the data 
has been addressed (Table 15). 
Table 15: Pediatric opioid exposure and SES characteristics (multivariable analyses) 
Characteristic Estimate (β) SE  Exp (β) (95% CI) t-value  p-value 
Covariance Parameter Estimates   
Intercept  
(Subject = ZC)a 
 0.299 0.008 -- -- -- 
Solution for fixed effects   
Intercept -8.719 0.320 -- -27.22 <.0001 
% Adults* -0.020 0.003 0.98 (0.97 - 0.99) -6.33 <.0001 
Gender 
% Males* 
 
0.092 
 
0.003 
 
1.10 (1.09 - 1.10) 
 
26.63 
 
<.0001 
Race and ethnicity 
% Non-Hispanic Whites* 
% Hispanic Whites* 
% Blacks 
 
 0.007 
-0.008 
-0.001 
 
0.001 
0.001 
0.001 
 
1.01 (1.01 - 1.01) 
0.99 (0.99 - 0.99) 
1.00 (1.00 - 1.00) 
 
8.62 
-6.0 
-1.4 
 
<.0001 
<.0001 
0.1628 
Median HH income  
(in $000s)* 
-0.011 0.001 0.99 (0.99 - 0.99) -24.49 <.0001 
Average HH size* -0.616 0.043 0.54 (0.50 - 0.59) -14.48 <.0001 
% Population >65 in HHs*  0.011 0.002 1.01 (1.01 - 1.02) 5.12 <.0001 
 
*Type III analysis, F-test p<.05. HH = Household. ZC = ZIP Code.  
aZ-vlaue = 38.83, p<.0001 
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3.3: Discussion 
Annually there were about 16,684 opioid exposures in children and roughly half of these resulted 
in poisonings. Nearly 10,214 of these opioid exposures occurred in children under 6 years of age. 
These constituted exposures to any opioid containing drugs including prescription or OTC, single-
substance or combination, and oral or non-oral formulations. No study provides direct comparison 
for these results mainly due to methodological differences. One previous investigation by 
Burghardt et al. reported 6,213 yearly prescription opioid exposures among children less than 20 
years, majority of which occurred in young children.31 Two other studies examined opioid 
exposures in children under the age of 6 years, and reported 2,640 to 3,823 opioid exposures per 
year. However, these analyses were either limited to a few single-substance opioids or to one drug 
involvement exposures that were presented to the ED.38,48  
There was an overall decline in the prevalence of opioid exposures over the 5-year period, even 
after adjusting for the number of calls received by PCs annually. This contrasts with previous 
studies that have found an increasing trend in drug, specifically opioid, exposures in children.31,48 
Past studies were based on data prior to 2010, while the current analyses used data from recent 
years thus providing an update to research conducted in the last decade. The decline in prevalence 
of opioid exposures and poisonings was largely in the 1 to 2 years age group. This decrease may 
be attributed to various interventions such as CDC’s Preventing Overdoses and Treatment Errors 
in Children Taskforce (PROTECT) collaborative initiative in 2008,82,83 advances in the use of 
child-resistant packaging such as unit packaging of opioids like buprenorphine,35,39 or the release 
of abuse-deterrent opioid formulations that resist crushing or chewing of pills. One study found a 
51% decrease in unintentional exposures of extended-release oxycodone among children 1 to 2.5 
years of age, after the release of the abuse-deterrent formulation.84 It can be postulated that because 
 
 
80 
 
these formulations deter adults from crushing pills, it prevents accidents in children that would 
otherwise result from licking the remnants of crushed pills found at home.   
Comparatively, the decline in opioid poisonings was smaller than the drop in opioid exposures in 
children from 2010 to 2014. This indicates that more opioid exposures among children are 
resulting in poisonings. This may be attributed to the corresponding rise in the use of stronger 
opioids among adults. A CDC survey found that the percentage of adults using weaker than 
morphine opioids had decreased from 26.5% to 20%, while the percentage of stronger opioids use 
had grown from 22.4% to 37% from 2007-2010 to 2011-2012.13 To our knowledge, none of the 
previous studies has examined such a parallel trend in pediatric opioid exposures and poisonings. 
State-level variations were observed in the rate of pediatric opioid exposures and poisonings. No 
previous studies have examined state-level differences. States vary in adoption of laws for 
prescription drug misuse and abuse such as controlling opioid prescribing practices, prescription 
drug monitoring or regulation of pain clinics.85 These laws may impact adults’ opioid availability 
at state-level, indirectly influencing the number of opioid exposures in children. States also differ 
with regards to the number of opioid prescriptions per 100 people and the nonmedical use rate, 
especially in the western region of the country. Most of the states that had a high prevalence of 
pediatric opioid exposures also had a corresponding high number of opioid prescriptions per 100 
persons in 2012. In fact, states such as Oklahoma and Oregon also had a higher percentage of 
prescription opioid nonmedical use.86,87 
The prevalence rate of opioid exposures was high among children under the age of 6 years, the 
rate then declined with age and then increased among adolescents. The total prevalence of opioid 
exposures and poisonings was particularly high among children 1 to 2 years of age. Past studies 
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have unanimously found a similar pattern for drug exposures and poisonings.31,35,38,48,49 This has 
been attributed to a combination of childhood factors such as increased mobility and dexterity 
since an average child starts to walk around the age of 12 months, observing and imitating adult 
drug-taking behavior, or attraction to “candy-like” appearance of the pills or eye-catching 
containers.35,88,89 Younger children are constantly exploring their environment and tend to put 
things in their mouth. These children are also cognitively less developed to realize the danger of 
their actions compared to their older counterparts.89  
Roughly half of total opioid exposures in children were from single-substance opioids and about 
one-fourth involved more than one product. No study has compared single-substance and 
combination opioid exposures in children. One prior study reported that 21.9% of young children 
with emergency hospitalization for prescription drug exposures had two or more products 
implicated.49 The morbidity in regards to poisoning, occurrence of clinical effects particularly 
moderate-to-severe effects, presentation to HCF or death were much higher among single-
substance opioid and multiple product exposures. This can be attributed to high potency of single-
substance opioid agents and increased medical complications following multi-product exposures. 
Buprenorphine and methadone were the two single-substance opioids that were significantly 
associated with negative medical outcomes in children following an exposure. Numerous prior 
studies including multiple case studies have reported similar results.38–40,42,43,52,53,62,90 A focused 
expert review of adverse events in young children with moderate-to-major clinical effects 
following buprenorphine exposures reported that 43.2% had a medically significant (defined as 
disabling or limiting) or life-threatening effect such as respiratory or CNS depression.39  Compared 
to other opioids, Bailey et al. found that buprenorphine and methadone exposures in young 
children resulted in a higher percentage of moderate-to-major effects.38 Among teenagers, 
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methadone exposures have been associated with high medical complication rates.42 In fact, 
methadone was associated with the most deaths among teenagers due to intentional exposures.43 
Buprenorphine and methadone are used for the treatment of opioid dependence and addiction and 
are prescribed heavily in the United States. There is also increasing evidence of misuse and abuse 
of these agents.16,39,91 It is possible that adults undergoing treatment with these agents for their 
opioid dependence or addiction may not be able to ensure proper storage of these drugs at home. 
Thus, it is imperative to increase awareness among adults of the dangers of unintentional exposures 
in young children and intentional exposures among teens at home.92   
The epidemiology of opioid exposures varied by age. Exposures in children under the age of 6 
years were mainly unintentional and had a higher involvement of single-substance opioids. Young 
children are generally not the intended recipients of single-substance opioids hence, exposure to 
these drugs may indicate that these children accidentally expose themselves to adults’ opioids. 
More young boys had opioid exposures compared to girls, which is analogous to previous studies 
that have examined drug or opioid exposures among young children.38,39  One possible explanation 
for this could be gender dissimilarities in risk-taking behavior.93  
On the contrary, exposures in teenagers were largely intentional. This is similar to past studies that 
have examined the intent of drug exposures among children.32,35 Multiple product involvement 
was more common among teenagers which conforms to previous findings that have reported 
frequent use of multiple substances such as alcohol or other drugs by teens.94 We also found that 
a higher proportion of exposures among teenagers involved combination opioids. This may suggest 
a high availability or easy accessibility of these drugs for recreational purposes or self-harm. Based 
on a national survey of adolescent drug use in 2011, one out of every 12 high schoolers reported 
nonmedical use of acetaminophen/hydrocodone combination (Vicodin®) in the past year, making 
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it one of the top abused drugs among adolescents.95,96 Opioid exposures among teenagers, 
specifically intentional opioid exposures, were more common in girls. Similar results were 
reported by a previous study that examined prescription opioid exposures among adolescents.43 
High prescription drug use among teenage girls has been attributed to numerous factors such as 
depression, peer pressure or suicidal ideation.42,43,97 In fact, 59.6% of the total opioid intentional 
exposures in the current study were recorded as suspected suicide and nearly three-fourth of these 
exposures were in girls. Although opioid exposures in children were predominantly acute and 
through oral routes, teenagers also had involvement of non-oral routes and non-acute exposures. 
This could indicate that teenagers are frequently involved in risky drug-taking behavior and may 
be using opioids for longer periods. A survey study that explored oxycodone abuse patterns among 
adolescents reported that intranasal administration (for example, snorting) was one of the preferred 
routes in addition to ingestion among these children.98  
Similar to findings from other studies, the current research indicated that the majority of pediatric 
opioid exposures occurred at home irrespective of the child’s age.38,39 This implies that children 
get into other’s opioids at home. A recent survey showed that over 60% of adults store leftover 
opioid medications at home for future use. Many of these adults reported that they did not receive 
information on safe storage or proper disposal practices for these drugs and only a few adults stored 
these medications in locked cabinets.99 Young children may gain access to opioids that are not 
securely stored such as medication left out on a nightstand or countertop thus, resulting in 
exposures and poisonings. Although the scenarios for opioid exposures were incompletely 
recorded in the current data, a previous study by Lavonas et al. identified improper storage as the 
root cause of buprenorphine exposures among young children.39 Exposure at home was also 
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common among children 13 to 17 years of age. This may suggest that teenagers may be misusing 
opioids or recreationally using opioids at home that belong to a family member.  
Pediatric opioid exposures in general were associated with considerable morbidity in regards to 
occurrence of negative medical outcomes, presentation to ED and hospital admissions. Among 
exposures that had information on clinical effects recorded, neurological effects such as dizziness 
or drowsiness were documented for 77.4% of exposures, followed by gastrointestinal effects and 
cardiovascular effects recorded for 27.8% and 18.4% of exposures, respectively. Previous studies 
have observed similar clinical effects following opioid exposures in children.39,44,46,53,100 Clinical 
effects were frequently recorded for teenagers which may be related to multiple product 
involvement or intentional exposures in this age group. Additionally, about 20,414 (40%) opioid 
exposures in children under the age of 6 years had negative medical outcomes, 15.8% of these 
were moderate-to-major medical outcomes. Nearly 15,942 (68.6%) exposures in teenagers had a 
negative medical outcome documented and 33.9% of these were moderate-to-major medical 
outcomes. These findings are comparable to those from previous investigations. Bailey et al. 
reported that 25% of exposures in children under 6 years of age had negative medical outcomes. 
However these analyses were limited to specific opioid agents.38 Another study found that about 
62.9% of opioid exposures among teenagers had moderate-to-major effects.43  
Nearly 1 in every 2 opioid exposures in children was presented to a HCF. On average, 
approximately 3,578 (35%) opioid exposures in children under the age of 6 years were admitted 
to the ED and another 1,334 (13.1%) were admitted to the hospital annually. While among opioid 
exposures involving adolescents, yearly 1,308 (28.1%) were admitted to the ED and about 1,899 
(40.8%) were admitted for medical or psychiatric care. These results are congruent with past 
research but with some discrepancies owing to different study periods, data sources and sampling 
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criteria. One study that examined HCF use following oral prescription opioid exposures reported 
approximately 4,565 ED visits and 1,666 admissions annually among young children.49 Another 
study reported yearly 3,823 ED visits and 447 admissions among young children with one opioid 
product ingestions.48 Burghardt et al. found nearly 48.4% ED visits and 20.1% admissions among 
children under the age of 20 years that were exposed to an oral, single-substance opioid. They 
found ED visit and admission rates of 46.4% and 12.9% among children less than 6 years, and 
58.2% and 33.4% among teenagers, respectively.31 Zosel et al. reported that 29.8% teenagers with 
intentional drug exposures, including opioids and stimulants, were treated in a HCF, and roughly 
half of them were admitted for care.43  
Naloxone was commonly used for the treatment of opioid exposures with severe outcomes. Prior 
research has also reported naloxone to be successfully used for the management of severe pediatric 
opioid exposures, even in young children.32,38 It is a recommended antidote for respiratory 
depression following opioid, particularly buprenorphine and methadone, exposures in children.45  
In addition to patient-level characteristics, area-level socioeconomic status factors were examined 
at 5-digit ZIP Code level for areas with one or more pediatric opioid exposures during the study 
period. It should be noted that there is no previous study that has examined such area-level factors 
associated with pediatric opioid exposures. These analyses were exploratory and certain 
unexpected findings, such as the inverse association of proportion of adults and the direct 
association of proportion of males with the rate of pediatric opioid exposures at area-level, merit 
further investigation. We found that a higher proportion of Non-Hispanic Whites in an area was 
significantly associated with a higher rate of pediatric exposures. Although not a direct comparison 
for these results, Schillie et al. found a higher rate of ED visits for medication overdoses compared 
to nondrug exposures among White children under the age of 19 years. 35 In fact, prescription 
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opioid use from 2007 to 2012 was reported to be highest among Non-Hispanic White adults 
compared to other racial groups.13 Area-level median household income was inversely associated 
with the rate of pediatric opioid exposures. Household income is reported to be an important 
indicator of socioeconomic status,101 and lower socioeconomic status has been linked to higher 
unintentional drug poisonings among young children.64,65 It can be postulated that areas with 
higher median household income may have access to better child care facilities thus resulting in 
lower rates of pediatric opioid exposures. Furthermore, higher average household size was 
associated with a lower rate of pediatric opioid exposures. Such an association is hard to explain 
since it was expected that over-crowding in households may lead to less parental supervision, 
thereby higher chances of opioid exposures among children. However, similar results have been 
found by some prior studies that have examined SES characteristics associated with unintentional 
pediatric drug exposures.54,65 Lastly, higher proportions of older adults in households was 
associated a higher rate of opioid exposures in children at area-level. This may be related to the 
substantial growth in opioid prescriptions among older adults,85 since grandparents are a common 
source of drugs among young children with unintentional drug exposures.88  
These analyses are limited by the biases inherent to a retrospective study design and the database 
used. First, NPDS data is collected passively and is based on voluntary reporting by a child’s 
family or healthcare professional. Hence these data may be under-reported or subjected to self-
reporting bias or coding errors. NPDS does not capture every occurrence of exposure and 
poisoning, it is limited to those occurrences that are reported to PCs. It is possible that parents may 
rush the child to the ED and neither the parents nor the treating provider may have reported the 
case to a PC thus underestimating the true frequency of exposures and poisonings. Also, these data 
are based on self-reported calls subjecting it to reporting bias. For example, intentional exposures 
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among teenagers may be under-reported by self or the family member. Previous researchers have 
also suggested variations in cases reported to the PCs due to lack of awareness, or cultural, 
language or literacy barriers among the general public.102,103 At least one prior study has found that 
fatal cases are underreported to the PCs.104 Hence these data may not accurately represent mortality 
associated with opioid exposures in children. To account for this limitation, we used the NVSS 
mortality data to examine deaths related to pediatric opioid poisonings (described in Specific Aim 
2). Additionally, PC specialists are trained to collect data over the phone but the amount of data 
that can be collected may be limited or variable from case to case and may be subjected to data 
coding errors or misjudgment of the specialist. However, the use of standard coding fields and 
additional review processes used by the AAPCC may reduce such data coding and human errors.  
Second, prevalence of opioid exposures and poisonings was calculated assuming that each 
exposure case was unique. It is possible that a child may have been exposed to opioids more than 
once during the study period which may lead to double-counting in our analyses. The NPDS 
captures relevant information related to a single opioid exposure event, which can involve more 
than one product. However, it does not have a mechanism to link multiple (repeated) exposure 
events of the same patient. To identify the extent of repeated cases of pediatric opioid exposures, 
Virginia PC data for children under the age of 18 years with opioid exposures, from 2010 to 2014, 
were manually inspected under the supervision of a PC employee. This search showed about 6% 
of potentially repeated opioid exposure cases. Such estimates cannot be derived for the national 
data. However, if this state-level estimate is similar to national-level data then existence of such 
repeated cases is expected to have a small impact on the prevalence estimates.  
Third, the data on exposures obtained from the NPDS are limited to those that are reported to PCs. 
Annual calls to the PCs have been declining in recent years due to various factors such as increased 
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use of text communications and internet resources.32 To account for this limitation, the prevalence 
of pediatric opioid exposures was examined after accounting for the total number of calls received 
by PCs each year during the study period.  
Fourth, the study sample included suspected opioid exposures since the lack of clinical lab data in 
the NPDS does not allow for confirmation of exposures. Yet, the NPDS has been validated as an 
effective pharmaceutical poisoning surveillance system and the data have been shown to correlate 
well with poisoning hospital data.71,105   
Next, Census data from 2011 to 2014 were estimates based on the base year (2010) and are likely 
to be reported with margins of errors (MOEs). However, it is a standard practice to use these data 
since these MOEs are expected to be small. Although some previous studies have established an 
association between opioid availability in an area and the corresponding pediatric opioid 
exposures, the current state-level analyses could not control for factors such as number of opioid 
prescribers or opioid availability in the state. However, these results still provide value for future 
state-level research.  
Additionally, area-level analyses were limited to 5-digit ZIP Codes. Census block groups or tracts 
are considered to be better area-level socioeconomic measures than ZIP Codes.106 The NPDS does 
not provide geographic data beyond patient’s 5-digit ZIP Code to identify Census block group or 
tract. Also, area based analyses did not control for area-level employment and education due to 
unavailability of such data. Further, ZIP Code area-level analyses were limited to cases whereby 
exposure and caller site were one’s own residence. But we found that cases reported by HCFs tend 
to be more severe, involving teenagers and those with intentional exposures. It is possible that our 
area-level analyses missed many such severe or intentional exposure cases, particularly among 
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teenagers. Despite these limitations, the current area based analyses at 5-digit ZIP Code level 
provide a starting point for future investigations.  
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Chapter 4: Specific Aim 2 
 
Aim 2: To estimate the economic costs associated with opioid poisonings in children  
 
4.1: Methods  
Conceptual framework  
After quantifying the prevalence of an illness, the subsequent step was to examine the economic 
burden of the illness to the society. In a typical opioid poisoning event, the child would be 
transported to the ED where he/she would be evaluated and treated using various diagnostic and 
therapeutic procedures and professional care. Depending on prognosis, the child would be released 
from the ED or admitted to the hospital. During the inpatient stay, there may be a multitude of 
other therapeutic, diagnostic and professional care resources used. Since opioid poisoning is an 
acute, reversible condition, we expected most of the children to be treated and released from the 
hospital. However, some children would be transferred to other short-term care facilities, or have 
a premature death, following a severe opioid poisoning. In addition, parents or caregivers would 
spend time taking care of the child in the hospital or during recovery. These various components 
following an opioid poisoning in children can add significantly to the economic burden. The 
economic burden of pediatric opioid poisonings was calculated using the cost-of-illness 
framework. Cost-of-illness has been widely used for decades to quantify the economic burden 
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related to an illness. It includes measurement of direct, indirect and intangible costs related to an 
illness.  
Direct medical costs constitute costs that are incurred from providing medical care for prevention 
and treatment such as hospitalization cost.  Direct nonmedical costs are costs which are not directly 
related to prevention and treatment but aid in provision of care such as transportation cost. Indirect 
costs provide a measure of the value of resources lost due to productivity losses because of an 
illness or injury. It includes short-term productivity losses due to morbidity and lifetime 
productivity losses due to premature mortality. Intangible costs are costs such as pain and suffering 
inflicted by the health condition and are hard to quantify in monetary value.107,108 The current 
analyses did not consider intangible costs because first, these analyses aim to examine the 
economic burden associated with an acute event of opioid poisoning in children and intangible 
costs are an important part of economic analyses for more chronic conditions. Second, there is lack 
of data on long-term effects of pediatric opioid poisonings on quality of life of these children.  
The three-step health care costing approach was used for this Specific Aim as follows: 109  
 Step 1: Identification of relevant HCRU (cost-items) 
 Step 2: Measurement of identified HCRU (cost-items) 
 Step 3: Valuing these HCRU (cost-items) 
The HCRU to be incorporated in these analyses was based on existing literature on pediatric opioid 
poisonings and the "Poisoning Pyramid" (refer to the Literature Review chapter). ED visits and 
hospital stays are major resources used following opioid poisonings in children. The 
ambulatory/outpatient department or office visits related to pediatric opioid poisonings were not 
examined because a majority of costs were expected to be incurred from ED and inpatient visits. 
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ED visits, inpatient stays, physician-related hospital services, transportation to health care facility, 
and mortality associated with pediatric opioid poisonings were identified and quantified. For 
valuing or assigning costs to the identified HCRU items, the bottom-up approach was used for 
estimating direct costs and the human capital method was used for estimating indirect costs.   
Methods for estimating direct costs 
The bottom-up costing approach allows for identification of costs at granular level. This method 
involves calculation of costs by multiplying the average cost of treatment of an illness with its 
prevalence. The average cost of a resource item is calculated by multiplying the average quantity 
used with the unit cost of that particular resource. This is repeated for every resource input, and 
summed to obtain average total cost per patient, which is then combined with illness prevalence 
to estimate the total costs. The total costs (TC) are expressed as (adapted from Haddix et al. 
(2003))107,108  
(TC)i = (Q1 * P1)i + (Q2 * P2)i +…..+ (Qn * Pn)i 
(TC) = (TC)i + (TC)j +…. + (TC)n 
Where: (TC) = TC for ith patient, 
Q1 = quantity of resource 1 and so on, and 
P1 = value of resource 1 and so on. 
 
Methods for estimating indirect costs 
Indirect productivity costs are the value of lost or reduced production of an individual due to 
morbidity and mortality. Productivity losses from morbidity result from absenteeism or 
presentism. Absenteeism refers to a patient or caregiver being unable to attend work or perform 
normal housekeeping services due to one’s illness, while presentism refers to reduced production 
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output of a patient or caregiver while at work. Lost productivity due to premature mortality is 
based on the premise that an individual would have contributed to the societal production if he/she 
had not died prematurely due to an illness. The human capital method and the friction cost method 
are the two commonly used methods for estimating lost productivity. The two methods produce 
very different estimates especially for productivity costs calculated over lifetime and have been 
heavily debated in the literature with no real consensus.107,108,110  
The human capital method measures lost productivity as the sum of lost earnings and household 
production from a societal or patients’ perspective. For example, if an individual dies prematurely 
at the age of 15 then the expected earnings and household production of that individual over the 
lost lifetime are calculated and discounted to the present value. The human capital method 
measures the potential or expected loss in future productivity. It has been criticized for 
overestimating the productivity losses thereby exaggerating the economic impact of an illness.111  
The friction cost method was developed in an attempt to measure the actual rather than the 
expected production loss. This method measures lost productivity only for the period required to 
replace the sick worker. This period needed for replacement is called the friction period. An 
average friction period of 6 months has been suggested by some researchers, but it can vary based 
on various factors such as the employment rate or industry. This method has been criticized for 
vastly underestimating productivity losses, and it is suggested to be more relevant for studies 
conducted from employers’ perspective or in a society with surplus of skilled labor.112,113  
The use of friction cost method may be complicated for analyses based on the pediatric population 
that is not currently in the work force. Despite the recognized limitations of the human capital 
method, it is still the dominant method used for cost-of-illness research. Thus, the human capital 
method was used for calculating productivity losses due to morbidity and mortality related to 
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pediatric opioid poisonings. The total costs of productivity loss due to morbidity were calculated 
as follows: 
(Number of ED or inpatient days + Number of recovery days) * Daily production value (DPV) 
 DPV = Daily market production + Daily household production 
 Daily market production = Average daily hours working at a job * usual hourly market 
compensation 
 Daily household production = Average daily hours of household service * usual hourly 
household compensation 
The sum of hospital days and recovery time provides a proxy for time off work. The DPV data 
was obtained from an analysis conducted by Grosse et al.110 In this analysis, DPV was calculated 
for the United States noninstitutionalized population over 15 years of age, weighted by age and 
gender.  
The value of productivity loss due to mortality was obtained by estimating the present value of 
expected future productivity (PVFP) which included earnings and household services. Grosse et 
al. calculated the average PVFP for the noninstitutionalized population in the United States by 
single-year of age and gender, after adjusting for 1% increase in annual labor productivity and 
survival probabilities obtained from the 2004 United States Life Tables. These total production 
estimates for 0 to 17 years of age and gender were used for calculating the lost future productivity 
costs due to premature deaths following opioid poisoning. 
Empirical Framework  
A comprehensive societal perspective was employed for these analyses. All cost calculations were 
made for the 2012 base-year since that was the most recent data available at the time of data 
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acquisition. An annual time horizon was used for calculating direct costs and indirect costs were 
calculated for lifetime. A prevalence-based approach was used for estimating the economic costs 
of pediatric opioid poisonings. Using this approach, all relevant annual direct costs and indirect 
costs due to morbidity were calculated for the base year and lifetime indirect costs due to mortality 
were calculated using present discounted value of future productivity losses. This approach is 
employed for illnesses that commonly do not extend beyond one year.108,114  
As for the costing method(s), Sum_All Medical method was used for estimating the total cost of 
pediatric opioid poisonings in the base-case. Total costs were calculated for all pediatric patients 
with any-listed diagnosis of opioid poisoning on their discharge record. This method assumes that 
all hospital costs incurred following an acute injury such as opioid poisoning were related to the 
poisoning.115   
As discussed above, the human capital method was employed for estimating indirect costs related 
to opioid poisonings in children. Since the target study population was less than 18 years of age, 
we considered indirect costs of short-term productivity loss due to morbidity for parents’ or 
caregivers’ alone, whereas future productivity losses due to premature mortality were considered 
for children with opioid poisoning. We assumed one caregiver per child. Discounting is used in 
economic evaluations to calculate the present value of future costs. A discount rate of 3% was used 
for these analyses as recommended by the Panel on Cost-Effectiveness in Health and Medicine.107 
Direct medical costs 
Data 
The Agency for Healthcare Research and Quality’s (AHRQ) Healthcare Cost and Utilization 
Project (HCUP) 2012 Nationwide Emergency Department Sample (NEDS) and 2012 Kids’ 
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Inpatient Database (KID) were used. HCUP databases contain the largest publicly-available, 
multistate, all-payer, encounter-level information for community hospitals. The NEDS includes 
ED discharge data from over 950 hospitals located in 30 states which comprises data from 
approximately 130 million ED visits per year. It captures information on all ED visits that may or 
may not have resulted in hospital admissions. The KID yields national estimates of hospital 
inpatient stays for patients younger than 21 years. It is based on administrative hospital discharge 
data and contains roughly 7 million pediatric discharges each year from about 44 states.  The most 
recently available data (at the time of data acquisition) were used for these analyses.  
Sample 
Discharge records from HCUP’s NEDS and KID databases were extracted for children under 18 
years of age with 1 or more opioid poisoning-related International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) diagnosis codes in any-listed diagnosis. Opioid 
poisoning-related ICD-9-CM codes are listed in Table 16. The sample for ED visits was limited to 
discharges that did not result in hospital admission to avoid double counting. ED visits that resulted 
in hospitalization were captured in the inpatient data. Also, it was assumed that if opioid poisoning 
was recorded in the patient’s discharge record then it was related to the reason for admission. This 
may be a reasonable assumption for a number of reasons. Firstly, opioid poisoning is an acute 
illness or injury and it is less likely to be a pre-existing condition. Secondly, the first-listed 
diagnosis is the principal diagnosis in the HCUP inpatient databases such as the KID. However, 
the first-listed diagnosis may not be the principal diagnosis in the HCUP outpatient databases such 
as the NEDS. Lastly, of the total opioid poisoning-related discharges, opioid poisoning was listed 
as the first or second-listed diagnosis in 91.6% of the ED data and 66.9% of the inpatient data. A 
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final total of 1,048 ED visits was identified from the NEDS and a total of 1,334 inpatient visits 
were identified from the KID. 
Table 16: Opioid poisoning-related ICD-9-CM diagnosis and E-codes 
ICD-9-CM Codes  Description (to identify diagnosis)   
965.00 
965.02  
965.09  
Poisoning by opium (alkaloids), unspecified 
Poisoning by methadone 
Poisoning by other opiates  
E-codes  Description (to identify intent) 
E850.1a  
E850.2a  
 
E950.0b 
 
 
E980.0c 
Accidental poisoning by methadone 
Accidental poisoning by other opiates and related narcotics 
 
Suicide and self-inflicted poisoning by analgesics, antipyretics, & 
antirheumatics 
 
Poisoning by analgesics, antipyretics & antirheumatics, undetermined 
whether accidentally or purposely inflicted 
  
aUnintentional; bIntentional; cUndetermined. 
ICD-9-CM = International Classification of Diseases, 9th Revision, Clinical Modification,  
E-codes = External Cause of Injury codes. 
 
Converting charges to costs and calculation of SE 
The HCUP databases provide total charges for ED visits and inpatient visits which include any 
facility charges or charges for any diagnostic labs or procedures. These charges represent the 
amount billed by the hospitals and not the payment amount reimbursed to hospitals or the actual 
cost of services. Charges are often higher than the underlying costs but actual costs are not 
obtainable.107 HCUP provides hospital-specific cost-to-charge ratios (CCR) for inpatient stay 
charges based on all-payer inpatient costs. HCUP obtains this cost information from hospital 
accounting reports collected by the CMS. Identified records from KID were merged to the 2012 
KID CCR linkable file using the ‘HOSP_KID’ (HCUP hospital identification number) variable. 
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Inpatient stay costs for every discharge record were obtained by multiplying inpatient charges with 
the appropriate CCR. 
HCUP NEDS does not provide CCR for ED charges. Detailed ED charges and accounting data are 
required for calculating a hospital specific CCR since the ratios can vary by state and between cost 
centers within a hospital. HCUP conducted a preliminary analysis for estimating the cost of T/E 
& R ED visits by grouping hospitals based on characteristics such as hospital ownership and 
location. Although these ratios cannot be used for calculating an institution specific ED costs, they 
still provide an estimate of average ED CCR based on certain hospital characteristics. The group 
average ED CCR from the HCUP report were used to convert ED visit charges to costs in the 
current study.116 The details of the HCUP report and the procedure used for estimating ED visit-
related CCR is described in Appendix C. 
Additionally, calculation of standard errors (SEs) of ED and inpatient costs accounted for the 
sampling design of NEDS and KID respectively, which is specified by HCUP. 
Dealing with outlier charges 
Outliers in the ED charge (or cost) data were examined (top/bottom 5%). Upon manual inspection, 
these charges looked reasonable and were included in further analyses. Suspiciously high charges 
in inpatient data were examined using the approach described by HCUP.117 To identify 
suspiciously high inpatient charges, average charge per day was calculated for each stay. HCUP 
calculates length of stay (LOS) by subtracting the admission date from the discharge date therefore, 
same-day inpatient stays are coded as 0. For these calculations, LOS that was recorded as 0 in the 
data was set to 1 prior to calculating charge per day. The top 1% of charges per day were identified. 
The difference between the 75th percentile and median average charge per day was multiplied by 
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4, and added to the median. This value was used as the cutoff value for suspiciously high charges 
in the inpatient data ($45,600 per day). Two observations were above this cut-off value and were 
excluded from cost analyses. 
Dealing with missing charges and CPT codes 
ED charges were missing for 182 (17.4%) of the total ED visits for opioid poisonings in children. 
Using only non-missing charges could result in an underestimate of total ED-related costs. Also, 
all the visits with missing ED charges were examined and they had corresponding diagnosis and 
all observations, except one, had procedures recorded. This indicates that non-zero charges may 
have been incurred during the visit. Similarly, inpatient charges were missing for 20 (1.5%) of 
total inpatient stays. HCUP suggests that the missing data are likely missing at random (MAR) 
and not missing completely at random (MCAR), hence deleting the missing observations may not 
be justified.118 Missing ED and inpatient charges were imputed. Several single and multiple 
imputations were undertaken as outlined below, in order to compare and contrast the results from 
these various methods.  
 Imputation 1 set missing charges as zero: This approach was used for both ED and inpatient 
data. Although straightforward, this is a very conservative approach that assumes that the 
observations with missing charges truly had zero charges incurred during their ED visit or 
hospitalization.  
 Imputation 2 used single imputation methods: Two single imputation techniques were used for 
the missing ED charges, overall mean imputation and subset mean imputation. First, the mean 
estimate of charges from the non-missing observations was used to impute the missing charges. 
Second, the mean estimates of charges from subgroups of the sample were used to impute the 
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missing charges. These subgroups were created based on age group and the intent of opioid 
poisoning. Medical outcomes following an opioid poisoning are shown to differ among 
children of different age groups and by intent (refer to Specific Aim 1). For instance, if the 
observation with missing charges was for a teenager with an intentional exposure then the 
mean estimate of non-missing ED charges of all teenagers with intentional exposure was used 
for imputation. Single imputation method using mean charges/day was used for the inpatient 
data. The mean charge per day was calculated for all observations with non-missing charges. 
This was then combined with the length of inpatient stay with missing charges to impute the 
missing charge for that stay. These single imputation methods have an advantage of 
computational ease, but are often criticized for deflating the sample variability.119 
 Imputation 3: Multiple imputation using Markov chain Monte Carlo (MCMC) was used to 
impute the missing charges. Multiple imputation is the recommended method of choice by 
HCUP for dealing with missing data.118 MCMC imputation is found to be a suitable technique 
for continuous data such as charges. This method involved three phases, imputation phase, 
analysis phase and pooling phase. In the imputation phase, the missing patterns of total charges 
were evaluated across all the variables of interest. The imputation model was then defined for 
ED charges and inpatient charges, respectively. The imputation models are recommended to 
be extensive rather than parsimonious. The imputation model for ED charges included child’s 
age group; gender; median household income at ZIP Code level and residence location; type 
of opioid; intent; indicators for multi-drug poisonings, multi-injuries and chronic conditions; 
number of diagnosis and procedures on record; disposition status; payer; hospital 
characteristics including hospital region, location, ownership, teaching status and trauma 
status; and (non-missing) ED physician cost. The imputation model for inpatient charges 
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included child’s age group; gender; race; median household income at ZIP Code level and 
residence location; type of opioid; intent; indicators for multi-drug poisonings and chronic 
condition; number of diagnosis and procedures on record; All Patients Refined Diagnosis 
Related Groups (APR-DRG) severity and mortality risk indices; Elixhauser comorbidities; 
disposition status; transfer-in and prior ED event indicators; LOS; payer; hospital 
characteristics including hospital region, ownership, bedsize, location and teaching status. 
The number of imputations was chosen as 5 which is a reasonable number unless the rate of 
missing data is unusually high. The relative efficiency of using 5 imputations was calculated 
as follows:120 
RE = (1 + λ / m) -1 
where, RE = relative efficiency 
λ = rate of missing information 
m = number of imputations  
 
Using m = 5, the relative efficiency for the estimation of ED charges and inpatient charges was 
96.6% and 99.7%, respectively.  Subsequently in the analysis phase, the parameters of interest 
were estimated i.e., unweighted and weighted mean ED charges and inpatient charges were 
estimated for each imputation dataset. Finally, the respective mean estimates were combined 
from the 5 imputation datasets to produce a single estimate and its variance in the pooling 
phase. This variance incorporates within-imputation and between-imputation variances, 
resulting in more unbiased estimates. The results from imputation were examined by 
comparing the distribution of non-missing observed and imputed charges from 5 imputations 
as shown in Appendix D. The distribution of imputed ED charges (mean = $2,968) was similar 
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to the distribution of non-missing observed ED charges (mean = $3,290). Distribution of 
imputed inpatient charges (mean = $21,239) was different from the distribution of non-missing 
observed inpatient charges (mean = $45,756). This may partly be attributed to low sample size 
for missing inpatient charges. Model convergence was assessed by inspecting the trace plot 
and the autocorrelation plot.  PROC MI and PROC MIANALYZE were used in SAS for the 
MCMC multiple imputation.118,119  
Current Procedural Terminology (CPT) procedure codes were missing for 340 (32.44%) ED visits 
and could not be mapped to the CMS Medicare Physician Fee Schedule (explained below). 
Missing physician services-related costs were imputed using imputation techniques similar to 
those described above. Imputations were performed by: (i) Setting missing physician costs as zero, 
(ii) Overall mean imputation and (iii) Subset mean imputation. The subset mean imputation was 
performed using subsets of age group, gender and quintile of non-missing total ED charges. It was 
assumed that if a child had high ED charges following an opioid poisoning then there is a high 
likelihood of corresponding high physician-services related costs. For example, if an ED visit for 
a young child with an unintentional poisoning had total recorded charges in the fifth quintile (80th 
percentile) but had missing physician costs, then the group mean physician cost of children under 
6 years of age with unintentional opioid poisoning and 80th percentile ED charges was used for 
imputation.  
Multiple imputation using MCMC was attempted for missing ED physician-related costs, but the 
imputation model exhibited poor fit with significant autocorrelation. The number of iterations were 
increased in the MCMC procedure but it did not help to overcome the autocorrelation in the 
sequence of the physician costs estimates. Thus, imputed mean using the subset mean imputation 
method was used for missing ED physician-related costs.  
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ED-related costs 
Total ED-related hospital costs were calculated using the total number of ED visits for pediatric 
opioid poisonings and its estimated mean cost of treatment. HCUP databases do not include 
physician service costs for hospital encounters. However, up to 15 CPT-4 procedure codes are 
recorded in the NEDS. The physician fee per ED visit was calculated by linking the CPT codes 
from NEDS to the publicly-available CMS 2012 Physician Fee Schedule. This schedule provides 
the national reimbursement rate for each CPT code. The sum of all CPT codes, after linking to 
their respective payment amount, was calculated for each ED visit. This was aggregated across 
visits to obtain the total ED-related physician service costs.  
Inpatient-related costs 
Total inpatient stay costs were calculated using the number of inpatient stays and the estimated 
mean cost of hospitalization for pediatric opioid poisonings. KID does not include physician 
service fees or CPT codes for calculating inpatient physician costs. Procedures are recorded in the 
inpatient data using ICD-9-CM procedure codes which cannot be used for estimating inpatient 
physician costs. Three standard CPT codes were assumed for all the inpatient stays as listed in 
Table 17. These CPT codes were then linked to their respective payment amount from the CMS 
2012 Physician Fee Schedule. This approach has been used by previous studies examining 
inpatient physician costs.121,122 The CPT codes were retrieved from the 2011 CMS Physician Fee 
Schedule manual. 
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Table 17: CPT codes used for calculating inpatient physician costs 
CPT code  Description CMS national reimbursement rate 
(in 2012 USD) 
99222  Initial hospital care (50 minutes)       133.09 
99231 Subsequent hospital care (15 minutes)       38.12 
99238  Hospital discharge day (30 minutes)       69.78 
 
Using these CPT codes, inpatient stays with LOS ≤ 1 day were assigned CPT codes for initial care 
(99222) and discharge day care (99238), and the total physician costs was the combined sum of 
their corresponding rates. Inpatient stays with LOS >1 were assigned CPT codes for initial 
admission care and discharge day care, and the CPT code for subsequent care (99231) for every 
additional day in between the admission and the discharge day.  HCUP calculates LOS by 
subtracting the admission date from the discharge date so the same-day stays are coded as 0. This 
was accounted for in the physician costs calculations. For example, if the LOS was 3 days then the 
total physician costs for that stay was calculated as, 
(CPT 99222 rate + CPT 99238 rate) + (CPT 99231 rate x 2 days) 
Total direct medical cost 
Total ED costs were calculated by aggregating ED hospital-related costs and physician-related 
costs. Similarly, total inpatient costs were computed by aggregating inpatient hospital-related costs 
and physician-related costs. Total direct medical costs of opioid poisonings in children were 
calculated by combining total ED costs and inpatient costs.  
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Direct non-medical costs 
Ambulance service use was not available in the HCUP databases. Larkin et al. used National 
Hospital Ambulatory Medical Care Survey (NHAMCS) from 1997-2003 and estimated ambulance 
use in about 39% of injury-related ED visits.123 A similar estimate has been used by another opioid 
poisoning study.55 However, these analyses were not specific to the pediatric population. Adults 
with opioid poisoning may avoid ED transport for various reasons such as fear of legal 
involvement or discrimination. These factors may not be a concern when using ambulance services 
for children. Hence, it was assumed that half of the total ED visits (50%) used ambulance services. 
This estimate is higher than the previous analyses but still provides a conservative assumption. 
The estimate was multiplied with the cost per ambulance transport to compute total ambulance 
costs. A report by Government Accountability Office (GAO) estimated the cost per ground 
ambulance transport at $429 in 2010.124 This cost was inflated to 2012 USD using Bureau of Labor 
Statistics’ (BLS) Medical Care Component of the Consumer Price Index (CPI).125  
Indirect productivity costs 
Morbidity-related costs 
Morbidity costs were calculated for caregivers’ lost productivity due to absenteeism during the 
child’s ED visit or average hospital stay plus a reasonable post-admission care time. There is no 
data on the average number of recovery days following pediatric opioid poisonings. For ED visit 
related morbidity costs, one recovery day was assumed following a day of the ED visit.  A total of 
2 absent work days was combined with the total weighted number of ED visits identified from the 
NEDS. This was then combined with the DPV obtained from Grosse et al.110 These DPV values 
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were reported in 2007 USD and were inflated to 2012 USD using the BLS Employment Cost Index 
(ECI) for all civilian workers.126 
For inpatient stays, different recovery days were assumed based on the severity of opioid 
poisoning, identified using the APR-DRG severity index in the KID. Average LOS was calculated 
by severity group (none-to-minor, moderate, or major-to-extreme severity). One, 3 and 7 recovery 
days were assumed for none-to-minor, moderate and major-to-extreme severity groups, 
respectively. A maximum of one week of recuperation time was assumed based on previous 
poisoning-related hospital analyses by Inocencio et al. and Walsh et al.55,127 Total caregiver absent 
days were calculated for each severity group and combined with the weighted number of inpatient 
stays for the respective group. This was then combined with the inflated DPV value from Grosse 
et al.110 Total morbidity costs were obtained by aggregating the ED-related and inpatient-related 
morbidity costs.  
Mortality-related costs 
The National Vital Statistics System’s (NVSS) 2012 Mortality Multiple Cause-of-Death (MCOD) 
file was used to estimate indirect costs due to premature mortality. Although deaths were recorded 
in the HCUP databases, they may be limited to cases that died during hospitalization and there was 
no data element to verify cause of death in these datasets. NVSS data are provided by the National 
Center for Health Statistics (NCHS) and vital registration systems and are widely used in research 
for studying mortality trends. Detailed information is recorded on decedent’s demographics, 
including age and gender, and medical characteristics including underlying cause of death 
identified using ICD-10 codes. Data is also documented on the record axis conditions which 
describes the cause of death and any other comorbidities that may exist. 
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Records of decedent’s less than 18 years of age that had a poisoning-related ICD-10 code recorded 
in the underlying cause of death field were extracted (ICD-10 code X42, X44, X62, X64, Y12, or 
Y14).  From these records, decedent’s that had an indication of opioid as a contributing cause of 
death were identified using the opioid specific ICD-10 code in the record axis fields (ICD-10 code 
T40.0, T40.2, or T40.3). Intent and type of opioid involved in a poisoning-related death were 
identified using the ICD-10 codes (Table 18).  Number of opioid poisoning deaths were identified 
by single-year of age and gender of the deceased children. The PVFP values obtained from Grosse 
et al. were weighted by age and gender in 2007 USD.110 These PVFP values at 3% discount rate 
were inflated to 2012 USD using the using the BLS ECI for all civilian workers. Total costs of 
mortality-related productivity loss were calculated by combining the number of deaths and PVFP 
for each age and gender group 
Table 18: Opioid poisoning-related ICD-10 diagnosis codes  
ICD-10 
Codes 
Description 
X42a 
 
X44a 
 
X62b 
X64b 
 
Y12c 
 
Y14c 
 
 
T40.2d  
T40.3e 
T40.4d 
Accidental poisoning by and exposure to narcotics and psychodysleptics 
(hallucinogens), NEC 
Accidental poisoning by and exposure to other and unspecified drugs, medicaments 
and biological substances 
Intentional self-poisoning by and exposure to narcotics and psychodysleptics, NEC 
Intentional self-poisoning by and exposure to other and unspecified drugs, 
medicaments and biological substances 
Poisoning by and exposure to narcotics and psychodysleptics, NEC, undetermined 
intent 
Poisoning by and exposure to other and unspecified drugs, medicaments, and 
biological substances, undetermined intent 
 
Other opioids (codeine, morphine) 
Methadone 
Other synthetic narcotics (pethidine) 
 
aUnintentional (or accidental poisonings); bIntentional poisonings; cUndetermined poisonings; 
dOther opioids-related poisonings; eMethadone-related poisonings. 
NEC = not elsewhere classified. 
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Methods used to estimate the economic costs associated with opioid poisonings in children are 
summarized in Table 19. Deterministic one-way sensitivity analyses were performed using a range 
of plausible parameter values to examine the robustness of cost estimates.  All analyses were done 
in SAS version 9.4 and Microsoft Excel 2013. 
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Table 19: Summary of methods for economic cost analyses  
Costs Data source(s) Data elements(s) Cost calculations 
 
 
 
 
Direct Medical 
ED visits (without 
hospitalization) 
HCUP NEDS (2012) 
ED visits, total ED 
charges* 
 # of ED visits x mean 
ED costs 
ED physician costs 
HCUP NEDS (2012), 
CMS MPFS (2012) 
CPT codes, 
CPT codes national rate 
∑ (Sum of CPT codes 
(rate) per record) 
Inpatient stays HCUP KID (2012) 
Inpatient stays, total 
inpatient charges* 
# of inpatient stays x 
mean inpatient costs 
Inpatient physician 
costs 
HCUP KID (2012), 
CMS MPFS (2012) 
CPT codes, 
CPT codes national rate 
∑ (Sum of CPT codes 
(rate) per record) 
Direct      
Non-medical 
Transportation 
HCUP NEDS (2012), 
Larkin et al. (2005), assumption 
GAO Report (2010), BLS CPI 
ED visits, 
Ambulance runs, 
Ambulance costs 
 # of ED visits x 0.5 x 
cost per ambulance run 
Indirect 
(productivity 
loss) 
Absenteeism 
HCUP NEDS & KID (2012) 
Assumption, 
Grosse et al. (2009), BLS ECI 
ED visit or LOS, 
Recovery time,** 
DPV 
# of absent days x DPV  
Mortality  
NVSS MCOD (2012), 
Grosse et al. (2009), BLS ECI 
Premature mortality, 
PVFP 
# of deaths x PVFP 
 
*Charges were converted to costs using CCR. 
**Recovery days for ED visits = 1; Recovery days for inpatient stays = 1 to 7 days (depending on severity-of-illness). 
HCUP = Healthcare Cost and Utilization Project; NEDS = Nationwide Emergency Department Sample; KID = Kids' Inpatient Database; 
CMS = Centers for Medicare & Medicaid Services; MPFS = Medicare Physician Fee Schedule; GAO = Government Accountability 
Office; BLS = Bureau of Labor Statistics; CPI = Consumer Price Index; ECI = Employment Cost Index; NVSS MCOD = National Vital 
Statistics System Multiple Cause-of-Death; LOS = Length of stay; DPV = Daily production value; PVFP = Present value of expected 
future productivity.
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4.2: Results 
Direct costs 
There were a total of 4,584 ED visits and 1,874 inpatient stays for opioid poisonings among 
children in 2012. The mean ED hospital and physician costs and inpatient hospital and physician 
costs calculated by various imputation methods are summarized in the Tables 20 and 21. The mean 
cost for an ED visit for treatment of pediatric opioid poisonings was calculated at $1,496, and the 
mean cost for an inpatient stay was estimated at $7,045. The total direct medical costs of pediatric 
opioid poisonings were estimated to be about $20.1 million annually. Approximately $13.2 million 
(65.8%) of these total direct costs were due to inpatient admissions, while ED visits constituted 
about $6.9 million (34.2%). For a total of 4,584 ED visits identified in the NEDS, 2,292 were 
assumed to have arrived to the ED using ambulance transport. Using this estimate, the total direct 
non-medical costs of opioid poisonings in children were calculated to be $1,050,318 per year (cost 
per ambulance run in 2012 USD = $458.25).  The total direct medical and non-medical costs of 
pediatric opioid poisonings in the United States were estimated to be over $21.1 million per year.  
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Table 20: ED costs associated with pediatric opioid poisonings (in 2012 USD) 
 
ED costs  
Costs, mean (SE) 
Costs, total Unweighted 
(N = 1,048) 
Weighted 
(N = 4,584) 
Hospital costs 
Original costs (not imputed)a 1,318.57  (45.13) 1,288.92  (54.10) -- 
Imputation 1 (missing values as 0) 1,089.58  (40.36) 1,071.66  (51.28) -- 
Imputation 2a (overall mean)b 1,334.78  (37.39) 1,310.10  (45.17) -- 
Imputation 2b (subset mean)b, c 1,332.92  (38.02) 1,307.24  (45.35) -- 
Imputation 3 (MCMC) 1,362.65  (41.58)   1,338.55  (46.62) -- 
Total hospital costsf 6,135,913 
Physician costs 
Physician costs (not imputed)d 162.88  (4.35) 164.88  (5.09) -- 
Imputation 1 (missing values as 0) 110.04  (3.77) 107.57  (5.37) -- 
Imputation 2 (overall mean) 162.88  (2.94) 164.19  (3.32) -- 
Imputation 3 (subset mean)e 156.61  (3.22) 157.42  (3.77) -- 
Total physician costsf 721,613 
Total ED costsf 1,519.26 1,495.97 6,857,526 
 
MCMC = Markov chain Monte Carlo. 
Total costs = Weighted mean cost x Weighted prevalence (N). 
aED costs were missing for 182 (17.4%) visits (N = 866). These were not included in the not 
imputed mean. 
bImputations 2a and 2b are single imputation methods.  
cSubset based on age group and intent. 
dCPT codes were missing for 340 visits. These were not included in the not imputed mean. 
eSubset based on age group, intent and quintiles of (non-missing) total ED charges. 
fHospital costs obtained from the multiple imputation using MCMC and physician costs obtained 
from the subset mean imputation were used.  
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Table 21: Inpatient costs associated with pediatric opioid poisonings (in 2012 USD) 
Inpatient costs 
Costs, mean (SE) 
Costs, total Unweighted 
(N = 1,332) 
Weighted 
(N = 1,874) 
Hospital costs 
Original costs (not imputed)a  6,624.60  (613.53) 6,633.41  (630.21) -- 
Imputation 1 (missing values 
as 0) 
6,525.13  (604.71) 6,537.48  (622.68) -- 
Imputation 2 (mean cost/day) 6,623.42  (604.82) 6,632.48  (621.48) -- 
Imputation 3 (MCMC) 6,759.91  (607.26)  6,766.03  (624.07) -- 
Total hospital costsb 12,679,540 
Physician costs 
Total physician costsb 279.63  (6.28) 279.18  (6.24) 523,183 
Total inpatient costsb 7,039.54 7,045.21 13,202,723 
 
MCMC = Markov chain Monte Carlo.  
Total costs = Weighted mean cost x Weighted prevalence (N). 
aInpatient costs were missing for 20 (1.5%) stays (N = 1,312) and were not included in the not 
imputed mean. 
bHospital costs obtained from the multiple imputation using MCMC and calculated physician costs 
were used. 
 
Indirect costs 
Table 22 summarizes the morbidity-related costs associated with pediatric opioid poisonings. 
Assuming 1 recovery day resulted in 2 caregiver absent days per child for opioid poisoning ED 
visit. Using the KID, the average LOS among children following an opioid poisoning with minor 
or moderate severity was 2 days, and average LOS following an opioid poisoning with major 
severity was 6 days. Total of 1 day, 3 days and 7 days of recuperation time was assumed following 
an opioid poisoning with minor, moderate or major severity, respectively. This resulted in a total 
of 3 to 13 caregiver absent days from work. The DPV for a caregiver in 2012 USD was estimated 
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at $142.99. The total morbidity-related costs due to caregiver absenteeism were estimated to be 
over $2.9 million annually. Inpatient stays for opioid poisonings in children constituted about 
55.5% of these total morbidity-related costs, and ED visits added up to the remainder of the costs 
(Table 22).  
Using MCOD 2012 file, 123 pediatric opioid poisoning-related deaths were identified.  About 
69.9% of these children were teenagers and 26% were under the age of 6 years. Over three-fourths 
of the opioid poisoning related deaths in children were unintentional (77.2%). Table 23 shows the 
characteristics of children with opioid poisoning-related deaths. Using the PVFP estimates from 
Grosse et al.,110 the total mortality costs were estimated to be $206,761,044 in 2012 USD. The 
total productivity costs for opioid poisonings in children in the United States were estimated at 
approximately $209.7 million. Mortality-related costs constituted about 98.6% of the total indirect 
costs for opioid poisonings in children. The total economic costs of opioid poisonings in children 
were calculated at $230.8 million in 2012 USD.  
Table 22: Morbidity-related absenteeism costs associated with pediatric opioid poisonings 
(in 2012 USD) 
 
Absent days Weighted 
N 
DPV lossb 
(Avg. DPV = 142.99) LOS Recovery Total  
ED visit 1 1 2 4,584 1,310,955 
Inpatient stay  
None to minor severitya 
Moderate severitya 
Major to extreme severitya 
Total 
 
2 
2 
6 
-- 
 
1 
3 
7 
-- 
 
3 
5 
13 
-- 
 
700 
747 
427 
1,874 
 
280,911 
573,229 
778,586 
1,632,726 
Total   2,943,681 
 
DPV = Daily Production Value; LOS = Length of stay; Avg = Average. 
aBased on APR-DRG severity-of-illness assigned in the KID. 
bAssumed one caregiver per child.  
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Table 23: Characteristics of children with opioid poisoning-related deaths in 2012 
Characteristic N % 
Total 123 100 
Sociodemographic 
Age groups (years) 
≤ 5  
6 - 12  
13 - 17  
 
32 
5 
86 
 
26.02 
4.07 
69.92 
Female 35 28.46 
Clinical  
Intenta 
Unintentional 
Intentional 
Undetermined  
 
95 
6 
22 
 
77.24 
4.88 
17.89 
Opioidb 
Methadone 
Other opioids   
 
31 
96 
 
25.2 
78.05 
 
aIntent of opioid poisonings was identified using ICD-10 codes which vary from the AAPCC 
intent definitions. For example, assume a teenager misused opioids not with an intent to 
suicide but to get a high and had subsequent poisoning. This scenario would be recorded as 
unintentional using ICD codes. However, the same situation would be recorded as intentional 
in the NPDS by the PC specialist. 
bTotal does not add up to 100% as there were cases with more than one opioid involvement. 
 
Sensitivity analyses 
Scenario analyses and multiple other one-way sensitivity analyses were performed primarily to 
examine the assumptions made for calculating the economic costs of opioid poisonings in children. 
In direct medical costs estimation, discharges with diagnosis of opioid poisoning in any-listed 
diagnosis field were included. The weighted mean cost of ED hospital visits was found to be   
$1,338.55 (SE = 46.62), and the mean inpatient hospital stay cost was $6,766.03 (SE = 624.07). 
To examine if the mean costs of ED or inpatient treatment were different for discharges with and 
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without principal diagnosis of opioid poisoning, mean ED cost was calculated for visits with opioid 
poisoning as the first-listed diagnosis (weighted N = 3,555). Also, mean inpatient stay cost was 
calculated by limiting the sample to discharges with opioid poisoning as the principle diagnosis 
(weighted N = 1,127). The weighted mean cost of ED visits with opioid poisoning as first-listed 
diagnosis was $1,227.63 (SE = 52.44). The weighted mean cost of inpatient stays with principal 
diagnosis of opioid poisonings was estimated at $5,587.66 (SE = 441.99). Total economic costs 
were examined using the mean costs of ED visits and inpatient stays with opioid poisoning as first-
listed or principal diagnosis. Total economic costs were also examined using the mean ED and 
inpatient costs for discharges with non-missing (non-imputed) costs.  
A series of other one-way sensitivity analyses were performed to examine the robustness of base-
case cost estimates by varying the proportion of ED visits involving ambulance runs, ambulance 
cost per run, caregiver absent days following an ED visit and inpatient stay, DPV and discount rate 
of PVFP. Proportion of ED visits involving ambulance runs and DPV were varied to +/- 25% of 
the base-case estimate. Cost per ambulance run was varied between the 95% CI from GAO report. 
Caregiver absent days following an ED visit was assumed to be 1 day i.e., 1 day of ED visit with 
no recovery days. Caregiver absent days following an inpatient stay was assumed to be 6 days 
which included average LOS of 3 days (obtained from the KID) and assumed 3 days of recovery, 
without accounting for severity-of-illness as done in the base-case analyses. Discount rate of PVFP 
was varied to 5% and 10%. Table 24 below summarizes the input parameters and their respective 
ranges or values tested in sensitivity analyses.  
Tornado diagram displays the results from sensitivity analyses (Figure 10). The total economic 
cost estimates were most sensitive to the discount rate of PVFP. Varying the discount rate to 5% 
and 10% (from base-case value of 3%) yielded total economic costs of $146.24 million and $69.36 
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million, respectively. Restricting the prevalence estimates for inpatient discharges to those with 
principal diagnosis of opioid poisoning yielded a total economic cost estimate of $228.61 million. 
Using the 95% CI limit for ambulance costs, the total economic costs varied from $230.38 million 
to $232.03 million. Varying the DPV value by +/- 25% resulted in total economic costs between 
$230.08 million and $231.55 million. Using the mean inpatient and ED costs for discharges with 
non-missing (non-imputed) costs lowered the total economic costs by about $1.30 million and 
$1.28 million, respectively. The shift in the base-case cost estimates was minimal for other 
parameters tested. 
Table 24: Parameters tested in sensitivity analyses 
Parameter Value or range tested 
Scenario analyses 
First-listed diagnosis (ED) Mean cost ($1,227.63) 
Principal diagnosis (Inpatient)  Mean cost ($5,587.66) 
Non-missing ED costs  Mean cost ($1,288.92) 
Non-missing inpatient costs Mean cost ($6,633.41) 
One-way sensitivity analyses  
Ambulance runs 
Base-case (50%) 
+/- 25% 
Ambulance costs 
Base-case ($458.25) 
95% CI limit ($270.25 - $987.01) 
Absent days after ED visit 
Base-case (2 days) 
1 day (0 recovery day) 
Absent days after inpatient stay 
Base-case (3 to 13 days) 
6 days (3 LOS and 3 recovery days) 
DPV 
Base-case ($142.99) 
+/-25% 
PVFP discount rate 
Base-case (3%) 
5% and 10% discount rate 
 
ED = Emergency department; DPV = Daily production value; PVFP = Present value 
of expected future productivity. 
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Base-case estimate = $230.82 million. 
PVFP = Present value of expected future productivity; DPV = Daily production value; 
Dx = Diagnosis; ED = Emergency department. 
Figure 10: One-way sensitivity analyses on selected parameters (Tornado diagram) 
 
4.3: Discussion 
Economic costs associated with opioid poisonings in children 
To our knowledge, this is the first study that estimated the economic burden of pediatric opioid 
poisonings in the United States. The mean cost for an ED visit related to opioid poisonings in 
children was calculated at $1,496 and the mean cost for an inpatient stay was estimated at $7,045 
in 2012. As a rough comparison, pediatric opioid poisoning-related inpatient costs are higher than 
230.79
230.31
230.55
230.16
229.54
229.52
230.08
230.38
228.61
146.24
69.36
230.82
230.82
231.08
230.82
230.82
230.82
231.55
232.03
230.82
230.82
230.82
50 100 150 200 250
Inpatient absent days
First-listed Dx (ED)
Ambulance runs
ED absent days
Non-missing ED costs
Non-missing inpatient costs
DPV
Ambulance costs
Principal Dx (Inpatient)
PVFP 5% discount rate
PVFP 10% discount rate
Difference from Base-case (in million USD)
 
 
118 
 
the national mean costs of $6,415 for all-hospital stays among children under the age of 18 years.128 
Three previous studies have examined opioid poisoning-related costs. Inocencio et al. estimated 
mean ED costs at $2,008 and inpatient costs at $9,897 for opioid poisonings, converted to 2012 
USD.55 Another study calculated the mean charges (did not report costs) for prescription opioid 
poisoning ED visits at $3,833 to $4,339, and mean hospitalization charges at $31,058 to $34,374, 
converted to 2012 USD.56 Xiang et al. estimated mean charges (did not report costs) for drug 
poisoning-related ED visits at $2,208, converted to 2012 USD.57 The costs from current analyses 
are lower than the costs reported by prior studies. One reason may be that previous cost estimates 
represent opioid poisonings in all age groups. Prognosis and management of opioid poisonings in 
adults and older adults can vary considerably from that in children due to factors such as higher 
prevalence of multiple health conditions, chronic opioid use and misuse, substance use disorders, 
or polypharmacy among adults. These factors may result in higher cost of treatment following an 
opioid poisoning in adults compared to children.  
The total direct costs for opioid poisonings in children were estimated to be over $21 million (or 
$0.02 billion) in the United States in 2012. Inocencio et al. examined economic costs associated 
with opioid poisonings and reported total direct costs of over $1.8 billion for opioid poisonings, 
converted to 2012 USD.55 As stated earlier, this study did not limit its analyses to children yet it 
provides an upper bound for cost results from the current study.  
As for indirect costs, the total morbidity costs due to absenteeism were estimated to be over $2.9 
(or $0.003 billion) million. Mortality costs for opioid poisonings in children were estimated at 
about $207 million (or $0.207 billion). The total indirect costs associated with opioid poisonings 
in children were calculated to be nearly $210 million (or $0.21 billion) in 2012. Similar to current 
analyses, Inocencio et al. reported mortality costs to be the largest contributor to the total costs for 
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opioid poisonings. The authors estimated absenteeism costs at about $261 million, mortality costs 
over $14 billion, and total indirect productivity costs at approximately $14.4 billion in the United 
States, converted to 2012 USD.55 These indirect cost estimates for opioid poisonings are much 
greater than the costs we calculated which is related to a higher number of opioid poisoning-related 
ED visits, inpatient stays and mortality rates found in the prior study compared to current analyses. 
Inocencio et al. examined opioid poisoning-related costs mainly in adults, and the number of 
opioid poisonings and related ED visits, hospitalization and deaths are higher among adults due to 
various factors described above. Opioid poisonings in adults may be more likely to be intentional 
and severe resulting in more deaths compared to young children.47,50,86 Additionally, the present 
value of expected future productivity estimated using the human capital method tends to be higher 
for younger, working adults due to their higher earnings and higher labor force participation 
compared to children.111   
The total economic costs of opioid poisonings in children were calculated at $230.8 million (or 
$0.23 billion) in 2012 USD. Comparison of these cost estimates to other childhood health 
conditions may provide some contextual reference for the societal burden of pediatric opioid 
poisonings. Wang et al. estimated the total economic burden for asthma in children aged 5 to 17 
years at $2.5 billion which comprised direct medical costs at approximately $1.3 billion, 
absenteeism costs at about $0.9 billion, and mortality costs at $0.3 billion (all costs converted to 
2012 USD).129 Patel et al. calculated annual total direct costs at $0.25 billion and indirect costs at 
$0.13 billion for allergic reactions due to food allergy and anaphylaxis. The annual direct medical 
costs were further calculated for children under the age of 19 years, which were estimated at 
approximately $0.13 billion (all costs converted to 2012 USD).121 The emergency associated with 
an asthma attack or food-allergy reaction can be acute and fatal which is analogous to an opioid 
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poisoning event. The economic costs associated with pediatric opioid poisonings is comparable to 
food allergy and anaphylaxis but is lower than asthma. The total economic burden of opioid 
poisonings in children is also considerably lower compared to the top five most costly health 
conditions in terms of medical expenditures among children in 2012: (1) Mental health disorders 
at $13.9 billion, (2) Chronic obstructive pulmonary disease (COPD) and asthma at $8.3 billion, (3) 
Trauma-related disorders at $7.8 billion, 4) Acute bronchitis and upper respiratory infections at 
$3.2 billion, and 5) infectious diseases at $2.5 billion.130 It should be noted that many of these 
pediatric health conditions are more chronic or long-term conditions and entail longer preventive 
and treatment efforts, and are much broader than opioid poisonings.  
These analyses have several limitations. Database(s) and methodological limitations are described 
under Specific Aim 3. Additionally, downstream costs could not be captured due to inability to 
identify downstream hospitalizations and other costs related to the opioid poisonings from the 
current data. Nearly 31% of children with an opioid poisoning inpatient stay were transferred to a 
short-term or intermediate care facility. Outcomes and costs related to long-term disability or post-
discharge care following an opioid poisoning hospitalization could not be examined. This indicates 
that our study probably underestimated the true economic burden associated with pediatric opioid 
poisonings.  
Second, HCUP ED and inpatient data did not include professional fees. ED physician costs were 
calculated using CPT codes made available in ED data. CPT codes were not available in the 
inpatient database so physician costs associated with hospitalizations were estimated based on 
some fundamental hospital stay-related CPT codes, as described earlier in the Methods. Some 
hospitalizations may have required fewer or additional physician services which could affect the 
estimated total inpatient physician costs in either direction. However, this is expected to have a 
 
 
121 
 
small impact on the economic cost estimates since hospital physician costs were less than 4% of 
total inpatient costs and less than 0.1% of total direct medical costs.   
Third, direct non-medical costs were limited to costs for ambulance runs but other costs such as 
non-ambulance travel, accommodations and meals may have incurred due to opioid poisoning in 
a child. The data we analyzed did not allow for inclusion of such costs thus underestimating the 
total economic costs associated with pediatric opioid poisonings.  
Fourth, indirect costs were limited to productivity costs associated with opioid poisonings in 
children that had a HCF encounter. However, such costs may also have incurred at home. For 
instance, parents or caregivers may have taken time-off work if they had to observe the child at 
home for a few hours after a suspected exposure. Lastly, an opioid poisoning event in a young 
child may have significant intangible costs resulting from stress, anxiety or suffering. Such costs 
were not included in the current economic burden analyses.  
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Chapter 5: Specific Aim 3 
 
Aim 3: To examine the characteristics associated with pediatric opioid poisoning-related 
health care resource use and costs 
A. To assess the characteristics associated with pediatric opioid poisoning ED visits 
B. To identify factors associated with ED visit costs among children with opioid 
poisonings 
C. To examine the characteristics associated with pediatric opioid poisoning inpatient 
stays 
D. To identify factors associated with inpatient stay costs among children with opioid 
poisonings 
 
5.1: Methods  
Design 
A retrospective, cross-sectional study design was implemented for this Specific Aim. 
Conceptual framework  
Examination of characteristics associated with pediatric opioid poisoning ED visits and inpatient 
stays can serve as a measure for identifying opioid poisonings in children that are associated with 
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high HCRU and costs. These characteristics include patient-level predisposing factors such as 
sociodemographics and clinical factors including severity of poisoning, comorbidities and chronic 
conditions that may predispose a patient to higher HCRU and costs. Similarly, patient-level 
enabling factors such as payer source and organizational-level enabling factors such as hospital 
characteristics can play a role in HCRU and costs associated with pediatric opioid exposures. Payer 
source influences receipt of care and payment for health care services, whereas hospital-level 
factors have an impact on practice patterns thereby influencing patient management and care.131  
Data 
The Agency for Healthcare Research and Quality’s (AHRQ) Healthcare Cost and Utilization 
Project (HCUP) Nationwide Emergency Department Sample (NEDS) and Kids’ Inpatient 
Database (KID) were used. These datasets are described in Specific Aim 2. 
Sample 
Discharge records from NEDS and KID databases were extracted for children under 18 years of 
age with 1 or more opioid poisoning-related International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) diagnosis codes in any-listed diagnosis. Opioid poisoning-
related ICD-9-CM codes are listed in Table 16 (Specific Aim 2). The sampling criteria are 
described in Specific Aim 2.  
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Variables 
Total charges/costs 
The HCUP databases provide total charges for ED visits and inpatient stays and not the actual cost 
of services. The charges reported in NEDS and KID were converted to costs using CCR provided 
by HCUP. The detailed methodology for implementing these CCR is described in Specific Aim 2.  
Clinical variables 
Opioid poisonings 
Specific opioids involved in poisonings were identified as methadone, other prescription opioids 
or unspecified opioids, using the ICD-9-CM diagnosis codes listed in Table 16 (Specific Aim 2).  
Intentionality 
Intentionality of opioid poisonings was identified as unintentional, intentional or undetermined 
using the ICD-9-CM External Cause of Injury codes (E-codes) listed in Table 16. Data is recorded 
for up to 4 E-codes for each visit or stay. Records that did not have a specific E-code were initially 
classified as missing. This resulted in about 7% ED visits with a missing or unknown intentionality 
in the NEDS. However, NEDS contains certain injury-related variables including intent (self-harm 
or unintentional) on every record. Information from these injury-related variables was used to 
impute intentionality to the extent possible. For instance, if the record was classified as 
undetermined (using E-code 980.0) or missing but had an indicator for self-harm, then the record 
was reclassified as intentional. Such injury-related variables are not recorded in the KID, inpatient 
stays that did not have a specific E-code were classified as unknown.  
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Other clinical variables 
Data is recorded for a number of diagnosis and procedure-related variables per visit. About 15 to 
25 ICD-9-CM diagnosis codes, Clinical Classification Software (CCS) category codes, CPT 
procedure codes or ICD-9-CM procedure codes and corresponding CCS categories, and chronic 
condition indicators are recorded for each visit.  
Common first-listed and any-listed diagnosis were examined using the ICD-9-CM and single-level 
CCS codes. CCS for diagnosis is an HCUP tool that collapses ICD-9-CM codes in 285 mutually 
exclusive and clinically meaningful categories. CCS for services and procedures categorizes CPT 
codes or ICD-9-CM procedure codes into distinct categories. Common chronic conditions were 
identified using the chronic condition indicators and the ICD-9-CM codes. Top primary procedures 
were identified using the CPT CCS codes in the ED data, and ICD-9-CM procedure CCS codes in 
the inpatient data. Discharge records with poisonings by other drugs (in addition to opioids) i.e., 
multi-drug involvement, were identified using the ICD-9-CM codes (960 - 979) in any-listed 
diagnosis. Detailed description of these codes is provided in Appendix E.  
As stated above, information on injury is recorded for every ED visit. HCUP identifies injuries 
such as burns, fractures, poisonings or others, using ICD-9-CM codes. The multi-injury variable 
from the NEDS was used to identify ED visits with more than one injury reported.  
Further, patient’s disposition status at the time of discharge was classified as routine (includes 
routine discharges or home health care), transfer (includes transfers to short-term hospital, skilled 
nursing facility (SNF), intermediate care or another type of facility), death, or unknown (not 
admitted or discharged alive but destination unknown).  
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In addition to data elements listed above, KID includes information on transferred-in cases which 
indicates if the patient was a transfer from another HCF. Data is also provided on Elixhauser 
comorbidities, APR-DRG severity index and mortality risk index, LOS, and Diagnosis-Related 
Groups (DRGs) for every inpatient stay.  
The AHRQ’s Elixhauser comorbidity measures identify presence of up to 30 co-existing condition 
groups such as alcohol abuse, depression, psychoses, that are not directly related to the key reason 
for admission (or the principal diagnosis), and are likely to have existed preceding the hospital 
admission.132 The list of AHRQ Elixhauser comorbidities can be found in Appendix F. The 
Elixhauser comorbidity measure is a validated tool for risk-adjustment in administrative data.133 
Comorbidity analyses were limited to Elixhauser comorbidities. No further comorbidities were 
explored because this study was examining outcomes in children so the likelihood of presence of 
co-existing conditions beyond those included in the HCUP data is low. Also, previous studies have 
examined other comorbidities in the adult population with opioid poisonings but there is a lack of 
such literature in the pediatric population.55  
APR-DRG severity-of-illness index and mortality risk index are provided in the inpatient data to 
adjust for case-mix complexity and are linked to the intensity of HCRU.134 These indices classify 
loss of function and likelihood of mortality into 4 distinct categories, respectively. The LOS and 
DRG variables were used as recorded in the data. In addition to the two poisoning-related DRGs, 
DRG 917 (Poisoning and toxic effects of drugs with major complications or comorbidities) and 
DRG 918 (Poisoning and toxic effects of drugs without major complications or comorbidities), 
other DRGs were explored in this population.  
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Payer and hospital-related variables  
Data is recorded in the NEDS on the primary payer and hospital location, region, ownership, 
teaching status and trauma level. Primary payer was classified as Medicaid, private, uninsured or 
other (includes Medicare). In the NEDS analysis, hospital ownership was grouped as public, 
private (includes private, non-profit or proprietary), or public/private (includes hospitals that could 
not be identified as public or private i.e., collapsed category). Hospital location was categorized as 
urban (includes large or small metropolitans, or micropolitans) or rural (areas that were neither 
metropolitan nor micropolitan), and hospital teaching status was classified as teaching (includes 
metropolitan teaching hospitals) or non-teaching (includes metropolitan non-teaching or non-
metropolitan hospitals). Hospital trauma-level status was categorized as trauma (includes trauma 
level I or II centers) or non-trauma (includes non-trauma or trauma level III centers). Hospital 
region was used as classified in the data. 
The KID provides data on primary payer, and hospital region, ownership, bedsize and 
location/teaching status (combined). All the hospital-related variables were used as categorized in 
the KID. Classification of payer source was similar to that described above. 
Sociodemographic variables 
The HCUP provides information on patient’s age, gender, residence location and national quartile 
of median household annual income for patient’s ZIP Code, for all ED visits and inpatient stays. 
Age was primarily categorized into 0 to <1, 1 to 2, 3 to 5, 6 to 12, and 13 to 17 years groups 
however, the age group of ≤5 years was combined for adjusted analyses. Patient’s residence 
location was classified as urban – mid to large (includes large central, large fringe or medium 
metropolitans), urban – small to mid (includes medium or small metropolitans, or micropolitans) 
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or rural (neither metropolitan nor micropolitan areas). Patient’s gender and ZIP Code level income 
information was used as recorded in the data.  
In addition to the variables listed above, data is recorded on patient’s race in the KID. Race was 
classified as White, Black, Hispanic or other (includes Asian or Pacific Islander, Native American 
or other). 
Other variables 
Discharge-level sampling weight is provided for every discharge record. This along with hospital 
identifier and sample stratum were used for weighted analyses.   
Table 25: HCUP NEDS and KID variables considered for Specific Aim 3 
Data 
Source 
Data Variables 
NEDS  Total charges 
Clinical 
▪ Number of diagnosis, procedures and E-codes 
▪ Up to 15 ICD-9-CM diagnosis and CCS codes 
▪ Up to 4 E-codes  
▪ Up to 15 CPT procedure and CCS codes  
▪ Up to 9 ICD-9-CM procedure codes 
▪ Up to 15 chronic condition indicators  
▪ Injury-related variables including number of injuries (multi-injury), intent 
▪ Disposition status   
Payer and Hospital-related 
▪ Expected primary payment source  
▪ Hospital level factors (including location, region, ownership, teaching 
status, trauma-level) 
Patient sociodemographics 
▪ Age, gender, residence location, median household annual income for 
patient’s ZIP Code 
Others 
▪ Patient discharge weights 
KID 
 
 
Total charges 
Clinical 
▪ Number of diagnosis, procedures and E-codes 
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▪ Up to 25 ICD-9-CM diagnosis and CCS codes 
▪ Up to 4 E-codes  
▪ Up to 15 ICD-9-CM procedure and CCS codes 
▪ Up to 25 chronic condition indicators  
▪ Elixhauser comorbidities 
▪ APR-DRG severity index and mortality risk index  
▪ LOS, DRGs 
▪ Disposition status, transfer-in, ED event on record 
Payer and Hospital-related 
▪ Expected primary payment source  
▪ Hospital level factors (including ownership, bedsize, region, and 
location/teaching status) 
Patient sociodemographics 
▪ Age, gender, race, residence location, median household annual income for 
patient’s ZIP Code 
Others 
▪ Patient discharge weights, hospital-specific CCR 
 
NEDS = Nationwide Emergency Department Sample, KID = Kids’ Inpatient Database, ED = 
Emergency department, ICD-9-CM = International Classification of Diseases, 9th Revision, 
Clinical Modification, E-codes = External Cause of Injury codes, CCS = Clinical Classification 
Software category codes, CPT = Current Procedural Terminology, APR-DRG = All Patients 
Refined Diagnosis Related Groups, LOS = Length of stay, DRGs = Diagnosis-Related Groups, 
CCR = Cost-to-charge ratios. 
 
Statistics analyses 
Descriptive statistics (frequency, %, mean, SD) were calculated to characterize pediatric opioid 
poisoning ED visits and inpatient stays. Bivariate analyses using Chi-square tests were performed 
to examine the association between various characteristics and pediatric opioid poisoning ED visits 
and inpatient stays by intent of exposure. 
Total charges were missing for 182 (17.4%)  ED visits in the NEDS, and 20 (1.5%) of inpatient 
stays in the KID. Mean costs of opioid poisoning-related ED visits and inpatient stays were 
computed and compared across various sociodemographic and clinical characteristics without 
imputing the missing cost data. Statistical tests were conducted prior to imputation to avoid any 
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statistical bias due to imputation of the dependent variable. Additionally, calculation of standard 
errors of ED and inpatient costs accounted for the sampling design of NEDS and KID respectively. 
The distribution of the dependent cost variable(s) was examined. Outliers for ED charges were 
examined (top/bottom 5%) manually for reasonability. Suspiciously high charges in inpatient data 
were examined and deleted from cost analyses using the method described by HCUP. This 
approach is explained in Specific Aim 2.  
Bivariate differences in mean ED visit-related costs were tested using t-tests and ANOVA, under 
the central-limit theorem (CLT) assumption, between the various sociodemographic, clinical, 
payer and hospital characteristics. Inpatient costs were highly skewed so nonparametric Wilcoxon 
Rank-Sum test and Kruskal-Wallis tests were used for bivariate comparisons of mean inpatient 
stay-related costs and the covariates. These analyses were exploratory so all sociodemographic, 
clinical, payer and hospital-related factors were examined.  
Adjusted analyses were performed using generalized linear model (GLM) to estimate the 
association of independent variables with ED and inpatient costs, respectively. The costs data were 
skewed and needed to be transformed. Health care costs are non-negative and tend to be skewed 
to the right with increasing variability with rising mean (heteroscedasticity or unequal variances).  
Ordinary Least Squares (OLS) regression technique with log transformation of cost can be used 
for dealing with such skewness and to stabilize variance. However, OLS provides cost results on 
a log scale and smearing factors have to be applied for retransformation of costs to the original 
scale. Such retransformation can introduce bias if the unequal variance assumption is violated. 
Generalized linear model (GLM) is an alternative technique that is widely used for analyzing 
health care costs data. GLM models do not require cost data to be normally distributed and can 
correct for heteroscedasticity. GLM allows for a relatively straightforward back transformation 
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compared to OLS, retaining the original scale.  Two important components in a GLM include: (1) 
the link function (g) which describes the relationship of dependent variable (Y) mean to the 
predictors, and (2) the family which specifies the distribution or the mean-variance relationship. 
Log-link function is commonly used for economic cost analyses. Health care cost data typically 
have log-normal or gamma distribution. The distribution of the GLM model was chosen using the 
Modified Park test. In this procedure, residuals and predicted value computed from an initial 
adjusted GLM model are tested. The parameter estimate from the model of residuals and predicted 
value (obtained from above) provide information on appropriate distribution for the data. For 
instance, an estimate of 2 corresponds to gamma distribution.135–137 GLM was performed in SAS 
using PROC GENMOD with a REPEATED statement, to account for HCUP sampling design 
using hospital-level clusters. REPEATED statement invokes the generalized estimating equations 
(GEE) method and gives robust standard errors in the specified model.  
For the adjusted ED cost analyses, GLM was initially performed with all covariates (Initial model 
QIC = 1014.9), and then excluding those that were insignificant in bivariate analyses and the initial 
model (Final model QIC = 1008). The latter model displayed a better fit and was selected as the 
final model for analyses. Quasi-likelihood criteria (or QIC) is a goodness of fit statistic and can be 
used to compare GEE models. QIC can be used for model selection even with non-nested 
models.138 Similar approach was followed for the adjusted analyses of inpatient costs. Initial GLM 
was performed with all covariates (Initial model QIC = 1605.26), and then excluding insignificant 
covariates (Final model QIC = 1562.13). The latter model displayed a better fit and was selected 
as the final model for analyses. 
All statistical tests were performed with a two-sided significance level of 0.05. All analyses were 
done in SAS version 9.4 and Microsoft Excel 2013.  
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5.2: Results 
Aim 3A: To assess the characteristics associated with pediatric opioid poisoning ED visits 
There were a weighted total of 4,584 ED visits for opioid poisonings among children. Table 26 
summarizes various characteristics of pediatric opioid poisoning ED visits. Majority of these ED 
visits were among teenagers (53.4%) followed by young children, particularly 1 to 2 years of age 
(28%). Most of these visits were among children from medium to large metropolitan areas 
(68.6%). About 64.6% of total ED visits were due to unintentional poisonings and 26.1% involved 
intentional poisonings. Nearly 70% of ED visits resulted from other prescription opioid 
poisonings, over one-fourth had multi-drug involvement (27.8%) and one-third (32.3%) had a 
multi-injury. About 35.5% of these visits had one or more chronic condition diagnoses. Nearly 
three-fourths of the visits were routine discharges (75.3%), while another one-fourth were transfers 
to a short-term hospital, SNF or intermediate care (24.2%). Medicaid was the most common payer 
(46.9%) followed by private insurance (41.4%). Most pediatric opioid poisoning ED visits were 
in hospitals in urban settings (93.2%), commonly in South (36.1%) and West (27.9%) regions of 
the country, private hospitals compared to public hospitals (33.4% vs. 7.6%), non-teaching 
(62.7%) and non-trauma institutions (70.2%) (Table 26).  
These characteristics were also examined by intent of opioid poisoning-related ED visits as shown 
in Table 27. Child’s age and gender, type of opioid involved, diagnosis of multi-drug poisonings, 
multi-injuries or chronic conditions, disposition status, payer source and hospital region were 
significantly associated with the intent of pediatric opioid poisoning ED visits.  
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Unintentional poisoning-related ED visits were more common among young children (61.2%), 
while intentional poisoning-related ED visits were common among teenagers (97.1% vs. 33.3%) 
and girls (69.7% vs. 49.6%). Methadone poisoning-related ED visits were higher among those 
with unintentional poisonings compared to those with intentional poisoning (5.8% vs. 1.1%), 
whereas other prescription opioids were more commonly involved in intentional poisoning 
compared to unintentional poisoning ED visits (79.6% vs. 65.3%).  
Compared to ED visits for unintentional poisonings, a higher number of intentional poisoning-
related visits were associated with multi-drug involvement (49.3% vs. 17.3%), multi-injuries 
(55.1% vs. 21.9%), chronic condition diagnosis (63.9% vs. 22.8%), and involved transfers to short-
term hospital, SNF or intermediate care facilities (58% vs. 12.3%). Medicaid was the most 
common payer for unintentional opioid poisoning-related ED visits (50.2% vs. 38%), while private 
insurance was the common source of payment for intentional opioid poisoning-related ED visits 
(51.1% vs. 36.3%).  Unintentional opioid poisoning-related ED visits were higher than intentional 
opioid poisoning-related visits in the Northeast hospitals (12.7% vs. 8.8%), while intentional 
opioid poisoning-related ED visits were more common than unintentional opioid poisoning-related 
ED visits in the Midwest hospitals (23.4% vs. 17.6%) (Table 27).  
Table 28 summarizes the common clinical diagnosis and procedures in opioid poisoning-related 
ED visits. On average, children with opioid poisoning ED visits had 3 diagnosis (range = 1 to 18) 
and 6 CPT procedures (range = 0 to 34) recorded. Substance-related disorder (includes diagnosis 
of opioid poisoning) was the most frequently recorded diagnosis followed by poisoning by other 
medications and psychotropic drugs, and mood disorders. Depression, tobacco use disorder, drug 
abuse, asthma and attention-deficit/hyperactivity disorder (ADHD) were common chronic 
conditions. Aromatic analgesics, benzodiazepines and propionic acid derivatives were commonly 
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involved in multiple drug poisonings. Most of the procedures in these ED visits were diagnostic 
(Table 28).  
Table 26: Characteristics of pediatric opioid poisoning ED visits 
Characteristic 
All opioid poisoningsa 
Unweighted, N (%) 
(N = 1,048) 
Weighted, N (%) 
(N = 4,584) 
Sociodemographic 
Age group (years)  
0 < 1  
1 - 2  
3 - 5  
6 - 12  
13 - 17  
 
48 (4.58) 
291 (27.77) 
97 (9.26) 
49 (4.68) 
563 (53.72) 
 
208 (4.55) 
1,283 (27.99) 
424 (9.25) 
220 (4.81) 
2,448 (53.41) 
Female 564 (53.82) 2,435 (53.11) 
Residence 
Urban (Mid to large) 
Urban (Small to mid) 
Rural  
Unknown 
 
736 (70.23) 
237 (22.61) 
74 (7.06) 
1 (0.1) 
 
3,144 (68.58) 
1,076 (23.48) 
360 (7.85) 
  4 (0.08) 
Median ZIP Code HH income 
$1 - 38,999   
$39,000 - 47,999   
$48,000 - 62,999   
≥ $63,000  
Unknown 
 
267 (25.48) 
272 (25.95) 
272 (25.95) 
216 (20.61) 
             21        (2.0) 
 
1,156 (25.22) 
1,157 (25.24) 
1,205 (26.28) 
 965 (21.04) 
102 (2.22) 
Clinical 
Intent 
Unintentional 
Intentional 
Undetermined  
Unknown 
 
675 (64.41) 
274 (26.15) 
63 (6.01) 
36 (3.44) 
 
2,963 (64.64) 
1,196 (26.09) 
253 (5.52) 
171 (3.74) 
Opioid 
Methadone 
Other prescription opioids 
Unspecified 
 
48  (4.58) 
726  (69.27) 
274  (26.15) 
 
209 (4.56) 
3,208 (69.97) 
1,167 (25.47) 
Multi-drug poisonings 284  (27.10) 1,275 (27.81) 
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Multi-injuries 334    (31.87) 1,482 (32.34) 
≥ 1 Chronic conditions 377  (35.97) 1,627 (35.49) 
Disposition status 
Routine  
Transfers  
Unknown  
 
781 (74.52) 
263 (25.10) 
4 (0.38) 
 
3,452 (75.29) 
1,110 (24.22) 
22 (0.49) 
Payer and hospital 
Payer 
Medicaid 
Private 
Other 
Uninsured  
Unknown 
 
492 (46.95) 
422 (40.27) 
53 (5.06) 
79 (7.54) 
 2  (0.19) 
 
2,148 (46.86) 
1,900 (41.44) 
198 (4.32) 
329 (7.18) 
  9 (0.20) 
Hospital location 
Rural  
Urban 
 
64 (6.11) 
984 (93.89) 
 
310 (6.77) 
4,274 (93.23) 
Hospital region 
Northeast 
Midwest 
South 
West 
 
116  (11.07) 
219 (20.90) 
420 (40.08) 
293 (27.96) 
 
 520 (11.34) 
1,130 (24.65) 
1,654 (36.07) 
1,281 (27.94) 
Hospital ownership  
Public 
Private 
Public or private 
 
99 (9.45) 
371 (35.40) 
578 (55.15) 
 
347 (7.58) 
1,533 (33.44) 
2,704 (58.98) 
Hospital teaching status 
Non-teaching 
Teaching 
 
669 (63.84) 
379 (36.16) 
 
2,873 (62.67) 
1,711 (37.33) 
Hospital trauma level 
Non-trauma or level III 
Trauma level I or II 
 
749 (71.47) 
299 (28.53) 
 
3,216 (70.15) 
1,368 (29.85) 
 
aAnalyses were limited to ED visits without hospitalization. This may have underestimated the 
actual number of pediatric opioid poisoning ED visits.  
HH = Household.   
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Table 27: Characteristics of pediatric opioid poisoning ED visits by intent 
Characteristic Unintentional (n = 675), 
unweighted n (%) 
Intentional (n = 274), 
unweighted n (%) 
Sociodemographic 
Age group (years)* 
0 < 1  
1 - 2  
3 - 5  
6 - 12  
13 - 17  
 
44 (6.52) 
278 (41.19) 
 91 (13.48) 
37 (5.48) 
225 (33.33) 
 
-- 
-- 
-- 
 8 (2.92) 
266 (97.08) 
Female* 335 (49.63) 191 (69.71) 
Residence 
Urban (Mid to large) 
Urban (Small to mid) 
Rural  
Unknown 
 
464 (68.74) 
161 (23.85) 
49 (7.26) 
 1 (0.15) 
 
208 (75.91) 
 52 (18.98) 
14 (5.11) 
-- 
Median ZIP Code HH income 
$1 - 38,999   
$39,000 - 47,999   
$48,000 - 62,999   
≥ $63,000  
Unknown 
 
178 (26.37) 
180 (26.67) 
174 (25.78) 
128 (18.96) 
15 (2.22) 
 
61 (22.26) 
67 (24.45) 
70 (25.55) 
71 (25.91) 
5 (1.82) 
Clinical  
Opioid* 
Methadone 
Other prescription opioids   
Unspecified 
 
39 (5.78) 
441 (65.33) 
195 (28.89) 
 
3 (1.09) 
218 (79.56) 
53 (19.34) 
Multi-drug poisonings* 117 (17.33) 135 (49.27) 
Multi-injuries* 148 (21.93) 151 (55.11) 
≥ 1 Chronic conditions* 154 (22.81) 175 (63.87) 
Disposition status* 
Routine  
Transfers  
Unknown  
 
590 (87.41) 
83 (12.3) 
2 (0.3) 
 
113 (41.24) 
159 (58.03) 
 2 (0.73) 
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Payer and hospital 
Payer* 
Medicaid 
Private 
Other  
Uninsured 
Unknown 
 
339 (50.22) 
245 (36.30) 
31 (4.59) 
58 (8.59) 
2 (0.3) 
 
104 (37.96) 
140 (51.09) 
14 (5.11) 
16 (5.84) 
-- 
Hospital location 
Rural  
Urban 
 
39 (5.78) 
636 (94.22) 
 
15 (5.47) 
259 (94.53) 
Hospital region* 
Northeast 
Midwest 
South 
West 
 
 86 (12.74) 
119 (17.63) 
262 (38.81) 
208 (30.81) 
 
24 (8.76) 
 64 (23.36) 
106 (38.69) 
 80 (29.20) 
Hospital ownership  
Public 
Private 
Public or private 
 
61 (9.04) 
241 (35.70) 
373 (55.26) 
 
 28 (10.22) 
100  (36.50) 
146 (53.28) 
Hospital teaching status 
Non-teaching 
Teaching 
 
431 (63.85) 
244 (36.15) 
 
168 (61.31) 
106 (38.69) 
Hospital trauma level 
Non-trauma or level III 
Trauma level I or II 
 
478 (70.81) 
197 (29.19) 
 
194 (70.80) 
  80       (29.20) 
 
*Chi-square p<.05. HH = Household.  
Results for undetermined or unknown intentionality not shown here. 
A total 7 visits had E-code for an adverse effect (E935.1: Methadone causing adverse effects in 
therapeutic use, or E935.2: Other opiates and related narcotics causing adverse effects in 
therapeutic use). 
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Table 28: Clinical conditions and procedures recorded in pediatric opioid poisoning ED 
visits 
Conditions/Procedures Unweighted, n (%) 
Clinical conditionsa,b,c,d 
Number of diagnoses, mean (SD) 2.77 (2.02) 
Primary (first-listed) diagnosis (n = 1,048) 
Substance-related disorders* 
Poisoning by other medications and drugs 
Poisoning by psychotropic agents 
Mood disorders 
Residual codes; unclassified** 
 
 821 (78.34) 
 78 (7.44) 
43 (4.1) 
 25 (2.39) 
 11 (1.05) 
 Any-listed diagnosis (n = 2,899) 
Substance-related disorders* 
Poisoning by other medications and drugs 
Mood disorders 
Poisoning by psychotropic agents 
Screening and history of mental health and substance abuse 
 
           1,209 (41.7) 
283 (9.76) 
161 (5.55) 
138 (4.76) 
 80 (2.76) 
Chronic Conditions (n = 1,639) 
Depressive disorder 
Tobacco use disorder  
Drug abuse, unspecified 
Asthma, unspecified  
Attention-deficit/hyperactivity disorder 
 
95 (5.8) 
 63 (3.84) 
 45 (2.75) 
 29 (1.77) 
 27 (1.65) 
Multi-drug poisonings (in addition to opioids) (n = 1,237) 
Aromatic analgesics 
Benzodiazepine-based tranquilizers 
Propionic acid derivatives 
Sedative and Hypnotics 
Antiallergics and antiemetics  
Hallucinogens 
Anticonvulsants 
Antidepressants 
 
 74 (5.98) 
 67 (5.42) 
 40 (3.23) 
 23 (1.86) 
 20 (1.62) 
 16 (1.29) 
 15 (1.21) 
 14 (1.13) 
Clinical proceduresa,b 
Number of procedures (CPT), mean (SD)*** 6.42 (6.37) 
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Primary (first-listed) procedures (n = 1,048)*** 
Other diagnostic procedures  
(interview, evaluation, consultation) 
Other therapeutic procedures 
Microscopic examination  
(bacterial smear; culture; toxicology) 
Laboratory - Chemistry and hematology 
Medications 
(Injections, infusions and other forms) 
 472 (45.04) 
 
 90  (8.59) 
 41 (3.91) 
 
 37  (3.53) 
 22        (2.10) 
 
Listed conditions or procedures that were top 5 or those >1%. 
*Includes ICD-9-CM codes for opioid poisoning.  
**Includes codes for organic sleep disorder, nonspecific abnormal findings, general symptoms 
and other unclassified ICD-9-CM codes. 
***322 (30.4%) visits had CPT codes missing. ICD-9-CM procedure codes were missing for 999 
(95.3%) of visits (not shown here). 
aN represents number of ED visits for primary diagnosis and procedures.   
N represents number of diagnosis for any-listed diagnosis. 
For chronic conditions and multi-drug poisonings, N represents number of diagnosis for those 
with ≥1 chronic conditions and ≥1 multi-drug poisonings, respectively.  
bPrimary or any-listed diagnosis were identified using HCUP’s single-level CCS. Multi-drugs 
and chronic conditions were identified using ICD-9-CM diagnosis codes. Primary procedures 
were identified using single-level CPT CCS. 
cTotal of 73 ED visits had a pain-related diagnosis (i.e., musculoskeletal pain, cancer pain, sickle 
cell anemia, headache, fracture or abdominal pain) in any-listed diagnosis.  
dOne record had ICD-9-CM code for heroin poisoning. 
 
 
Aim 3B: To identify factors associated with ED visit costs among children with opioid 
poisonings 
Bivariate comparisons of mean ED hospital cost across various sociodemographic, clinical, payer 
and hospital characteristics is summarized in Table 29 below. Child’s age group and gender; intent 
of poisoning; diagnosis of one or more multi-drugs, multi-injuries and chronic conditions; total 
number of diagnoses and procedures; disposition status; hospital ownership and teaching status 
were found to be significantly associated with the cost of opioid poisoning-related ED visits. The 
weighted mean cost for a pediatric opioid poisoning-related ED visit was estimated to be $1,288.92 
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(SE = 54.10). Mean cost was higher for teenagers compared to the young children ($1,712.79 vs. 
$763.34), and for girls compared to boys ($1,391.02 vs. $1,176.20).  
Mean cost of ED visits was significantly higher for intentional opioid poisonings in children 
($1,835.24 vs. $1,052.76). However, the mean cost did not vary much by the type of opioid 
involved. Diagnoses of multi-drug poisonings ($1,567.36 vs. $1,181.33), multi-injuries ($1,563.99 
vs. $1,154.45), and chronic conditions ($1,652.52 vs. $1,083.60) were associated with a higher 
mean ED cost. Mean ED costs were also higher for visits with 3 or more diagnosis or performed 
procedures ($1732.13 and $1756.62, respectively). ED visits that were transferred to another HCF 
had higher mean cost compared to those routinely treated and released ($1,989.98 vs. $1,056.07).  
Mean ED cost of treatment was higher among private hospitals compared to public centers 
($1,597.61 vs. $1,293.86), and non-teaching hospitals compared to teaching institutions 
($1,389.29 vs. $1,122.97) (Table 29).  
Table 29: Mean ED hospital costs by characteristics (in 2012 USD) 
Characteristic 
Unweighted cost,  
(N = 1,048) 
Weighted cost,  
(N = 4,584) 
Mean SE Mean SE 
Total (original costs)a 1,318.57 45.13 1,288.92 54.10 
Sociodemographic 
Age group (years)* 
≤ 5  
6 - 12  
13 - 17  
 
768.19 
1,122.03 
1,757.75 
 
47.16 
166.73 
67.65 
 
763.34 
1,095.13 
1,712.79 
 
56.57 
191.97 
75.52 
Gender* 
Male 
Female 
 
1,214.13 
1,411.19 
 
61.8 
64.94 
 
1,176.20 
1,391.02 
 
60.87 
75.84 
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Residence 
Urban (Mid to large) 
Urban (Small to mid) 
Rural  
Unknown 
 
1,357.34 
1,142.32 
1,509.63 
682.50 
 
54.50 
73.57 
226.69 
-- 
 
1,307.40 
1,173.49 
1,460.53 
682.50 
 
60.97 
83.06 
209.94 
-- 
Median ZIP Code HH income 
$1 - 38,999   
$39,000 - 47,999   
$48,000 - 62,999   
≥ $63,000  
Unknown 
 
1,272.79 
1,226.63 
1,392.02 
1,336.75 
1,934.93 
 
85.27 
90.80 
91.09 
85.43 
529.53 
 
1,234.95 
1,242.02 
1,338.32 
1,280.25 
1,895.77 
 
81.53 
100.56 
103.41 
104.44 
495.87 
Clinical  
Intent* 
Unintentional 
Intentional 
Undetermined 
Unknown  
 
1,066.13 
1,877.04 
1,743.46 
926.50 
 
52.34 
82.22 
246.03 
134.66 
 
1,052.76 
1,835.24 
1,660.20 
929.76 
 
64.07 
88.96 
196.76 
133.98 
Opioid 
Methadone 
Other prescription opioids  
Unspecified 
 
1,213.00 
1,323.19 
1,324.01 
 
134.69 
54.97 
89.44 
 
1,157.57 
1,279.02 
1,338.05 
 
134.49 
60.81 
101.00 
Multi-drug poisonings* 
No 
Yes 
 
1,203.66 
1,623.55 
 
53.57 
80.46 
 
1,181.33 
1,567.36 
 
59.74 
91.17 
Multi-injuries* 
No 
Yes 
 
1,178.21 
1,607.72 
 
56.51 
71.43 
 
1,154.45 
1,563.99 
 
62.60 
84.60 
≥ 1 Chronic conditions* 
No 
Yes 
 
1,098.63 
1,695.72 
 
55.39 
72.81 
 
1,083.60 
1,652.52 
 
64.16 
78.01 
Number of diagnoses* 
1 
2 
≥ 3 
 
805.28 
1,182.72 
1,761.96 
 
74.05 
76.40 
69.87 
 
776.25 
1,130.70 
1,732.13 
 
72.44 
83.35 
81.98 
Number of procedures (CPT)*b 
1 
2 
≥ 3 
 
401.26 
462.11 
1,788.03 
 
42.66 
51.50 
69.84 
 
394.75 
415.33 
1,756.62 
 
49.32 
43.72 
82.71 
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Disposition* 
Routine  
Transfers  
Unknown  
 
1,054.21 
2,062.97 
1,037.8 
 
45.11 
101.92 
274.23 
 
1,056.07 
1,989.98 
932.35 
 
53.13 
104.75 
254.07 
Payer and hospital 
Payer 
Medicaid 
Private 
Other  
Uninsured 
Unknown 
 
1,283.79 
1,369.39 
1,434.51 
1,218.97 
1,121.52 
 
71.17 
64.80 
256.68 
108.67 
115.62 
 
1,252.74 
1,346.36 
1,331.67 
1,200.72 
1,107.87 
 
72.01 
80.27 
250.57 
116.15 
80.62 
Hospital location 
Rural  
Urban 
 
1,435.19 
1,309.58 
 
189.89 
46.38 
 
1,477.88 
1,272.62 
 
197.23 
50.47 
Hospital region 
Northeast 
Midwest 
South 
West 
 
1,233.47 
1,164.82 
1,372.3 
1,500.95 
 
109.61 
66.64 
73.78 
122.67 
 
1,220.39 
1,179.25 
1,306.47 
1,536.79 
 
142.22 
75.94 
79.19 
135.90 
Hospital ownership* 
Public 
Private 
Public or private 
 
1,207.71 
1,652.53 
1,152.18 
 
148.03 
101.40 
45.98 
 
1,293.86 
1,597.61 
1,137.61 
 
188.16 
102.35 
57.62 
Hospital teaching status* 
Non-teaching 
Teaching 
 
1,417.59 
1,150.45 
 
64.35 
52.54 
 
1,389.29 
1,122.97 
 
69.77 
60.47 
Hospital trauma level 
Non-trauma or level III 
Trauma level I or II 
 
1,354.92 
1,218.67 
 
55.38 
73.6 
 
1,313.88 
1,227.19 
 
57.88 
92.65 
 
*p-value <.05. T-test and ANOVA (under the CLT assumption) were used to examine 
unweighted mean costs. HH = Household.  
aTotal ED hospital costs were missing for 182 (17.4%) visits.  
bNumber of ED procedures were missing or zero for 30.44% of visits.  
 
For the adjusted analyses of ED-related costs, multiple injuries and multiple drug involvement 
variables were found to be highly correlated (|r| ≥ 0.8). Multi-injury covariate was removed from 
further analyses. Also, patient’s residence, median ZIP Code level income, disposition status, and 
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payer constituted ≤2% of missing data. Since the rate of missing values for these variables was 
low, the missing observations were dropped from further analyses. The initial adjusted model 
included all covariates from bivariate analyses. However, characteristics that were found to be 
insignificant in both the bivariate analyses and the initial model were excluded from the final 
adjusted analyses. Type of opioid involved was included in the final model irrespective of the 
statistical significance. 
Adjusted analyses exhibited a significant association between age group, number of diagnosis and 
procedures, disposition status, and ED costs. The results from the adjusted model of ED hospital 
costs are summarized in Table 30. Other things constant, teenagers had 1.39 (95% CI = 1.15 - 
1.68) times higher ED costs compared to the young children. The ED costs for opioid poisoning 
in children increased by 3% (95% CI = 0% - 6%) and 7% (95% CI = 6% - 8%) for every one 
additional diagnosis or procedure performed in the ED, respectively. ED visits that resulted in a 
transfer to another HCF had 1.28 (95% CI = 1.09 - 1.50) times higher costs compared to those 
routinely treated and released. Although hospital region was not significant, hospitals in the South 
had significantly lower costs by 0.59 (95% CI = 0.38 - 0.92) times compared to hospitals in the 
Northeast.  
Table 30: Adjusted analyses of ED hospital costs 
Characteristic Estimate (β) SE Exp (β)  (95% CI) Z p-value 
Intercept 6.126 0.515 -- 11.91 <.0001 
Sociodemographic 
Age group (years)* 
≤ 5  
6 - 12  
13 - 17  
 
-- 
0.081 
0.326 
 
-- 
0.157 
0.097 
 
-- 
 1.08     (0.80 - 1.48) 
 1.39     (1.15 - 1.68) 
 
-- 
0.52 
3.36 
 
-- 
0.605 
0.0008 
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Gender 
Male 
Female 
 
-- 
0.070 
 
-- 
0.072 
 
-- 
1.07 (0.93 - 1.24) 
 
-- 
0.97 
 
-- 
0.3321 
Clinical  
Intent 
Unintentional 
Intentional 
Undetermined  
Unknown 
 
-- 
-0.053 
0.121 
-0.073 
 
-- 
0.088 
0.170 
0.114 
 
 
0.95 (0.80 - 1.13) 
1.13 (0.81 - 1.57) 
0.93 (0.74 - 1.16) 
 
-- 
-0.6 
0.71 
-0.65 
 
-- 
0.5503 
0.4754 
0.5179 
Opioid 
Methadone 
Other Rx opioids 
Unspecified 
 
-- 
0.078 
0.042 
 
-- 
0.146 
0.145 
 
-- 
1.08 (0.81 - 1.44) 
1.04 (0.79 - 1.39) 
 
-- 
0.53 
0.29 
 
-- 
0.5941 
0.771 
Multi-drug poisonings 
No 
Yes 
 
-- 
-0.090 
 
-- 
0.070 
 
-- 
0.91 (0.80 - 1.05) 
 
-- 
-1.29 
 
-- 
0.1982 
≥ 1 Chronic conditions 
No 
Yes 
 
-- 
-0.141 
 
-- 
0.103 
 
-- 
0.87 (0.71 - 1.06) 
 
-- 
-1.36 
 
-- 
0.1737 
Number of diagnoses* 0.032 0.014 1.03 (1.00 - 1.06) 2.23 0.0261 
Number of procedures* 0.066 0.006 1.07 (1.06 - 1.08) 11.5 <.0001 
Disposition status* 
Routine  
Transfers  
 
-- 
0.246 
 
-- 
0.081 
 
-- 
1.28 (1.09 - 1.50) 
 
-- 
3.06 
 
-- 
0.0022 
Hospital 
Hospital region 
Northeast 
Midwest 
South 
West 
 
-- 
0.166 
-0.527 
-0.309 
 
-- 
0.201 
0.224 
0.382 
 
-- 
1.18 (0.80 - 1.75) 
0.59 (0.38 - 0.92) 
0.74 (0.35 - 1.55) 
 
-- 
0.83 
-2.36 
-0.81 
 
-- 
0.4078 
0.0185 
0.4198 
Hospital ownership  
Public 
Private 
Public or private 
 
-- 
0.170 
0.400 
 
-- 
0.336 
0.397 
 
-- 
1.19 (0.61 - 2.29) 
1.49 (0.69 - 3.25) 
 
-- 
0.51 
1.01 
 
-- 
0.612 
0.3135 
Hospital teaching status 
Non-teaching 
Teaching 
 
-- 
-0.009 
 
-- 
0.372 
 
 
0.99 (0.48 - 2.06) 
 
-- 
-0.02 
 
-- 
0.9806 
*Type 3 analyses p-value <.05 (Model QIC = 1008.03). Rx = Prescription.  
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Aim 3C: To examine the characteristics associated with pediatric opioid poisoning 
inpatient stays 
There were a total of 1,877 weighted inpatient stays for opioid poisonings among children and 
56.8% had prior ED-related services on record. Table 31 summarizes various characteristics of 
pediatric opioid poisoning-related inpatient stays. Majority of inpatient stays involved teenagers 
(63.7%) followed by children 1 to 2 years of age (18.6%), females (55.3%), and Whites (59.4%).  
Most of these hospitalizations were in children were from medium to large metropolitan areas 
(67.6%), and ZIP Code areas with median household income less than $48,000 (56.7%).  
About 41.7% of the total inpatient stays were due to unintentional poisonings and another 40.5% 
were due to intentional poisonings. Nearly 55.8% of inpatient stays resulted from other 
prescription opioid poisonings and 12.7% from methadone. Multi-drug involvement was recorded 
in 46.3% of total inpatient stays. Nearly 71.9% of inpatient discharges had one or more chronic 
condition diagnoses, 66.7% had one or more comorbidities, and 62.7% had moderate-to-extreme 
loss of function and 24.7% had moderate-to-extreme likelihood of dying.  
One-third of inpatient stays were transfers from another acute care hospital or HCF (30.3%). About 
67.7% resulted in routine discharges and 30.9% were transferred to a short-term hospital, SNF or 
intermediate care. Medicaid was the most common payer for these hospitalizations (51.7%). A 
higher proportion of pediatric opioid poisoning inpatient stays were in hospitals in the southern 
region (36.5%), private non-profit institutions (77.2%), larger hospitals (68.5%), and urban 
teaching centers (74.8%) (Table 31).  
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These characteristics were also examined by intent of opioid poisoning as shown in Table 32. 
Child’s age, gender, race and median household income at ZIP Code level; type of opioid involved; 
presence of multi-drug poisonings, chronic conditions and comorbidities; severity and mortality 
indices; disposition status; payer and hospital region, ownership and location/teaching status were 
significantly associated with the intent of pediatric opioid poisoning hospitalizations.  
Unintentional poisoning-related hospitalizations were more common among children under 6 
years (65.8%), while intentional hospitalizations were common among teenagers (96.3%), and 
girls (68.8%). Intentional poisoning-related stays had a higher proportion of Whites (60.7% vs. 
56.7%) and Hispanics (12.8% vs. 8.5%), and a lower proportion of Blacks (9.7% vs. 16.3%). 
Unintentional opioid poisoning-related inpatient stays were more common in children from ZIP 
Code areas with median household income of less than $48,000 (63.8% vs. 48.8%). Methadone 
was more commonly involved in unintentional poisoning hospitalizations (19.9% vs. 5%), whereas 
other prescription opioids were commonly involved in intentional poisonings (65.1% vs. 48.6%).  
A higher number of intentional opioid poisoning-related hospitalizations were associated with 
multi-drug involvement (64.2% vs. 24.8%), chronic condition diagnosis (92.7% vs. 48.6%), 
comorbidities (80.9 % vs. 50.4%), moderate-to-severe loss of function (70.3% vs. 51.9%), and 
transfers following hospitalization (54.9% vs. 7.3%). However, moderate-to-major likelihood of 
mortality was higher for unintentional opioid poisoning-related hospitalizations among children 
(27.6% vs. 19.3%).  
Medicaid was the most common payer for unintentional opioid poisoning-related inpatient stays 
(61.8% vs. 39.8%), while private insurance was the more common source of payment for 
intentional opioid poisoning-related stays (51.4% vs. 28.6%). Unintentional poisoning admissions 
were higher in the Northeast hospitals (18.7% vs. 12.1%), in public hospitals (13.6% vs. 7.9%) 
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and urban teaching institutions (78.6% vs. 71.6%). Intentional opioid poisoning-related 
hospitalizations were more common in the Midwest hospitals (29% vs. 21%), in private institutions 
(92.1% vs. 86.4%), and urban non-teaching hospitals (22.4% vs. 15.8%) (Table 32).  
Table 33 summarizes the common DRGs, clinical diagnosis and procedures in opioid poisoning-
related hospitalizations. In addition to poisoning DRGs, DRGs related to psychoses and depressive 
neurosis were most common. Opioid poisoning-related hospitalizations had 6 diagnosis on average 
(range = 1 to 25), while the number of ICD-9-CM procedures ranged from 0 to 15. Substance-
related disorder (includes diagnosis of opioid poisoning) was the most frequently recorded 
diagnosis followed by poisoning by psychotropic drugs, other medications, and mood disorders. 
Mental health disorders including depression, ADHD, anxiety and depress psychoses, substance-
use disorders including tobacco use disorder, cannabis abuse and drug abuse, and asthma were the 
most common chronic conditions. Mental health and substance use disorders including psychoses, 
depression, drug abuse and alcohol abuse, other neurological disorders, fluid and electrolyte 
disorders, chronic pulmonary disease and obesity were the most common comorbidities. 
Poisonings by benzodiazepines and aromatic analgesics were frequently involved in multi-drug 
poisonings. Most of the recorded procedures in these inpatient stays were related to respiratory 
intubation and mechanical ventilation and other therapeutic procedures such as injections or 
infusions of therapeutic and prophylactic substances (Table 33). 
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Table 31: Characteristics of pediatric opioid poisoning inpatient stays 
Characteristic 
All opioid poisonings 
Unweighted, N (%) 
(N = 1,334) 
Weighted, N (%) 
(N = 1,877) 
Sociodemographics 
Age group (years)  
0 < 1a  
1 - 2  
3 - 5  
6 -12  
13 -17  
 
          102       (7.65) 
245 (18.37) 
64 (4.80) 
68 (5.10) 
855 (64.09) 
 
144 (7.66) 
 349 (18.59) 
 92 (4.90) 
 97 (5.16) 
 1,196   (63.69) 
Female 739 (55.40) 1,038  (55.30) 
Race  
White 
Black 
Hispanic 
Others 
Unknown 
 
786 (58.92) 
169 (12.67) 
135 (10.12) 
          106       (7.95) 
138 (10.34) 
 
1,114 (59.37) 
 240 (12.78) 
187 (9.94) 
146 (7.76) 
 190 (10.14) 
Residence 
Urban (Mid to large) 
Urban (Small to mid) 
Rural  
Unknown 
 
909 (68.14) 
333 (24.96) 
90 (6.75) 
 2 (0.15) 
 
1,269 (67.61) 
 472 (25.13) 
132 (7.05) 
  4 (0.21) 
Median ZIP Code HH income 
$1 - 38,999   
$39,000 - 47,999   
$48,000 - 62,999   
≥ $63,000  
Unknown 
 
406 (30.43) 
345 (25.86) 
306 (22.94) 
239 (17.92) 
38 (2.85) 
 
574 (30.60) 
491 (26.14) 
426 (22.69) 
331 (17.65) 
55 (2.91) 
Clinical  
Intent 
Unintentional 
Intentional 
Undetermined 
Unknown  
 
552 (41.38) 
545 (40.85) 
          113       (8.47) 
124  (9.30) 
 
 783 (41.71) 
 759 (40.45) 
160 (8.53) 
175 (9.31) 
Opioid 
Methadone 
Other prescription opioids  
 
169 (12.67) 
746 (55.92) 
 
238 (12.65) 
         1,048    (55.82) 
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Unspecified opioids 419 (31.41) 592 (31.53) 
Multi-drug poisonings 619 (46.40) 870 (46.32) 
≥ 1 Chronic conditions 962 (72.11)         1,350     (71.93) 
≥ 1 Elixhauser comorbidities 890 (66.72)         1,252     (66.71) 
APR-DRG severity index  
(loss of function) 
Minor  
Moderate  
Major  
Extreme  
No class specified 
 
 
495 (37.11) 
532 (39.88) 
225 (16.87) 
81 (6.07) 
 1 (0.07) 
 
 
699 (37.25) 
748 (39.84) 
314 (16.75) 
114  (6.07) 
  2  (0.10) 
APR-DRG mortality risk index 
(likelihood of dying) 
Minor  
Moderate  
Major  
Extreme  
No class specified 
 
          
1,004    (75.26) 
188 (14.09) 
87 (6.52) 
54 (4.05) 
 1 (0.07) 
 
 
1,412 (75.25) 
 266 (14.16) 
 121  (6.44) 
  76  (4.06) 
   2  (0.10) 
Transfer-In  
Not a transfer 
Transfer  
Unknown 
 
926 (69.42) 
403 (30.21) 
 5 (0.37) 
 
1,301 (69.31) 
 568 (30.26) 
  8 (0.43) 
Disposition status 
Routine  
Transfer  
Death 
Unknown  
 
902 (67.62) 
413 (30.96) 
 9 (0.67) 
10 (0.75) 
 
1,271 (67.71) 
 579 (30.86) 
 13 (0.67) 
 14 (0.75) 
Payer and hospital 
Payer 
Medicaid 
Private 
Other 
Uninsured  
Unknown 
 
686 (51.42) 
529 (39.66) 
61 (4.57) 
52 (3.90) 
 6 (0.45) 
 
971 (51.73) 
740 (39.40) 
86 (4.57) 
72 (3.85) 
 8 (0.44) 
Hospital region 
Northeast 
Midwest 
South 
 
198 (14.84) 
355 (26.61) 
463 (34.71) 
 
277 (14.76) 
481 (25.63) 
685 (36.52) 
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West 318 (23.84) 433 (23.09) 
Hospital ownership  
Public 
Non-profit private 
Proprietary private 
 
156 (11.69) 
         1,047    (78.49) 
          131      (9.82) 
 
 241 (12.83) 
1,450 (77.24) 
186 (9.93) 
Hospital Bedsize 
Small 
Medium 
Large 
 
117 (8.77) 
 293 (21.96) 
 924 (69.27) 
 
175 (9.31) 
 417 (22.22) 
1,285 (68.47) 
Hospital Location and teaching status  
Rural non-teaching 
Urban non-teaching 
Urban Teaching 
 
83 (6.22) 
252 (18.89) 
999 (74.89) 
 
129 (6.85) 
  345  (18.39) 
1,403    (74.76) 
 
a89 of these children were neonates and 7 children had neonatal abstinence syndrome diagnosis 
(ICD-9-CM code 779.5). HH = Household.  
 
Table 32: Characteristics of pediatric opioid poisoning inpatient stays by intent 
Characteristic Unintentional (n = 552), 
unweighted n (%) 
Intentional (n = 545), 
unweighted n (%) 
Sociodemographics 
Age group (years)* 
0 < 1  
1 - 2  
3 - 5  
6 -12  
13 -17 
 
 83 (15.04) 
 221      (40.04) 
 59 (10.69) 
 35  (6.34) 
154       (27.9) 
 
-- 
-- 
-- 
20 (3.67) 
525 (96.33) 
Female* 248 (44.93) 375 (68.81) 
Race* 
White 
Black 
Hispanic 
Others 
Unknown 
 
313 (56.70) 
 90 (16.30) 
47 (8.51) 
44 (7.97) 
 58 (10.51) 
 
331 (60.73) 
53 (9.72) 
 70 (12.84) 
40 (7.34) 
51 (9.36) 
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Residence 
Urban (Mid to large) 
Urban (Small to mid) 
Rural  
Unknown 
 
381 (69.02) 
129 (23.37) 
41 (7.43) 
 1 (0.18) 
 
368 (67.52) 
144 (26.42) 
32 (5.87) 
 1 (0.18) 
Median ZIP Code HH income* 
$1 - 38,999   
$39,000 - 47,999   
$48,000 - 62,999   
≥ $63,000  
Unknown 
 
209 (37.86) 
143 (25.91) 
113 (20.47) 
69 (12.5) 
18 (3.26) 
 
124 (22.75) 
142 (26.06) 
130 (23.85) 
135 (24.77) 
14 (2.57) 
Clinical  
Opioid* 
Methadone 
Other prescription opioids  
Unspecified opioids 
 
110 (19.93) 
268 (48.55) 
174 (31.52) 
 
27 (4.95) 
355 (65.14) 
163 (29.91) 
Multi-drug poisonings* 137 (24.82) 350 (64.22) 
≥ 1 Chronic conditions* 268 (48.55) 505 (92.66) 
≥ 1 Elixhauser comorbidities*  278  (50.36 ) 441 (80.92) 
APR-DRG severity index 
(loss of function) * 
Minor loss of function  
Moderate loss of function 
Major loss of function 
Extreme loss of function 
 
 
265 (48.01) 
157 (28.44) 
 92 (16.67) 
38 (6.88) 
 
 
162 (29.72) 
276 (50.64) 
 87 (15.96) 
20 (3.67) 
APR-DRG mortality risk index 
(likelihood of dying)* 
Minor  
Moderate  
Major  
Extreme  
 
 
400 (72.46) 
 92 (16.67) 
33 (5.98) 
27 (4.89) 
 
 
440 (80.73) 
 58 (10.64) 
34 (6.24) 
13 (2.39) 
Transfer-In 
Not a transfer 
Transfer  
Unknown 
 
367 (66.49) 
182 (32.97) 
 3 (0.54) 
 
398 (73.03) 
146 (26.79) 
 1 (0.18) 
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Disposition* 
Routine  
Transfer  
Death 
Unknown  
 
508 (92.03) 
40 (7.25) 
 3 (0.54) 
 1 (0.18) 
 
237 (43.49) 
299 (54.86) 
 1 (0.18) 
 8 (1.47) 
Payer and hospital 
Payer* 
Medicaid 
Private 
Other  
Uninsured 
Unknown 
 
341 (61.78) 
158 (28.62) 
26 (4.71) 
25 (4.53) 
 2 (0.36) 
 
217 (39.82) 
280 (51.38) 
25 (4.59) 
21 (3.85) 
 2 (0.37) 
Hospital region* 
Northeast 
Midwest 
South 
West 
 
103 (18.66) 
116 (21.01) 
194 (35.14) 
139 (25.18) 
 
 66 (12.11) 
158 (28.99) 
192 (35.23) 
129 (23.67) 
Hospital ownership* 
Public 
Non-profit private 
Proprietary private 
 
 75 (13.59) 
427 (77.36) 
50 (9.06) 
 
 43  (7.89) 
         436       (80.0) 
  66  (12.11) 
Hospital Bedsize 
Small 
Medium 
Large 
 
46 (8.33) 
108 (19.57) 
398 (72.10) 
 
47 (8.62) 
118 (21.65) 
380 (69.72) 
Hospital Location and teaching 
status* 
Rural non-teaching 
Urban non-teaching 
Urban Teaching 
 
 
31 (5.62) 
 87 (15.76) 
434 (78.62) 
 
 
33 (6.06) 
122 (22.39) 
390 (71.56) 
 
*Chi-square statistic p<.05  
Results for undetermined or unknown intentionality not shown here. HH = Household.  
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Table 33: DRGs, clinical conditions and procedures recorded in pediatric opioid poisoning 
inpatient stays 
DRGs/Conditions/Proceduresa,b,c,d Unweighted, n (%) 
DRGs (n = 1,334) 
918: Poisoning and toxic effects of drugs without MCC 
917: Poisoning and toxic effects of drugs with MCC 
885: Psychoses 
881: Depressive neurosis 
208: Respiratory system diagnosis with ventilator support (<96 hours) 
882: Neuroses (except depressive) 
 
 901 (67.54) 
 216 (16.19) 
88 (6.6) 
32 (2.4) 
 8 (0.6) 
 8 (0.6) 
Clinical conditions 
Number of diagnoses, mean (SD) 6.34  (3.87) 
Primary (first-listed) diagnosis (n = 1,334) 
Substance-related disorders* 
Poisoning by psychotropic agents 
Poisoning by other medications and drugs 
Mood disorders 
Adjustment disorders 
 
805 (60.34) 
159 (11.92) 
158 (11.84) 
118  (8.85) 
  9  (0.67) 
 Any-listed diagnosis (n = 8,451) 
Substance-related disorders* 
Poisoning by other medications and drugs 
Mood disorders 
Poisoning by psychotropic agents 
Residual codes, unclassified** 
 
      1,840   (21.77) 
675     (7.99) 
628     (7.43) 
464     (5.49) 
407     (4.82) 
Number of chronic conditions, mean (SD) 1.84   (1.75) 
Chronic Conditions (n = 7,223) 
Depressive disorder, NEC 
Attention-deficit/hyperactivity disorder 
Tobacco use disorder 
Cannabis abuse, unspecified 
Asthma, unspecified  
Anxiety state, NOS  
Drug abuse, unspecified 
Depress psychoses, unspecified 
 
227    (3.14) 
126    (1.74) 
121    (1.68) 
110    (1.52) 
104    (1.44) 
 98     (1.36) 
 93     (1.29) 
 75     (1.04) 
Number of Elixhauser comorbidities, mean (SD) 1.16  (1.11) 
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Elixhauser comorbidities (n = 1,334) 
Drug abuse 
Psychoses 
Other neurological disorders 
Depression 
Fluid and electrolyte disorders  
Chronic pulmonary disease 
Alcohol abuse 
Obesity 
Hypertension (uncomplicated and complicated) 
Deficiency anemias 
 
292 (21.89) 
259 (19.42) 
255 (19.12) 
241 (18.07) 
158 (11.84) 
      126       (9.45) 
70 (5.25) 
41 (3.07) 
29 (2.17) 
17 (1.27) 
Multi-drug poisonings (in addition to opioids) (n = 4,742) 
Benzodiazepine-based tranquilizers 
Aromatic analgesics 
Propionic acid derivatives 
Antidepressants 
Hallucinogens 
Antiallergics and antiemetics 
 
192 (4.05) 
157 (3.31) 
 69 (1.46) 
 67 (1.41) 
 65 (1.37) 
 52 (1.10) 
Clinical procedures 
Number of procedures, mean (SD)*** 0.49  (1.32) 
Primary (first-listed) procedures (n = 1,334) *** 
Respiratory intubation and mechanical ventilation  
Other therapeutic procedures 
 
156 (11.69) 
26 (1.95) 
 
Listed conditions or procedures that were top 5 or those >1%. 
MCC = major complications or comorbidities, NEC = not elsewhere classified, NOS = Not 
otherwise specified. 
*Includes ICD-9-CM codes for opioid poisoning.  
**Includes codes for organic sleep disorder, nonspecific abnormal findings, general symptoms 
and other unclassified ICD-9-CM codes. 
***1,044 (78.3%) had ICD-9-CM procedure codes missing. 
aN represents number of discharges for DRGs, Elixhauser comorbidities and primary diagnosis 
and procedures.  But N represents number of diagnosis for any-listed diagnosis. 
For chronic conditions and multi-drug poisonings, N represents number of diagnosis for those 
with ≥1 chronic conditions and ≥1 multi-drug poisonings, respectively.  
bPrimary or any-listed diagnosis identified using HCUP’s single-level CCS. Multi-drugs and 
chronic conditions were identified using ICD-9-CM diagnosis codes. Primary procedures were 
identified using CPT codes. 
cSix records had ICD-9-CM code for heroin poisoning. 
dOnly 10 Elixhauser comorbidities were considered for analyses, other comorbidities were 
recorded for ≤ 10 inpatient stays. 
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Aim 3D: To identify factors associated with inpatient stay costs among children with opioid 
poisonings 
Bivariate comparisons of mean inpatient stay cost across various sociodemographic, clinical, payer 
and hospital characteristics is summarized in Table 34.  Child’s age group, residence location and 
median household income at ZIP Code level, intent of poisoning, type of opioid involved, 
involvement of multiple drugs, diagnosis of chronic conditions and Elixhauser comorbidities, total 
number of diagnosis and procedures, APR-DRG severity and mortality risk indices, disposition 
status, payer source, and hospital region, ownership and bedsize were found to be significantly 
associated with the mean cost of opioid poisoning-related inpatient stays in children.  
The mean weighted cost for a pediatric opioid poisoning-related inpatient stay was estimated to be 
$6,633.41 (SE = 630.21). Mean cost was much higher for children under 6 years compared to 
teenagers ($8,254.42 vs. $5,846.34), and those living in mid-to-large urban areas ($7,401.2). 
Although mean cost of pediatric opioid poisoning inpatient stays was lower for children from ZIP 
Code areas with low median household income ($5,021.91), income did not show a linear trend 
with hospitalization cost.  
Compared to intentional opioid poisonings, mean cost of inpatient stays was significantly higher 
for unintentional opioid poisonings in children ($7,563.64 vs. 5,083.98). However, the mean costs 
were higher for those with undetermined or unknown intent as well ($7,448.40 and $8,466.77, 
respectively). Mean inpatient stay cost for methadone poisonings in children was significantly 
higher compared to other opioid poisonings ($12,390 vs. $5,555.35). Mean costs were also higher 
for hospital stays with 3 or more diagnosis or performed procedures ($7270.35 and $41,525, 
respectively). Surprisingly, the mean inpatient cost of opioid poisonings was not higher for those 
with multi-drug poisonings compared to stays without such diagnosis ($5,275.14 vs. $7,805.43). 
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However, diagnosis of one or more chronic conditions ($7,642.33 vs. $4,060.12) and Elixhauser 
comorbidities ($7,608.18 vs. $4,695.81) were associated with a higher mean hospitalization costs. 
Inpatient stay costs were significantly higher for children with major or extreme loss of function 
($8,611.57 and $40,447, respectively), and moderate, major or extreme likelihood of mortality 
($7,558.02, $21,395 and $34,996, respectively). Hospitalizations that resulted in transfer to 
another HCF had a higher mean cost compared to those routinely discharged ($8,246.33 vs. 
$5,815.38). Mean cost was significantly higher for children that died in the hospital ($14,937) or 
those with an unknown disposition ($8,220.81). 
Pediatric opioid poisoning inpatient stays with private insurance as a source of payment had higher 
mean cost compared to Medicaid ($7,611.92 vs. $5,972.72). At hospital-level, mean 
hospitalization cost of treatment for pediatric opioid poisonings was significantly higher among 
hospitals in the western region ($10,109), among private non-profit hospitals or private proprietary 
hospitals ($6,995.39 and $5,801.9, respectively) compared to public centers ($5,099.34), and 
among large institutions compared to small centers ($6,782.31 vs. $5,822.18) (Table 34).  
Inpatient stay costs for pediatric opioid poisonings were also compared across Elixhauser 
comorbidities. Results are summarized in Appendix G. Presence of drug abuse, other neurological 
disorders, fluid and electrolyte disorders, deficiency anemias, hypertension and obesity were 
significantly associated with inpatient costs. 
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Table 34: Mean inpatient hospital costs by characteristics (in 2012 USD) 
Characteristic 
Unweighted cost 
(N = 1,332) 
Weighted cost 
(N = 1,874) 
Mean SE Mean SE 
Total (original costs)a 6,624.60   613.53 6,633.41 630.21 
Sociodemographic 
Age group (years)* 
≤ 5  
6 - 12  
13 - 17 
 
8,214.04 
6,626.64 
5,862.79 
 
1,786.25 
 891.69 
 421.33 
 
8,254.42 
6,593.14 
5,846.34 
 
1,815.03 
886.66 
435.63 
Gender 
Male 
Female  
 
7,501.30 
5,916.96 
 
1,293.11 
373.45 
 
7,568.76 
5,875.70 
 
1,338.17 
334.88 
Race 
White 
Black 
Hispanic 
Others 
Unknown 
 
6,764.01 
4,658.41 
7,434.65 
6,310.79 
7,640.3 
 
942.34 
412.57 
2,073.44 
883.34 
1,170.9 
 
6,767.80 
4,640.42 
7,540.30 
6,314.56 
7,664.28 
 
951.35 
461.98 
2,194.15 
921.12 
795.58 
Residence* 
Urban (Mid to large) 
Urban (Small to mid) 
Rural  
Unknown 
 
7,348.56 
4,805.79 
6,261.44 
2,179.97 
 
884.66 
406.11 
1,116.82 
203.97 
 
7,401.20 
4,762.74 
6,189.75 
2,113.45 
 
915.55 
398.26 
1,072.16 
128.89 
Median ZIP Code HH 
income* 
$1 - 38,999   
$39,000 - 47,999   
$48,000 - 62,999   
≥ $63,000  
Unknown 
 
 
5,054.54 
6,312.23 
9,287.42 
6,627.32 
5,015.01 
 
 
382.03 
883.00 
2,249.09 
1,194.83 
812.43 
 
 
5,021.91 
6,314.57 
9,414.34 
6,658.68 
4,839.01 
 
 
379.46 
887.26 
2,357.34 
1,240.82 
801.83 
Clinical  
Intent* 
Unintentional 
Intentional 
Undetermined  
Unknown 
 
7,563.26 
5,108.61 
7,381.03 
8,437.59 
 
1,327.81 
281.56 
1,331.89 
2,361.07 
 
7,563.64 
5,083.98 
7,448.40 
8,466.77 
 
1,367.34 
287.58 
1,326.72 
2,384.55 
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Opioid* 
Methadone 
Other prescription opioids  
Unspecified 
 
12,344.01 
5,556.24 
6,221.89 
 
3,942.68 
451.90 
788.42 
 
12,390.00 
5,555.35 
6,233.21 
 
4,014.43 
476.85 
777.79 
Multi-drug poisoning* 
No 
Yes 
 
7,776.83 
5,294.52 
 
1,109.14 
321.73 
 
7,805.43 
5,275.14 
 
1,127.88 
327.11 
≥ 1 Chronic conditions* 
No 
Yes 
 
4,031.2 
7,631.77 
 
271.45 
843.11 
 
4,060.12 
7,642.33 
 
286.59 
847.03 
≥ 1 Elixhauser comorbidities* 
No 
Yes 
 
4,701.98 
7,591.41 
 
358.53 
902.68 
 
4,695.81 
7,608.18 
 
374.89 
917.22 
Number of diagnoses* 
1 
2 
≥ 3 
 
2,299.29 
2,857.85 
7,259.02 
 
231.35 
209.25 
709.49 
 
2,301.42 
2,855.53 
7,270.35 
 
230.55 
209.88 
721.47 
Number of proceduresb* 
1 
2 
≥ 3 
 
6,548.98 
10,877.48 
40,586.1 
 
483.74 
1,286.44 
8,753.77 
 
6,561.19 
10,808.00 
41,525.00 
 
490.39 
1,288.07 
8,828.69 
APR-DRG severity index 
(loss of function)* 
No class specified 
Minor  
Moderate  
Major  
Extreme  
 
 
2,075.64 
3,140.85 
4,204.38 
8,617.03 
39,936.31 
 
 
-- 
125.76 
214.74 
607.72 
9,538.57 
 
 
2,075.64 
3,122.97 
4,188.76 
8,611.57 
40,447.00 
 
 
-- 
138.83 
225.18 
623.67 
9,132.29 
APR-DRG mortality index 
(likelihood of dying)* 
No class specified 
Minor  
Moderate  
Major  
Extreme  
 
 
2,075.64 
3,805.75 
7,507.92 
21,007.09 
34,940.58 
 
 
-- 
126.09 
723.85 
7,497.64 
7,748.13 
 
 
2,075.64 
3,783.16 
7,558.02 
21,395.00 
34,996.00 
 
 
-- 
143.82 
761.41 
7,900.55 
7,896.15 
Transfer-In 
Not a transfer 
Transfer  
Unknown 
 
6,723.41 
6,432.34 
4,196.75 
 
822.23 
764.62 
1,441.09 
 
6,734.83 
6,442.92 
4,005.52 
 
852.71 
800.50 
1,414.78 
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Disposition* 
Routine  
Transfer  
Deathc 
Unknown  
 
5,823.48 
8,188.41 
15,048.13 
8,223.89 
 
423.58 
1,740.5 
3,468.5 
2,607.64 
 
5,815.38 
8,246.33 
14,937.00 
8,220.81 
 
410.29 
1,827.45 
3,024.70 
2,202.55 
Payer and hospital 
Payer* 
Medicaid 
Private 
Other  
Uninsured 
Unknown 
 
5,966.27 
7,567.92 
7,327.17 
5,251.82 
4,909.94 
 
514.85 
1,391.47 
1,503.38 
1,171.45 
2,081.8 
 
5,972.72 
7,611.92 
7,223.21 
5,139.36 
5,064.08 
 
510.54 
1,457.21 
1,405.39 
1,296.22 
2,005.40 
Hospital region* 
Northeast 
Midwest 
South 
West 
 
6,228.38 
5,988.44 
5,157.01 
9,844.77 
 
558.41 
533.02 
711.99 
2,302.52 
 
6,222.25 
5,983.36 
5,140.49 
10,109.00 
 
562.46 
519.75 
706.16 
2,385.32 
Hospital ownership* 
Public 
Non-profit private 
Proprietary private 
 
5,275.5 
6,925.45 
5,826.87 
 
622.73 
730.77 
2,132.82 
 
5,099.34 
6,995.39 
5,801.90 
 
415.85 
756.07 
2,192.38 
Hospital Bedsize* 
Small 
Medium 
Large 
 
5,938.29 
6,420.98 
6,769.01 
 
864.63 
973.82 
817.37 
 
5,822.18 
6,489.36 
6,782.31 
 
884.74 
987.55 
846.05 
Hospital Location and 
teaching status 
Rural non-teaching 
Urban non-teaching 
Urban Teaching 
 
 
3,831.86 
5,666.92 
7,104.46 
 
 
395.86 
1,082.68 
772.74 
 
 
3,782.37 
5,719.06 
7,126.32 
 
 
373.20 
1,146.96 
789.46 
 
*p-value <.05. Wilcoxon rank sum and Kruskal-Wallis tests were used to examine unweighted 
mean costs. HH= Household.  
aTotal inpatient hospital costs were missing for 20 (1.5%) discharges and these were not included 
in the mean cost calculation.     
bThese are ICD-9-CM inpatient procedures. The number of procedures were zero or missing for 
78.23% of the total stays.  
cDeaths were recorded for 9 discharges. 
 
 
 
160 
 
For the adjusted analyses of inpatient stay costs, APR-DRG severity index and mortality index 
were highly correlated (|r| ≥ 0.7). APR-DRG mortality index was removed from further analyses. 
Also, patient’s residence, median ZIP Code level income, disposition status, severity index and 
payer constituted ≤2% of missing data. Since the rate of missing values for these variables was 
low, the missing observations were dropped from further analyses. Race was unknown for 10.4% 
(138 observations) of the total observations. Race was included in the initial GLM model (making 
‘unknown race’ as one level of the variable), but excluded from the final model due to statistical 
insignificance. The initial adjusted model included all covariates from bivariate analyses however, 
characteristics that were found to be insignificant in both the bivariate analyses and the initial 
model were excluded from the final adjusted analyses. Also, Elixhauser comorbidities were not 
included in this final model for two reasons. First, presence of one or more chronic conditions was 
included as an independent variable in the model which allows for risk adjustment. Second, 
Elixhauser comorbidities and presence of one or more chronic conditions were highly collinear.  
Adjusted analyses showed a significant association of inpatient stay costs with ZIP Code level 
median household income, multi-drug poisonings, number of diagnosis and procedures, severity 
index, disposition status, payer and hospital region. The results from the adjusted model of 
inpatient hospital costs are summarized in Table 35.  
ZIP Code level median household income of $48,000 to $62,999 was associated with 1.32 (95% 
CI = 1.08 - 1.61) times higher inpatient stay costs compared to low area-level income. Compared 
to children under 6 years of age, children 6 to 12 years had 0.38 (95% CI = 0.21 - 0.69) times lower 
hospitalization costs for opioid poisoning but age was not a significant factor. Also child’s 
residence location was not significant but opioid poisoning-related hospitalization costs of children 
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in rural areas was 1.64 (95% CI = 1.24 - 2.17) times higher compared to that of children from 
medium to large urban areas. 
Surprisingly, diagnosis of multiple drug poisonings was associated with 0.79 (95% CI = 0.67 - 
0.94) times lower inpatient stay costs compared to those without such diagnosis. The inpatient 
costs for opioid poisoning in children increased by 6% (95% CI = 4% - 8%) and 24% (95% CI = 
19% - 29%) for every additional diagnosis or procedure performed during the stay, respectively. 
Inpatient stays of children with major or extreme loss of function were associated with 2.02 (95% 
CI = 1.60 - 2.57) times and 3.32 (95% CI = 2.53 - 4.35) times higher costs, compared to minor loss 
of function. Transfer was associated with 1.24 (95% CI = 1.01 - 1.51) times higher inpatient costs 
while death had 0.43 (95% CI = 0.27 - 0.69) times significantly lower costs compared to inpatient 
stays with routine discharge. Death was documented for a small number of discharge records (n = 
9), hence this finding should be interpreted with caution. 
Private insurance was associated with 1.52 (95% CI = 1.29 - 1.80) times and other insurance had 
1.59 (95% CI =   1.14 - 2.20) times higher hospitalization costs for pediatric opioid poisonings 
compared to Medicaid. Lastly, hospitals in the West had 0.56 (95% CI = 0.37 - 0.86) times 
significantly lower costs compared to hospitals in the Northeast (Table 35).  
Table 35: Adjusted analyses of inpatient hospital costs 
Characteristic 
Estimate 
(β) 
SE Exp (β)  (95% CI) Z p-value 
Intercept 8.927 0.531 -- 16.81 <.0001 
Sociodemographics 
Age group (years)**  
≤5 
6 -12  
13 -17  
 
-- 
-0.968 
-0.267 
 
-- 
0.109 
0.055 
 
-- 
 0.38 (0.21 - 0.69) 
 0.77 (0.57 -  1.03) 
 
-- 
-8.88 
-4.83 
 
-- 
<.0001 
<.0001 
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Residence 
Urban (Mid to large) 
Urban (Small to mid) 
Rural  
 
-- 
0.021 
0.495 
 
-- 
0.053 
0.080 
 
-- 
1.02 (0.83 - 1.25) 
1.64 (1.24 - 2.17) 
 
-- 
0.40 
6.18 
 
-- 
0.6909 
<.0001 
Median ZIP Code HH 
income* 
$1 - 38,999   
$39,000 - 47,999   
$48,000 - 62,999   
≥ $63,000  
 
 
-- 
-0.221 
 0.275 
 0.049 
 
 
-- 
0.058 
0.053 
0.075 
 
 
-- 
0.81 (0.64 - 1.03) 
1.32 (1.08 - 1.61) 
1.05 (0.84 - 1.32) 
 
 
-- 
-3.62 
 5.19 
 0.66 
 
 
-- 
0.0003 
<.0001 
0.5166 
Clinical  
Intent 
Unintentional 
Intentional 
Undetermined 
Unknown 
 
-- 
-0.188 
-0.020 
 0.235 
 
-- 
0.060 
0.069 
0.067 
 
-- 
0.83 (0.64 - 1.08) 
0.98 (0.70 - 1.37) 
1.27 (0.94 - 1.69) 
 
-- 
-3.15 
-0.28 
 3.49 
 
-- 
0.0017 
0.7764 
0.0005 
Opioid 
Methadone 
Other Rx opioids  
Unspecified opioids 
 
-- 
-0.168 
-0.192 
 
-- 
0.049 
0.058 
 
-- 
0.85 (0.70 - 1.03) 
0.83 (0.65 - 1.05) 
 
-- 
-3.41 
-3.31 
 
-- 
0.0006 
0.0009 
Multi-drug poisonings*  
No 
Yes 
 
-- 
-0.233 
 
-- 
0.056 
 
-- 
0.79 (0.67 - 0.94) 
 
-- 
-4.13 
 
-- 
<.0001 
≥ 1 Chronic conditions 
No 
Yes 
 
-- 
-0.050 
 
-- 
0.071 
 
-- 
0.95 (0.73 - 1.24) 
 
-- 
-0.70 
 
  -- 
0.4869 
Number of diagnoses* 0.059 0.006 1.06 (1.04 - 1.08) 10.51 <.0001 
Number of procedures * 0.217 0.009 1.24 (1.19 - 1.29) 25.14 <.0001 
APR-DRG severity 
index (loss of function)* 
Minor  
Moderate  
Major  
Extreme  
 
 
-- 
0.371 
0.705 
1.199 
 
 
-- 
0.094 
0.092 
0.097 
 
 
-- 
1.45 (1.15 - 1.83) 
2.02 (1.60 - 2.57) 
3.32 (2.53 - 4.35) 
 
 
-- 
3.95 
7.70 
12.32 
 
 
-- 
<.0001 
<.0001 
<.0001 
Disposition status* 
Routine 
Transfer  
Death 
 
-- 
 0.214 
-0.842 
 
-- 
0.043 
0.150 
 
-- 
1.24 (1.01 - 1.51) 
0.43 (0.27 - 0.69) 
 
-- 
 4.94 
-5.60 
 
-- 
<.0001 
<.0001 
Payer and hospital 
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Payer* 
Medicaid 
Private 
Other 
Uninsured  
 
-- 
0.420 
0.461 
0.260 
 
-- 
0.045 
0.071 
0.144 
 
-- 
1.52 (1.29 - 1.80) 
  1.59    (1.14 - 2.20) 
1.30 (0.89 - 1.90) 
 
-- 
9.32 
6.46 
1.80 
 
-- 
<.0001 
<.0001 
0.0724 
Hospital region* 
Northeast 
Midwest 
South 
West 
 
-- 
 0.010 
-0.089 
-0.572 
 
-- 
0.103 
0.100 
0.093 
 
-- 
1.01 (0.66 - 1.55) 
0.92 (0.65 - 1.29) 
0.56 (0.37 - 0.86) 
 
-- 
0.10 
-0.88 
-6.17 
 
-- 
0.9242 
0.3779 
<.0001 
Hospital ownership  
Public 
Non-profit private 
Proprietary private 
 
-- 
-0.293 
-1.735 
 
-- 
0.108 
0.910 
 
-- 
0.75 (0.50 - 1.11) 
0.18 (0.09 - 0.36) 
 
-- 
-2.72 
-1.91 
 
-- 
0.0065 
0.0567 
Hospital Bedsize 
Small 
Medium 
Large 
 
-- 
 0.162 
-0.449 
 
-- 
0.086 
0.101 
 
-- 
1.18 (0.74 - 1.86) 
0.64 (0.38 - 1.06) 
 
-- 
1.89 
-4.43 
 
-- 
0.0584 
<.0001 
Hospital Location and 
teaching status 
Rural non-teaching 
Urban non-teaching 
Urban Teaching 
 
 
-- 
0.219 
-0.377 
 
 
-- 
0.512 
0.487 
 
 
-- 
1.25 (0.62 - 2.50) 
0.69 (0.41 - 1.15) 
 
 
-- 
 0.43 
-0.77 
 
 
-- 
0.6682 
0.4391 
 
*Type 3 analysis p-value <.05 (Model QIC = 1562.13).  
**Type 3 analysis of age group p-value = 0.0512. 
 HH = Household and Rx = Prescription.  
 
5.3: Discussion 
Characteristics associated with pediatric opioid poisoning ED visits and inpatient stays 
After examining the prevalence of pediatric opioid exposures and poisonings and estimating its 
economic costs to the society, the next step was to explore the characteristics associated with two 
major components of direct medical costs i.e., ED visits and inpatient stays. The second part of 
this section highlighted the factors associated with costs of ED visits and hospital stays. To our 
knowledge, no previous study has examined factors associated with costs of opioid poisonings in 
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children. Evaluation of pediatric opioid poisonings that result in high costs can help to plan 
interventions from clinical and economic perspectives.  
It is important to note two points before discussing these results. First, ED visits and inpatient stays 
for Specific Aims 2 and 3 were identified using ICD-9-CM and ICD-10 codes and represent opioid 
poisonings. Specific Aim 1 characterized all opioid exposures in children including those that did 
not result in poisonings (i.e., a clinical effect following an exposure). Second, unintentional and 
intentional opioid poisonings in Specific Aims 2 and 3 were identified using the ICD-9-CM or 
ICD-10 codes. In Specific Aim 1, intent of exposure was identified using AAPCC definitions 
which vary from those obtained by ICD codes. For example, assume a teenager misused opioids 
not with an intent to suicide but to get a high and had subsequent poisoning. This scenario would 
be recorded as unintentional using ICD codes. However, the same situation would be recorded as 
intentional in the NPDS by the PC specialist.   
There were about 4,584 annual ED visits and 1,877 annual inpatient stays for pediatric opioid 
poisonings. This indicates that nearly 41% of ED visits for opioid poisonings in children resulted 
in hospitalization. This finding is similar to another study that examined opioid exposures and 
poisonings in children.31 Opioid poisoning-related ED visits and inpatient stays mostly involved 
teenagers and children 1 to 2 years of age. This validates our results from Specific Aim 1 wherein 
we found high prevalence of opioid exposures and poisonings in these age groups. Furthermore, 
hospitalizations related to pediatric opioid poisonings were higher among Whites. Rates of opioid 
prescribing in adults and use and misuse of opioids in adolescents and adults is reported to be 
higher among Whites compared to other racial groups.139–141 Hence it can be postulated that there 
is higher availability of opioids in these households resulting in more exposures in children at 
home. Interestingly, opioid poisoning-related hospitalizations occurred more frequently among 
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children from areas with low income. Two prior studies that examined drug poisoning ED visits 
reported similar results but these studies were not specific to children.56,57 This finding indicates 
some association of severe opioid poisonings and socioeconomic status among children and should 
be investigated further.  
Pediatric opioid poisoning-related ED visits and inpatient stays were more frequently in hospitals 
located in the South and in private institutions. Similar hospital characteristics were reported by 
some previous studies that examined drug or opioid poisoning-related ED visits across all age 
groups.50,56,57,67 Opioid poisoning-related inpatient stays in children were also more commonly 
treated in large hospitals and teaching institutions. These hospital characteristics coincide with the 
national pattern of hospital stays. All-stay hospital admissions are reported to be higher in the 
South, in large hospitals, and in private and teaching institutions.142–144 
Three out of every 5 opioid poisoning hospitalizations in children were recorded to have moderate-
to-extreme loss of function i.e., high severity-of-illness. Respiratory intubation and mechanical 
ventilation were performed in about 12% of inpatient stays. Although there is no direct comparison 
for these results, Burghardt et al. found that about 70% of children with admissions following 
opioid exposures and poisonings had a significant injury (i.e., moderate-to-severe effects).31 The 
current results reiterate our previous findings (from Specific Aim 1) that opioid poisoning in 
children is associated with significant morbidity. Additionally, over one-fourth of ED visits and 
inpatient stays related to opioid poisonings in children resulted in transfer to short-term stay 
facilities. We found that over 20% of children with opioid poisoning hospitalizations had major-
to-extreme loss of function which may have necessitated transfer to short-term or intermediate 
care. Also, psychiatric care admissions frequently occur after an opioid poisoning among 
teenagers, particularly after a suspected suicide.43 We found that 15.3% of teenagers were admitted 
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to psychiatry care service following an opioid exposure (Specific Aim 1) while Zosel et al. reported 
that 35.3% of teenagers had psychiatric admission after a suspected suicidal drug exposure.43   
We found that intentional opioid poisoning-related ED visits and admissions were more common 
among teenagers and females. Teenagers often intentionally use opioids to self-harm and have 
severe opioid poisonings leading to ED visits and subsequent hospital admissions.43 Adolescent 
girls particularly are shown to be involved in such drug-taking behavior.42,43,57 One study using 
recent data from NSDUH reported that among adolescents more females were nonmedical users 
of opioids during the past year.139 Previous research has also found female predominance in 
intentional opioid exposures resulting from suicide attempts.43 These gender differences among 
adolescents can partly be attributed to the high prevalence of behavioral health conditions such as 
depression among teenage girls.66   
Multiple drugs, particularly benzodiazepines and aromatic analgesics, were involved in 49.3% and 
64.2% of intentional opioid poisoning-related ED visits and inpatient stays in children. One study 
that examined opioid exposures and poisonings in teenagers reported that over half had 
involvement of more than one substance.43 Another study found benzodiazepines as the commonly 
involved substance in prescription opioid poisoning-related ED visits and inpatient stays but these 
analyses were not limited to children.55 Poisonings by aromatic analgesics include acetaminophen 
poisonings. Hence, the ED visits or inpatient stays with diagnosis of poisonings by opioids and 
poisonings by aromatic analgesics may suggest involvement of combination opioids. Past studies 
have reported that co-diagnosis of poisonings by aromatic analgesics for such cases is not 
completely recorded since the opioid effects are more acute and prominent.145 Additionally, 80.9% 
of hospital discharges for intentional pediatric opioid poisonings in the current analyses indicated 
presence of comorbidities such as depression, psychoses, drug abuse and other neurological 
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disorders. Co-occurrence of these mental health conditions with substance use disorders is reported 
to be common among teenagers. Kline-Simon et al. reported that among adolescents with 
substance use disorders, 58.2% had at least one psychiatric comorbidity diagnosis in the electronic 
health record.66   
Interestingly, Medicaid was the more common payer for unintentional opioid poisoning ED and 
hospital visits while private insurance was more common among intentional opioid poisoning ED 
and hospital visits in children. The literature on payer source for opioid or drug related poisonings 
has been inconclusive, and none of the past studies have inspected the source of payment for 
children by intent of poisoning. These findings may indicate that unintentional opioid poisoning-
related hospitalizations were higher among children from lower socioeconomic status as most of 
these children had Medicaid coverage. Moreover, opioid poisoning-related hospitalizations 
especially for unintentional poisonings were found to be higher among children from lower area-
level income (above). Access to private insurance may indicate higher socioeconomic status 
among children with intentional opioid poisonings. 
Factors associated with ED and inpatient costs among children with opioid poisonings 
Next, the association of various factors with mean ED and inpatient costs for pediatric opioid 
poisonings was examined. A few other studies have investigated ED or inpatient costs of opioid 
poisonings. However, these studies have not specifically examined factors that are associated with 
high cost of treatment or they were not limited to the pediatric population. This makes it harder to 
compare cost results from the current study.  
Teenagers had significantly greater ED costs compared to children under the age of 6 years. Such 
age-specific cost differences were not significant for inpatient stays. Teenagers presenting to the 
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ED may have medically more complicated opioid poisonings requiring more treatment and 
services. In the earlier part of the study, we found that teenagers frequently engaged in intentional 
opioid exposures and poisonings, had multiple product involvement and often presented with 
mental health-related comorbidities and severe poisonings. These factors may have contributed to 
the high costs of emergency treatment. However, it is possible that the management of opioid 
poisonings may not vary by age once an ED visit reaches the threshold for subsequent admission.  
Children from areas with higher income had higher hospitalization costs for opioid poisonings. It 
would be expected that children from low income areas would have lower health outcomes and 
consequently high cost of care but such an association was not observed for opioid poisonings in 
children. We found more intentional opioid poisoning-related inpatient stays among children from 
high income areas. It can be postulated that children from high income areas presented with more 
severe or medically complicated opioid poisonings thus resulting in higher costs of care.   
Severity-of-illness showed a significant linear trend with inpatient costs for opioid poisonings in 
children. This is an expected finding as high severity-of-illness corresponds to higher loss of body 
function which may necessitate more care and management in the hospital resulting in higher costs. 
Surprisingly, children with involvement of multiple drugs had lower hospitalization costs. Similar 
findings were reported by another study that found inpatient costs of opioid poisonings with 
benzodiazepines to be lower than costs of opioids only hospitalizations.55 Involvement of co-
ingestants in opioid poisonings would be expected to result in more medical complications and 
consequently higher cost of care. One possible explanation for this unexpected finding is that the 
association of multi-drug opioid poisonings with treatment costs may depend on the potency of 
the opioid agent itself. Future costs studies should further investigate opioid poisonings with 
multiple drug involvement. Additionally, children transferred to short-term stay facilities had 
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significantly greater ED and inpatient costs. Transfer to short-term or intermediate care facilities 
may indicate that these poisonings were medically complicated or severe and have high cost of 
care during ED visit or inpatient stay.  
Inpatient costs were greater for children with private or other insurance compared to those with 
Medicaid. Although not specific to pediatric opioid poisonings, the mean cost per hospital stay 
was found to be higher for patients with private insurance compared to those with Medicaid.143 
This may point towards higher costs of care for non-public insurance beneficiaries.   
As for hospital characteristics, hospitals in the West had higher mean inpatient costs for pediatric 
opioid poisonings.  This same pattern has been observed for all-stay hospitalizations nationally.144 
Interestingly, after controlling for disposition status and number of diagnoses in the adjusted 
analyses, hospitals in the West were associated with lower inpatient costs compared to the 
Northeast. At least one prior study has reported a significant association between hospital region 
and disposition status.146 We found that opioid poisoning-related hospitalizations in the West had 
a higher proportion of transfers (34.2%) compared to hospitals in the Northeast (26.5%). 
Moreover, opioid poisoning-related discharges in the West also had a slightly higher mean number 
of diagnoses compared to hospitals in the Northeast. Lastly, larger hospitals had significantly lower 
inpatient stay costs for opioid poisonings in children compared to smaller hospitals. Although 
literature on the association of hospital bedsize and costs has been inconclusive, in theory hospitals 
with a higher number of beds are thought to have lower average cost per patient due to economies 
of scale.69  
Several limitations exist, particularly the biases and confounding integral to a retrospective study 
design. First, summary CCR data were used for ED analyses from the 2003 HCUP preliminary 
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report. These CCRs may have changed since 2003 but there is no other updated data for converting 
ED charges to costs. Second, some limitations are inherent with the use of administrative 
databases. Opioid poisonings and intentionality were identified using the ICD-9-CM codes. 
Although ICD-9-CM poisoning diagnosis codes are reported to have a high positive predictive 
value for identifying opioid poisonings cases,147 potential coding errors are possible with the use 
of secondary databases. Third, HCUP data are discharge-level and not patient-level hence repeated 
ED visits or admissions could not be linked in the databases used. Such readmissions may be 
common among teenagers with intentional poisonings, therefore it is possible that children may 
be counted more than once in the current analyses. But the goal was to estimate the economic costs 
of opioid poisonings and examine the factors associated with costs. So repeated admissions, if any, 
should have a small impact on the results.  
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Chapter 6: Conclusions and Future Research 
 
Conclusions  
Our study examined the epidemiology of medicinal opioid poisonings in children using PC data 
and the associated economic burden to society using national ED, hospital admission and mortality 
data. We conclude that opioid exposures and poisonings in children continue to occur. Although 
the prevalence of pediatric opioid exposures and poisonings has declined over the 5-year study 
period, the magnitude of annual decreases has been low. Morbidity associated with opioid 
exposures and poisonings in children remains high. We documented a total of 83,418 opioid 
exposures in children and about 39,202 ED visits and hospital admissions from 2010 to 2014. We 
also identified 123 opioid poisoning-related deaths in children annually.  
One common theme across the study results using different data sources was that the epidemiology 
of opioid exposures and poisonings differs significantly by age. Opioid exposures and poisonings 
were more prevalent, but less severe and mainly accidental in younger children. Exposures in 
adolescents were more likely to be intentional and severe, and were more common in girls. 
Adolescents also had higher health care use and greater ED costs. Exposures to buprenorphine and 
methadone in children were more likely to result in negative medical outcomes. Development of 
educational efforts and targeted prevention strategies particularly those that are age- and agent-
specific is warranted. 
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Quantifying health care resource use and costs associated with pediatric opioid poisonings can 
help decision makers to understand the economic trade-offs in planning interventions. Our study 
estimated a total economic burden of pediatric opioid poisonings at $230.8 million of which $21 
million were attributed to direct medical costs annually. Given such societal spending on opioid 
poisonings in children, investment in primary prevention strategies such as education and 
counselling of providers and caregivers in order to promote adoption of safe use, storage and 
disposal of opioids may be worthwhile.  
Naloxone was the common antidote used for severe opioid poisonings in children. Take-home 
naloxone programs have increased access to naloxone and have shown to be a successful strategy 
to prevent opioid poisoning-related morbidity and mortality among adults.148 Opioid poisoning in 
children is acute and can be fatal if not treated promptly. Exploring a similar naloxone distribution 
strategy for children may be valuable. To provide rough estimates of one such strategy from an 
economic perspective, consider distribution of naloxone to adults on long-term opioid therapy. 
Assuming that about 9.6 to 11.5 million adults are prescribed long-term opioid therapy based on a 
prior CDC report149 and the price of prescription naloxone injection at $18.7 (average wholesale 
price (AWP) obtained from Lexicomp online resource), the cost of distributing naloxone would 
be approximately at $179 to $215 million per year. This could roughly result in cost-savings of 
$15 to $51 million to society.  
Our study reported a high prevalence of opioid exposures and poisonings among young children. 
We also found buprenorphine and methadone pediatric exposures to be highly associated with 
negative medical outcomes. These findings may provide a good starting point for exploring 
clinically and economically feasible strategies that would benefit children from such naloxone 
distribution program. 
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Future Research 
In addition to addressing the weaknesses of the current study, future research can use results from 
this exploratory study to generate hypotheses related to individual-level sociodemographic and 
clinical factors as well as area-level socioeconomic factors that were found to be associated with 
opioid exposures and poisonings in children. The current study could not examine the correlation 
of opioid exposures in children and opioid use and misuse in the family. Past research has 
established a link between pediatric opioid exposures and poisonings and adults’ opioid 
availability.31,38 But literature on the correlation of opioid exposures in children and parental or 
caregiver opioid misuse, abuse or addiction is sparse. One study conducted in Iran reported that a 
history of addiction in the family was indirectly correlated with drug exposures in children.150 
Future studies can examine such association of adults’ opioid use and misuse with opioid 
exposures in children. This would aid in identifying children at risk for future opioid exposures 
and poisonings. It would also be interesting to explore the impact of CDC’s new pain management 
guidelines on the prevalence of pediatric opioid exposures and poisonings. We also found 
differences in the rate of pediatric opioid exposures by state. Further research can investigate the 
factors related to such differences at state-level. Lastly, future work can incorporate a complete 
assessment of health care resource use and economic burden associated with opioid poisonings in 
children by monitoring long-term outcomes and costs.   
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Appendix A 
 
Table 36: List of Opioids included in Specific Aim 1 analyses 
Acetaminophen (APAP) combinations 
Acetaminophen with codeine 
Acetaminophen with hydrocodone 
Acetaminophen with other narcotics or narcotic  analogs  
Acetaminophen with oxycodone 
Acetaminophen with propoxyphene 
Acetylsalicylic acid (ASA) combinations  
Acetylsalicylic acid with codeine 
Acetylsalicylic acid with other narcotics or narcotic analogs 
Acetylsalicylic acid with oxycodone 
Acetylsalicylic acid with propoxyphene 
Nonsteroidal anti-inflammatory drug (NSAIDs) combinations 
Ibuprofen with hydrocodone 
Opioids 
Alfentanil 
Buprenorphine 
Butorphanol 
Codeine 
Difenoxin  
Dihydrocodeine 
Fentanyl    
Hydrocodone alone or in combination (excluding combination products with APAP, ASA or 
ibuprofen)    
Hydromorphone 
Levorphanol 
Meperidine 
Methadone   
Morphine 
Nalbuphine 
Oxycodone alone or in combination (excluding combination products with APAP or ASA) 
Oxymorphone 
Pentazocine 
 
 
193 
 
Propoxyphene 
Remifentanil 
Sufentanil 
Tapentadol 
Tramadol 
Other or unknown narcotics 
Cough and cold (CNC) products 
APAP and codeine combinations with decongestant and/or  antihistamine without 
phenylpropanolamine (PPA) 
APAP and other opioid combinations with decongestant and/or antihistamine without PPA 
APAP, ASA and opioid combinations with decongestant and/or antihistamine without PPA 
APAP, PPA, and codeine combinations with decongestant and/or antihistamine 
APAP, PPA, and other opioid combinations with decongestant and/or antihistamine 
APAP, ASA, PPA and opioid combinations with decongestant and/or antihistamine 
ASA and codeine combinations with decongestant and/or antihistamine without PPA 
ASA and other opioid combinations with decongestant and/or antihistamine without PPA 
ASA, PPA and codeine combinations with decongestant and/or antihistamine 
ASA, PPA and other opioid combinations with decongestant and/or antihistamine 
Antihistamine and/or decongestant with PPA and codeine 
Antihistamine and/or decongestant with PPA and other opioid 
Antihistamine and/or decongestant with codeine without PPA 
Antihistamine and/or decongestant with other opioid without PPA 
Non-ASA salicylates, PPA and opioid combinations with decongestant and/or antihistamine 
Non-ASA salicylates and opioid combinations with decongestant and/or antihistamine without 
PPA 
Gastrointestinal (GI) agents 
Antidiarrheals: diphenoxylate and atropine containing 
Antidiarrheals: paregoric containing 
Antidiarrheals: other narcotic containing 
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Appendix B 
 
 
 
 
Y-axis represents semivariance in observed pairs of 5-digit ZIP Code areas and X-axis 
represents distance bins. 
 
Figure 11: Semivariogram for 5-digit ZIP Code data (Specific Aim 1D) 
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Appendix C 
 
Cost-to-Charge Ratios (CCR) for ED visits  
HCUP 2003 preliminary report provides ED CCR based on certain hospital characteristics 
including hospital ownership, location and volume (or bedsize) as listed in Table 37. However, the 
2012 NEDS has different categories for hospital ownership and location as listed in Tables 38 and 
39. Additionally, hospital bedsize is not included in the NEDS. Hence certain mean CCR provided 
in the HCUP report were combined for the current analyses. For example, CCR for hospital in 
urban areas with private, collapsed (i.e., proprietary or PNFP) ownership was calculated using the 
mean CCR and the sample size provided in the HCUP report as shown below. Table 40 lists the 
CCR used for the current analyses. 
 
CCR for Urban, private collapsed (proprietary or PNFP): 
      185         * 0.552    +               46          * 0.395   =    0.521 
   
   185 + 46                                 185 + 46 
 
 
  
Table 37: ED hospital mean CCR provided by HCUP 
 N of hospitals Weighted mean CCR 
Rural, low volume, Government 41 0.570 
Rural, low volume, PNFP or Prof 33 0.571 
Rural, Non-low volume, Government 70 0.527 
Rural, Non-low volume, PNFP 110 0.529 
Rural, Non-low volume, Prof 42 0.361 
Urban, Government 30 0.457 
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Urban, PFNP 185 0.552 
Urban, Prof 46 0.395 
All hospitals 556 0.514 
PFNP= Private not-for-profit, Prof = for profit (proprietary) 
 
 
Table 38: Hospital ownership categories provided in NEDS 2012 
 
 
 
 
 
 
 
 
Table 39: Hospital location categories provided in NEDS 2012 
 
 
 
 
 
 
 
 
 
 
Table 40: ED CCR used in the current analyses 
 Weighted mean CCR 
Rural, Government* 0.543 
Rural, PNFP  0.529 
Rural, Proprietary  0.361 
Rural, PNFP or proprietary (collapsed) 0.571 
Rural, Government or private (collapsed)* 0.570 
Urban, Government 0.457 
Urban, PFNP 0.552 
Urban, Proprietary 0.395 
Urban, PNFP or proprietary (collapsed)* 0.521 
Urban, Government or private (collapsed)* 0.419 
*Calculated CCR 
  PFNP= Private not-for-profit. 
  
Hospital ownership 
Government or private (collapsed) 
Government 
Private, not-for-profit 
Private, proprietary 
Private, not-for-profit or proprietary (collapsed) 
Hospital Location 
Large metropolitan (urban) 
Small metropolitan (urban) 
Micropolitan (urban) 
Small metropolitan and micropolitan, collapsed (urban) 
Large and small metropolitan, collapsed (urban) 
Not metropolitan or micropolitan  (rural) 
Micropolitan and non-urban, collapsed (rural) 
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Appendix D 
 
 
 
 
N represents sample size from 5 imputed datasets.  
Missing charges = 0 correspond to non-missing observations. 
Missing charges = 1 correspond to missing observations that were imputed. 
 
Figure 12: Distribution of ED missing and non-missing charges 
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N represents sample size from 5 imputed datasets.  
Missing charges = 0 correspond to non-missing observations. 
Missing charges = 1 correspond to missing observations that were imputed. 
 
Figure 13: Distribution of inpatient missing and non-missing charges 
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Appendix E 
 
Table 41: ICD-9-CM codes for identifying multi-drug involvement 
ICD-9-CM code       Description 
960                             Poisoning by antibiotics 
961                             Poisoning by other anti-invectives 
962                             Poisoning by hormones and synthetic substitutes 
963                             Poisoning by primarily systemic agents 
964                             Poisoning by agents primarily affecting blood constituents 
965                             Poisoning by analgesics antipyretics and antirheumatics 
966                             Poisoning by anticonvulsants and anti-parkinsonism drugs 
967                             Poisoning by sedatives and hypnotics 
968                             Poisoning by other central nervous system depressants and anesthetics 
969                             Poisoning by psychotropic agents 
970                             Poisoning by central nervous system stimulants 
971                             Poisoning by drugs primarily affecting the autonomic nervous system 
972                             Poisoning by agents primarily affecting the cardiovascular system 
973                             Poisoning by agents primarily affecting the gastrointestinal system 
974                             Poisoning by water mineral and uric acid metabolism drugs 
975                             Poisoning by agents primarily acting on the smooth and skeletal muscles 
and respiratory system 
976                             Poisoning by agents primarily affecting skin and mucous membrane 
ophthalmological otorhinolaryngological and dental drugs 
977                             Poisoning by other and unspecified drugs and medicinal substances 
978                             Poisoning by bacterial vaccines 
979                             Poisoning by other vaccines and biological substances 
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Appendix F 
 
Table 42: List of Elixhauser comorbidities 
Acquired immune deficiency syndrome (AIDS) 
Alcohol abuse  
Deficiency anemias  
Rheumatoid arthritis/collagen vascular diseases  
Chronic blood loss   
Congestive heart failure  
Chronic pulmonary disease 
Coagulopathy  
Depression  
Diabetes, uncomplicated  
Diabetes with chronic complications  
Drug abuse 
Hypertension, uncomplicated and complicated  
Hypothyroidism  
Liver disease  
Lymphoma  
Fluid and electrolyte disorders  
Metastatic cancer  
Other neurological disorders  
Obesity  
Paralysis  
Peripheral vascular disorders  
Psychoses  
Pulmonary circulation disorders  
Renal failure  
Solid tumor without metastasis  
Peptic ulcer disease excluding bleeding  
Valvular disease  
Weight loss 
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Appendix G 
 
Table 43: Mean inpatient hospital costs (in 2012 USD) by Elixhauser comorbidities 
Selected Elixhauser comorbidity 
Weighted cost (N = 1,874) 
Mean SE 
Psychoses 
No  
Yes  
 
6939.53 
5365.91 
 
769.61 
447.61 
Alcohol abuse  
No  
Yes 
 
6648.09 
6356.30 
 
656.77 
981.10 
Deficiency anemias* 
No  
Yes 
 
6321.44 
31206.00 
 
602.05 
16102.00 
Chronic pulmonary disease 
No  
Yes 
 
6749.20 
5512.05 
 
688.03 
615.46 
Depression  
No  
Yes 
 
7042.11 
4778.48 
 
758.63 
298.63 
Drug abuse* 
No  
Yes 
 
6626.71 
6657.45 
 
790.63 
535.69 
Hypertensiona* 
No  
Yes 
 
6431.81 
16026.00 
 
640.19 
5025.38 
Fluid and electrolyte disorders* 
No  
Yes 
 
5194.58 
17820.00 
 
309.34 
4861.85 
Other neurological disorders* 
No  
Yes 
 
6649.19 
6567.47 
 
764.17 
811.32 
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Obesity* 
No  
Yes 
 
6582.94 
8217.44 
 
642.33 
1295.08 
 
*p-value <.05.  
aIncludes uncomplicated & complicated. 
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Appendix H 
 
Table 44: Sociodemographic and clinical characteristics of sample for Aim 1D 
Characteristic, n (%) 
Total opioid exposures 
(N = 83,418) 
Sample for Aim 1D 
(n = 43,701) 
Age group 
0 < 1  
1 - 2 
3 - 5 
6 - 12 
13 - 17 
Unknown (child) 
 
5,042  (6.04) 
32,204  (38.61) 
13,744  (16.48) 
8,819  (10.57) 
23,245  (27.87) 
364  (0.44) 
 
2,881  (6.59) 
18,736  (42.87) 
9,370  (21.44) 
6,361  (14.56) 
6,130  (14.03) 
223  (0.51) 
Gender 
Female 
Male 
Unknown 
 
42,022 (50.38) 
41,081 (49.25) 
315  (0.38) 
 
20,859  (47.73) 
22,692  (51.93) 
150  (0.34) 
Opioid type involved 
Single substance 
APAP combinations 
CNC combinations 
Other combinations 
 
40,651  (48.73) 
37,472  (44.92) 
5,406  (6.48) 
1,028  (1.23) 
 
19,620  (44.90) 
19,555  (44.75) 
4,182  (9.57) 
554  (1.27) 
Route 
Ingestion 
Other 
Unknown 
 
82,322  (98.69) 
1,602  (1.92) 
375  (0.45) 
 
43,371  (99.24) 
382  (0.87) 
71  (0.16) 
Chronicity 
Acute 
Non-acute 
Unknown 
 
77,602  (93.03) 
4,609  (5.53) 
1,207  (1.45) 
 
41,396  (94.73) 
2,111  (4.83) 
194  (0.44) 
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Reason 
Unintentional 
Intentional 
Adverse reaction 
Other 
Unknown 
 
61,206  (73.37) 
20,064  (24.05) 
1,088  (1.3) 
227  (0.27) 
833  (1) 
 
38,989  (89.22) 
3,723  (8.52) 
702  (1.61) 
33  (0.08) 
254  (0.58) 
Scenario 
Therapeutic error 
Storage/Access 
Other 
Unknown 
 
15,666  (18.78) 
2,917  (3.5) 
778  (0.93) 
64,458  (77.27) 
 
12,570  (28.76) 
1,917  (4.39) 
419  (0.96) 
29,014  (66.39) 
Related effect 
Any 
Neurological 
Gastrointestinal 
Cardiovascular 
Ocular 
Respiratory 
Other 
 
27,846  (33.38) 
21,544  (25.83) 
7,751  (9.29) 
5,136  (6.16) 
3,126  (3.75) 
2,863  (3.43) 
4,275  (5.12) 
 
8,039  (18.40) 
5,890  (13.48) 
2,438  (5.58) 
297  (0.68) 
527  (1.21) 
352  (0.81) 
1,180  (2.7) 
Performed therapy 
Decontamination 
Naloxone 
Other therapy 
 
19,571  (23.46) 
5,300  (6.35) 
14,591  (17.49) 
 
11,748  (26.88) 
548  (1.25) 
2,608  (5.97) 
HCF 
None 
T/E and R 
Critical care 
Non-critical care 
Psychiatric care 
Other 
Unknown 
 
30,093  (36.07) 
25,983  (31.15) 
7,097  (8.51) 
6,122  (7.34) 
3,658  (4.39) 
9,836  (11.79) 
629  (0.75) 
 
26,121  (59.77) 
8,573  (19.62) 
778  (1.78) 
1,090  (2.49) 
232  (0.53) 
6,491  (14.85) 
416  (0.95) 
Outcome 
No effect 
Minor 
Moderate 
Major 
Death 
Unknown 
 
32,944  (39.49) 
32,443  (38.89) 
7,709  (9.24) 
1,368  (1.64) 
111  (0.13) 
8,843  (10.6) 
 
18,912  (43.28) 
17,907  (40.98) 
971  (2.22) 
47  (0.11) 
6  (0.01) 
5,858  (13.4) 
Poisoning 43,503  (52.15) 19,990  (45.74) 
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